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Dankwoord 
 
Na het afronden van mijn opleiding geneeskunde vatte ik de opleiding “Anesthesie en 
Reanimatie” aan.  Van bij de start werd deze in goede banen geleid door Prof. Dr. Eric 
Mortier.  Onder zijn alziend oog en dat van zijn collega’s stafleden, werden mijn jaargenoten 
en ikzelf de klinische vaardigheden die ons vak vereist, aangeleerd.  De wetenschappelijke 
gangmakers binnen onze dienst waren op dat ogenblik Prof. Dr. Michel Struys, Dr. Hugo 
Vereecke en Dr. Luc De Baerdemaeker.  Hun prikkelend enthousiasme rond wetenschap 
zorgde ervoor dat ik, al vanop “jonge” leeftijd, de mogelijkheid om te participeren aan 
onderzoek als een meerwaarde zag.  En van het één kwam het ander… Na het beëindigen 
van mijn opleiding anesthesie had ik het geluk te kunnen aansluiten bij een toffe equipe.  
Anderzijds kreeg ik de kans om naast het vele klinische werk ook wat aan wetenschappelijk 
onderzoek te doen.  Prof. Dr. Vereecke en Prof. Dr. De Baerdemaeker werden mijn steun en 
toeverlaat om deze wetenschappelijke ambitie verder vorm te geven.  Zowel op theoretisch, 
technisch, organisatorisch als praktisch vlak kon ik met elke vraag bij hen terecht.  De 
verandering der levenslopen had er intussen voor gezorgd dat ik, ondanks de afstand tussen 
Gent en Groningen, eveneens kon rekenen op een ally in het hoge noorden : Prof. Dr. Struys.  
Zonder deze vier mensen had ik zelfs niet kunnen dromen van een doctoraat.  Daarom : 
ongelofelijk bedankt !!! 
 
Een thesis maken is teamwerk.  En het team dat ik nodig had was groot, heel groot.  Ik wil 
mijn diensthoofd, Prof. Dr. Wouters, maar ook alle stafleden van onze dienst bedanken voor 
hun inzet.  Zij zorgden ervoor dat ik vrijgesteld werd van klinische taken zodat ik ongestoord 
kon werken en stonden me, te gepasten tijde, bij met praktische en professionele 
ondersteuning.  Ik mag natuurlijk ook mijn medeauteurs niet vergeten : voor het verwerken 
van de data, uitschrijven van de bevindingen, voor de talrijke discussies, voor de heldere 
uitleg, enz…  Zonder jullie was deze thesis natuurlijk onbestaande.   
 
Voor elke patiënt had ik, vóór aanvang van chirurgie, een tweetal uur onderzoek nodig in de 
operatiezaal.  Wetende dat de zaal, met of zonder studie, toch om 16 uur dicht moest, wil ik 
de collega’s van de snijdende disciplines danken voor hun geduld en kalmte ! Ook de 
verpleegkundigen ben ik het één en ander verschuldigd : het kan niet makkelijk zijn om 
tijdens dergelijk onderzoek, waarbij absolute stilte in de zaal vereist is, aan alle willetjes van 
een veeleisende anesthesist te voldoen.  Vervolgens wil ik ook het secretariaat van onze 
dienst danken voor de administratieve ondersteuning.   
 
Het doornemen van dit werk was vermoedelijk een hele opdracht.  Ik wens dan ook de leden 
van de examencommissie te danken voor hun constructieve en to the point opmerkingen.   
 
Maar ondanks het grote belang van alle vooraf genoemde personen zijn er toch nog enkele 
mensen die ik buitengewoon veel verschuldigd ben…  Mijn ouders : voor alle wijze raad, het 
luisterend oor en voor de geboden mogelijkheden… van welke aard dan ook.  Mijn 
echtgenote : voor alle steun en begrip, in makkelijke en moeilijkere tijden.  En vooral Bo en 
Oona : voor alle geduld, omdat ik er zoveel niet geweest ben wanneer ik er wel had moeten 
zijn….  Ik hoop dat het resultaat ook voor jullie alle moeite waard was.  
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Chapter 1  Introduction and aims 
 
It has always been challenging to describe the phenomenon “anesthesia”.  For nearly a 
century, and inspired by the single drug anesthesia, the state of general anesthesia has been 
described as a multi-featured phenomenon with one underlying mechanism, and, to be 
common for all general anesthetics with diverse chemical structures, this mechanism is 
supposed to be non-specific.1,2  Using this theory, anesthesia is based on unitary non-specific 
mechanisms of anesthetic actions, one anesthetic may be replaced freely by another.  In the 
case of anesthetic combinations, the anesthetic effect of mixtures is expected to be additive.  
The problem with the classic concept of the state of anesthesia became obvious when 
neuromuscular blocking agents, opioids, and barbiturates began to be widely used in 
combination with inhaled anesthetics.   
 
It took until 1957, when Woodbridge described anesthesia by quoting its components : 
Amnesia, Analgesia, Akinesia and Attenuation of autonomic responses and sensory reflex 
blockade.3  In 1998, Peter Glass described an eminent paradigm shift of the definition of 
general anesthesia.4  He depicts the latter as a balance between a state of unconsciousness 
of the brain, mediated by hypnotics and on the other hand a form of inhibition of the 
noxious stimuli reaching the brain.  This inhibition can be mediated by the action of opioids 
at the opioid receptors situated in the spinal cord or by local anesthetics on peripheral 
nerves.  Since then, general anesthesia can be described by its two components : the 
“hypnotic” and the “analgesic” component.   
 
The hypnotic component of anesthesia can be measured by using intermittent clinical 
endpoints (e.g. a response from the patient to a verbal command)5,6 or by continuous 
measures of cerebral drug effect (e.g. spontaneous or evoked electro-encephalographic 
monitoring).7,8  The analgesic component of anesthesia is the net physiological result of the 
simultaneously opposing effects of nociception and anti-nociception mediated by 
medication.  Controlling the hypnotic component of anesthesia is rather easy as more 
hypnotic drug will result in a more extensive cerebral drug effect.  In contrast, the balance 
between nociception and anti-nociception is more complex and more difficult to control as 
anesthesiologists can only manage anti-nociception.  The nociceptive part is the result of 
varying noxious stimuli during the surgical procedure.  Dichotomous measures (e.g. 
movement of the patient in response of a tactile or noxious stimulus) or continuous 
measures (e.g. arousal responses measured by electro-encephalographic alterations or 
changes at the level of the autonomic nervous system such as heart rate or blood pressure 
changes) of the analgesic component of anesthesia will always be the result of both anti-
nociception and nociception (if present).9   
 
Each drug given to control one of the components of anesthesia is governed by a specific 
dose-response relation.  This relation can be divided into a pharmacokinetic and a 
pharmacodynamic part.  The pharmacokinetic relation describes the time course of the 
plasma concentration of this drug after a given dose.  The pharmacodynamic relation depicts 
the connection between that specific plasma concentration and the resulting clinical effect.  
As the site of drug effects is mostly outside the plasma, hysteresis or a delay between the 
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plasma concentration and the effect arises.  This can be modeled by using a virtual effect-
site concentration or biophase.  For every effect-site concentration there is a corresponding 
effect without time delay.   
 
 
It is apparent that when administering two (or more) drugs to a patient in an attempt to 
control both components of anesthesia, these drugs will interact which each other at both 
the kinetic and dynamic level.  Although kinetic interaction nearly always exists, we will 
focus in this thesis on the pharmacodynamic interactions solely hereby accepting the fact 
that a kinetic interaction will always result in a dynamic one.  Classically, pharmacodynamic 
drug interactions are described as additive, synergistic or antagonistic (see  
Figure 1).10   
 
 
 
 
Figure 1 
Isoeffective doses of a two drug combination 
 
Classical isobolographic representation of the pharmacodynamic drug interaction between two drugs, A and B 
with the corresponding doses a and b.  Each point in an isobole represents a dose combination of A and B, 
resulting in an equal effect.  If the drugs have an additive relationship the isobole is a straight line (blue curve).  
If the isobole deviates away from the origin, indicating that more drug is needed to achieve an equal effect, the 
relation is infra-additive (yellow curve).  If, in the opposite, the isobole bends towards the origin, the 
interaction is synergistic (green curve).11   
 
 
The classical two-dimensional representation of a drug interaction can only depict one level 
of combined drug effect.  If one wants to study the entire range of drug effect (between no 
effect and maximal effect, respectively E0 and Emax) a three dimensional study design and 
representation is required as shown in Figure 2.  This representation is called “response 
surface drug model”.  (see Chapter 2).   
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Figure 2 
Relationship between a response surface and a standard isobologram 
 
A three dimensional response surface offers the possibility to characterize the full concentration-response 
relation.  In fact, an isobologram is a horizontal section of the response surface (e.g., 50% drug effect as in the 
right part of the picture).  (Modified from Miller’s Anesthesia, 8th ed., Chapter 33, used with permission.) 
 
 
In order to study the drug interaction for both hypnotic and analgesic components of 
anesthesia, we have to document the drug interactions between these two.  As such, we 
focused in this thesis on the interaction between hypnotics and opioids.  Previously, others 
described interactions between propofol-fentanyl,12–14 propofol-midazolam-alfentanil,11,15 
propofol-alfentanil-nitrous oxide,16 propofol-alfentanil17–19, propofol-opioids,20,21 propofol-
remifentanil,22–27 desflurane-fentanyl,28 desflurane-remifentanil,29 sevoflurane-fentanyl,30–32 
sevoflurane-remifentanil,33,34 isoflurane-fentanyl35–37, isoflurane-alfentanyl,36 isoflurane-
sufentanyl,38 isoflurane-remifentanil,39... and hereby also described various surface modeling 
strategies for pharmacodynamic interactions.   
 
During anesthesia, volatile anesthetics such as sevoflurane (with or without nitrous oxide) 
are frequently combined with opioids such as remifentanil.  Therefore, we aimed at 
describing the relationship between those two (or three) drugs.  The published knowledge 
on these drug interactions can be considered incomplete.  Previously, Manyam and 
colleagues developed a response surface model for various pharmacodynamic responses 
using a Logit model approach and found synergy between sevoflurane and remifentanil for 
all responses.40  Unfortunately, as this study suffered from nonsteady-state conditions at the 
moment of the observations, these researchers improved their data using calculated effect-
site sevoflurane concentrations and a specific surface model instead of a Logit approach.41  
Accounting for the lag time between sevoflurane effect-site concentration and end-tidal 
concentration improved the predictions of responsiveness during anesthesia but had no 
effect on the accuracy of prediction of a response to a noxious stimulus in recovery.  They 
concluded that models may be useful in predicting events of clinical interest, but large-scale 
evaluations with numerous patients are needed to better characterize the interaction.   
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As a result, we aimed in this thesis to enlarge the knowledge on the interaction between 
sevoflurane, nitrous oxide and opioids using both dichotomous and continuous measures of 
drug effect.  Secondly, we hypothesized that the applied surface model approach might 
influence the resulting interaction and has to be explored during the model development. 
Thirdly, we aimed at using a response surface interaction model to develop a new predictive 
anesthetic state index.  
 
 
Initially, we studied the interaction between sevoflurane and remifentanil using tolerance to 
shake and shout, tolerance to a tetanic stimulus, tolerance to the insertion of a laryngeal 
mask and tolerance to laryngoscopy as clinical measures.  Additionally, we studied the 
influence of the various surface modeling approaches on the interaction model using these 
data (Chapter 3).  We also studied the response surface model approach during sevoflurane-
remifentanil interaction using various EEG and autonomic nervous system derived 
continuous measures with or without noxious stimulus (“the pharmacodynamics shift”) (see 
Chapter 4).  As nitrous oxide is still used to supplement inhaled anesthetics such as 
sevoflurane, we analyzed the triple interaction between nitrous oxide, sevoflurane and 
opioids on the hypnotic and analgesic component of anesthesia using the response surface 
approach (Chapter 5).   
 
In an attempt to use drug interaction models as the input of a predictive anesthetic state 
index, we developed the NSRI (noxious stimulation response index).  The NSRI is proposed to 
predict, based on the effect-site concentrations of an opioid and an anesthetic, the 
likelihood of response to a noxious stimulus, being the tolerance to laryngoscopy (Chapter 
6).  More recently, we enlarged and adapted the original NSRI to deal with triple interaction 
models estimating the potency of any combination of sevoflurane, propofol and remifentanil 
in terms of the probability to tolerate laryngoscopy (Chapter 6).   
 
In order to assist the less experienced reader, we added a chapter (see Chapter 2) to explain 
the basic and theoretical concepts used in our studies.  
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Chapter 2  Basic principles and review of the literature 
 
Anesthesiologists combine several agents in order to achieve multiple goals simultaneously.  
Rapid loss of consciousness during induction, adequate depth of anesthesia during 
maintenance, analgesia during surgery and afterwards, fast emergence, hemodynamic 
stability and control of the respiratory depression are some of the challenges.  To redeem 
these objectives, intravenous drugs, inhaled anesthetics, opioids, neuromuscular blocking 
agents and locoregional techniques are routinely combined.  Nowadays these drugs are 
usually administered using standard dosing regiments, the clinical evolution of the patient, 
and the clinical experience of the anesthesiologist.   
 
Optimisation of combing anesthetic drugs to obtain a predefined level of anamnestic and 
analgetic effect requires the ability to measure these effects.  Furthermore, thorough 
knowledge of multiple single drug dose response relationships is needed to adjust the dose 
of the administered medications to achieve the intended effects.  Additionally, well-defined 
interaction models are nessecary to estimate the effects of the applied drugs on eachother.   
 
1 Measuring the effect 
 
11 Continuous parameters 
 
General anesthesia can be achieved by an extremely diverse group of drugs.  Nevertheless, 
the mechanisms of action to produce a reversible loss of consciousness are still a mystery.1  
EEG monitors have been used in different anesthetic states in an effort to gain insights into 
the working principle of anesthetics.  It revealed that, with increasing depth of anesthesia, 
there was a progressive increase in low frequency, high amplitude activity and a decrease in 
the high frequency activity.42,43  This observation has led to a search for an objective, 
reproducible and continuous measure of cerebral hypnotic drug effect and subsequently to 
the development of monitors that interpret the changes in neurophysiologic endpoints.44  
The major advantage of this technology is the availability of continuous information on the 
cerebral state even during conditions during which patients have lost all responses to a 
verbal or painful stimulus.   
 
 
111 The Bispectral index  
 
The bispectral index (BIS, Covidien) is an empirically derived complex parameter, derived 
from a raw EEG signal measured with a specific sensor taped on the forehead.  Three 
different processing techniques including bispectral analysis, power spectral analysis, and 
time domain analysis are used to calculate disparate descriptors from the collected EEG 
signal.  Each descriptor is designed to discriminate different EEG signals corresponding with 
different levels of anesthesia.  Consequently, they all have a specific range at which they 
 
16 
 
perform best.  A proprietary algorithm combines these different descriptors to optimize the 
correlation between the obtained EEG signal and the clinical effects of anesthesia.43,44  A 
schematic depiction can be found in Figure 3.45   
 
The resulting dimensionless number ranges between 100 (fully awake) and 0 (isoelectric 
EEG).  A BIS value between 40 and 60 indicates an appropriate level for general anesthesia.  
There are numerous studies that demonstrate a good correlation between clinical hypnotic 
effects and BIS.6,22,25,46–49  Although there is a good correlation between BIS and  the level of 
hypnosis, there are many potentially confounding variables.43   
 
 
 
Figure 3 
Development process of the BIS.  
 
(modified from Bispectral Guidelines, Aspect ®, Natick, USA) 
 
 
112 Entropy 
 
In the context of information theory, entropy describes the irregularity, the randomness or 
the unpredictability of a signal.  A completely predictable signal such as a fixed magnitude or 
a sine wave gives an entropy of zero.  If a signal exists of sequential, but randomly chosen 
values, following unknown values are difficult to estimate and therefore such a signal has 
high entropy.  Absolute scales like amplitude or frequency of a signal have no influence on 
regularity or predictability of that signal, and will not affect entropy.  The idea of using 
entropy to estimate the depth of anesthesia originates form the preposition that the 
irregularity within an EEG signal decreases with increasing levels of anesthetic drugs in the 
brain.  To quantify this “amount of order” in the EEG, different entropy concepts have been 
applied.50–52   
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To define entropy in real time, a time window or “epoch” is needed.  The optimal length of 
the epoch is related to the frequency range of interest.  Estimation of lowest frequency 
variations in the signal must be feasible and therefore the time window must be sufficiently 
long.  Since the EEG signal consist of a wide frequency range, a set of window lengths is 
chosen in order to achieve an optimal balance between time and reliability to estimate 
accurate data.  This way short epochs for high frequency ranges result in a short response 
time and long epochs ensure accurate data even for low frequency ranges.52   
 
With spectral entropy, it is possible to calculate the contribution of a defined frequency 
range to the total entropy.  EEG derived from the forehead of a patient contains a 
considerable amount of electric noise created by muscle activity or frontal 
electromyographic activity (EMG).  During anesthesia, the EEG signal dominates the 
frequencies lower than 30 Hz.  At higher frequencies, an exponential decrease in EEG power 
is noted and EMG dominates the signal.24,52   
 
The first commercial available monitor based on spectral entropy is the Datex-Ohmeda S/5 
Entropy Module (GE Healthcare, Helsinki, Finland).  This monitor generates two indices, the 
State Entropy (SE) and the Response Entropy (RE).  Response Entropy is calculated from the 
signals in the 0.8 to 47 Hz range, and thus enclosing both the EEG and EMG dominant part of 
the spectrum.  The response time of RE is very fast, typically less than two seconds.  In 
analogy of the BIS, this is reflected in a dimensionless number between 0 and 100.  EMG 
activity is especially noted during the awake state.  The epochs of RE are selected in such 
way that very fast response times are achieved.  Considering the two latter, the objective of 
RE is to provide an indicator of arousal.  However, RE can also be affected by other 
confounding factors, for example neuromuscular blocking agents.53–55   
 
The range from 0.8 to 32 Hz excludes the EMG dominant part of the spectrum and the 
entropy calculated from this frequency range is called State Entropy (SE).  Therefore, the 
State Entropy value is always less or equal to the Response Entropy value, with a maximum 
value of 91.  In an attempt to create a stable indicator of the effects of hypnotics on the 
cortex, the epochs of SE are determined to remove transient fluctuations from the data.  So 
SE tries to reflect the cortical state of the patient more precisely but with a bigger time delay 
than RE.  The clinically relevant target range for both entropy values is 40 - 60.   
 
As for BIS, various papers concluding that there is a good correlation between the hypnotic 
state and entropy have been published.7,22,24,49,51,54   
 
 
113 Surgical Pleth Index 
 
Although different EEG derived parameters, such as BIS and entropy, have been validated as 
measures of the hypnotic component of anesthesia, their ability to estimate the analgesic 
component of anesthesia accurately, is limited.7,48,56,57  Injury, trauma or surgery results in a 
stress response, mediated by autonomic, metabolic and hormonal changes.  Since those 
changes will influence other physiological parameters like heart rate, blood pressure, levels 
of circulating catecholamines, etc… various physiological measures have been studied with 
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the objective to reflect the balance between nociception and anti-nociception.  One of them, 
the Surgical Pleth Index (formerly known as the Surgical Stress Index58, GE Healthcare, 
Helsinki, Finland), is a multivariate numerical index, ranging between 0 and 100.  A value of 
100 indicates a high stress level, values between 20 and 50 have been proposed as adequate 
analgesia.59  It is based on the pulse wave amplitude of photoplethysmography (PPGA) and 
the heart beat interval (HBI) derived from the photoplethysmographic waveform.  To 
decrease the inter-individual variability that is not related to surgical stress, the two 
parameters are normalized using histogram transformation.58,60  Furthermore, this 
normalization procedure adjusts the individual values so that they are in a scale between 0 
and 100.  In the following formula PPGAnorm and HBInorm are respectively the normalized 
PPGA  and HBI.   
 
Equation 1 
ࡿࡼࡵ = ૚૙૙ − (૙. ૠ × ࡼࡼࡳ࡭࢔࢕࢘࢓ + ૙. ૜ × ࡴ࡮ࡵ࢔࢕࢘࢓) 
 
Published data show that SPI is capable of detecting noxious stimuli and the influence of 
analgesics on it.61–65  However, other factors like pacing, drugs affecting the heart rate66, 
intravascular volume status67,68,  posture69, etc … may influence the measured variables and 
consequently the SPI.   
 
 
114 Composite Variability Index 
 
Alterations in BIS values in response to noxious stimulation have been extensively 
documented.  Different authors have reported that these responses can be blunted with the 
addition of opioids or higher doses of hypnotics.57,70,71  These findings gave birth to the idea 
that the magnitude of the fluctuations in BIS values in response to noxious stimulation may 
provide a direct measure of antinociception.  Analysis of a retrospective dataset yielded the 
Composite Variability Index (CVI), a weighted combination of 3 variables : sBIS, sEMG, and 
BIS.72  sBIS and sEMG are respectively the standard deviations of BIS and EMG signal over 
the previous 3 minutes, and are computed every second.  So CVI should be regarded as an 
index scaled between 0 and 10 representing the total variability in a single measure.  The 
function describing the Composite Variability Index (CVI) algorithm has the following form :  
 
Equation 2 
࡯ࢂࡵ = ૚૙ × ൬
૚
૚ + ࢋି(ࢻ૚࢙࡮ࡵࡿା ૛࢙ࡱࡹࡳାࢻ૜࡮ࡵࡿାࢻ૝)
൰ 
 
 
Artifact removal and preprocessing of BIS and EMG, as well as the specific weights, αi, are 
proprietary and unpublished.  As for other indices, confounding variables like the application 
of neuromuscular blocking drugs, may impede the interpretation.  Some authors even 
question the usefulness of this parameter as an index of the balance between nociception 
and anti-nociception.9   
 
19 
 
 
 
12 Dichotomous parameters  
 
The Observer's Assessment of Alertness/Sedation (OAA/S) Scale was developed to measure 
the level of alertness in sedated patients.5  This scale is assessed by applying progressively 
more intense stimuli, ranging from a moderate speaking voice to physical shaking until a 
response is observed.   shows the five levels of the OAAS scale.73  In order to have the 
possibility to assess the response to moderate noxious stimuli (trapezius squeeze), a level 0 
was added later as a modification of the scale (Modified OAAS).74  The Observer's 
Assessment of Alertness/Sedation Scale has been used in numerous articles to validate the 
performance of depth of anesthesia monitors such as BIS7,75 or AAI.56  Responses to verbal 
commands are defined by an OAAS scale of 3 – 5.  Responses to tactile or noxious stimuli are 
defined by the lower levels 0 – 2.  The OAAS scale is one of the few scales whose reliability 
has been documented.5,6  Nevertheless, in certain conditions, patients might not respond to 
the verbal and tactile stimuli, although awake.  Furthermore the highest practically feasible 
frequency of assessments of a patient’s degree of sedation is approximately every 10 
seconds.73   
 
Table 1 
 
 
The results from an OAA/S score can be seen as dichotomous data since each assessment 
will result in a present or absent response.  To test the extent of an analgesic effect, 
different painful stimuli can be applied which may be or may not be followed by a response.  
Throughout the literature multiple noxious stimuli such as tetanic stimulus applied to the 
forearm, laryngeal mask placement, and others have been used to estimate the influence of 
an analgesic effect.  In the current literature laryngoscopy has been routinely applied as a 
standard noxious stimulus.26,27,37,40,41,76   
 
 
2 Single drug dose-response relationship 
 
To better understand the full dose response relationship for two drugs it is necessary to 
elaborate on the single drug dose relationship.   
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For each drug, the relation between an administered dose and effect, summarized in Figure 
477, can be divided into three parts: pharmacokinetics, pharmacodynamics and the coupling 
of them.  The relationship between the dose and the resulting blood concentration is 
described in the pharmacokinetic phase.  The Pharmacodynamic phase depicts the 
association between the blood concentration of a drug and the clinical effect.  Stated 
otherwise : pharmacokinetics is “what the body does to the drug” whereas 
pharmacodynamics can be described as “what the drug does to the body”.  The coupling 
between the pharmacokinetics and dynamics is the final step which involves taking into 
account hysteresis by defining a (virtual) effect stie concentration and invoking a ke0.   
 
 
 
Figure 4 
 
Schematic representation of the pharmacokinetic and dynamic processes determining the relationship 
between administered dose and resulting clinical effect.   
 
 
When drugs are injected, they are distributed to different groups of tissues, where they are 
taken up.  The speed and amount of the uptake is depending on multiple factors : tissue 
perfusion, concentration differences, permeability characteristics, lipid solubility, etc ... 
Drugs can be bound at different binding sites and if the drug is metabolized 
biotransformation occurs, with or without formation of active metabolites.  The drugs (and 
metabolites) are also distributed to the eliminating organs, so clearance starts immediately.  
The time course of the drug concentration is affected by all those factors.  To make a 
description of the time course of the drug concentration, compartment models have been 
created.  Compartments are mathematical concepts which do not correspond to a 
physiological or anatomical volumes but they can be used as parameters to make a model.  
Many drugs used in anesthesia distribute extensively into different body tissues.  The 
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concentration changes over time of these drugs are often poorly described by a single 
compartment advocating the use of multi-compartment models.78–81   
 
The concept can be illustrated graphically (Figure 5) if we replace a compartment by a barrel 
of water.  The drug concentration could be the height of the water in the barrel.  The 
amount of water added to the barrel represents the amount of drug administrated to the 
patient.  A hole made in the barrel represents drug elimination.  Multi-compartment models 
can be depicted as a system with multiple barrels connected by small hoses of different 
diameters.82,83  There are several ways to parameterize compartment models.  It can be 
described by rate constants and volumes of the compartments.  Otherwise it can be 
expressed using a poly-exponential equation. 
 
 
 
Figure 5 
 
Hydraulic model analogy of three-compartment pharmacokinetic model.  
 
The height, hi (t), represents the water level in each compartment. Each bucket is characterized by a cylindrical 
area, CAi , and the pipes connecting the buckets to each other or to the outside world are characterized by a 
conductance, Gi . Water enters bucket 1 at the rate r(t) and leaks irreversibly through G1.   
From Hughes MA, Glass PS, Jacobs JR: Context-sensitive half-time in multicompartment pharmacokinetic 
models for intravenous anesthetic drugs. Anesthesiology 76:334–341, 1992.   
 
Apart from the difficulties in calculating the dosage scheme to obtain a constant blood 
concentration, this is not the anesthesiologist’s target.  Anesthetics have their intended 
effect in the brain, not in the blood.  It is well known that after an intravenous bolus dose, it 
takes time to establish an effect : the drug must be transported to the tissue, diffuse to the 
cytoplasm, bind to a receptor, and give rise to a process which can evoke an effect.  Each 
step will delay the time course of the effect.  In contrast to non-anesthetic drugs, where the 
delay between administration and peak effect may not be so important, the lag time has a 
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huge impact on the modelling of the effect of anesthetics.  To avoid this problem the effect 
compartment with a corresponding effect-site compartment was introduced.84–86  For any 
concentration in this virtual compartment there is, by definition, a corresponding effect 
without time delay between the effect-site concentration and the effect.  Like the other 
compartments, the concentration in the effect-site compartment can be described by rate 
constants (ke0).  To avoid influence of the effect-site compartment on the estimates of the 
rate constants, the volume is, by convention, zero.  In order to obtain accurate estimates of 
the effect and reproducible effect-site concentrations most pharmacodynamic studies tend 
to use steady state conditions.78 
 
The relation between a single drug concentration and the effect can be described by the Hill 
equation or sigmoidal Emax model.87   
 
Equation 3 
ࡱ = ࡱ૙ + ࡱ࢓ࢇ࢞ ൬
࡯ࢽ
ࡱ࡯૞૙ࢽ + ࡯ࢽ
൰ 
 
E0 represets the baseline effect, Emax represents the maximum effect, C is the durg 
concentration, EC50 is the drug concentration for which 50% of maximum effect is obtained 
and γ defines the steepness and is called the “Hill coefficient of sigmoidicity”.  While Emax is a 
measure of the drug efficacity, C50 provides a measure of drug potency.  Since the baseline 
effect for anesthetic agents is normally equal to zero, E0 is frequently omitted (Figure 5).   
 
 
Figure 5 
Sigmoidal Emax curve 
 
 
The potency of inhaled anesthetics is often described using the minimal alveolar 
concentration (MAC).  This parameter, introduced by Eger et al. reflects the alveolar 
concentration at which 50 % of subjects are unresponsive to a standard surgical stimulus88.   
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Consequently, it is rather a description of a quantal response in the population than a 
quantification of the magnitude of effect like the C50.   
 
3 Interaction 
 
The word synergism originates from the Greek words sun (= together) and ergon (=work).  
They were combined in the mid-19th century to the Greek word “sunergos”.  An intuitive 
pharmacological definition is that synergism occurs between two agents when the observed 
effect of a combination is more than what would be predicted from the sum of the individual 
effects from each agent.  Antagonism can be determined as the opposite of synergism : the 
resulting effect of the combination of drugs will be less than in additive conditions.  If drugs 
are additive the effect is equal to the sum of the individual effects of each agent.10,89   
 
Interaction may occur at different levels, even before absorption or delivery (eg physical 
drug interactions).  Drug interactions may also involve the pharmacokinetics, the 
pharmacodynamics or both processes.  An example could be the interaction of propofol and 
midazolam : they have an interaction on the pharmacokinetic level by reducing the 
clearance of each other.  They both act on the gamma-aminobutyric acid (GABA) receptors 
resulting in a pharmacodynamic interaction as well90,91.   
 
 
31 Isobolograms and response surfaces 
 
The full dose-response relationship for two drugs can be displayed using a three dimensional 
representation.  Every combination of the two drugs (represented on the X and the Y axis, 
respectively drugs A and B) corresponds with a point on the vertical Z axis, the height of 
which is the drug effect.  Together, all these points will form a response-surface representing 
the relation between the effect and the administered combination of drugs.11,92  There are 
multiple steps between the administration of a drug and the effect, resulting in significant 
interindividual differences.  In order to describe the effect of interaction it is mandatory that 
patients receive comparable doses of each drug or, stated otherwise, that the concentration 
of the drugs is expressed in terms of effect-site concentration.   
 
Multiple mathematical models have been used to clarify interaction characteristics.  The 
result of these models can be presented in various graphs.  In an isobologram, the 
concentrations of two drugs are represented on the axes of a two dimensional figure.  Each 
point in the isobole represents a dose combination of the studied drugs, resulting in an equal 
effect.  If the drugs have an additive relationship the isobole is a straight line.  If the isobole 
deviates away from the origin, indicating that more drug is needed to achieve an equal 
effect, the relation is infra-additive.  If, in the opposite, the isobole bends towards the origin, 
the interaction is synergistic.11  Although isobolograms are valuable tools that can 
demonstrate the equal effect for a scala of drug concentrations, it must be clear that 
isobolograms have significant shortcommings.  First, the extent of interaction is not 
necessarily a constant in the total range of effect : drugs could exert synergism in the high 
effect range and show antagonism in the low effect range.93  This problem can be partially 
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circumvented by simultaneous plotting isobolograms of different levels of effect in one 
graph : a “multiple isobologram”.  Secondly, in certain interactions, the isobologram 
indicates both antagonism and synergy in different regions of the curve.94,95   
 
 
Figure 6 
Relationship between a response surface and a standard isobologram 
 
A three dimensional response surface offers the possibility to characterize the full concentration-response 
relation.  In fact, an isobolgram is a horizontal section of the response surface (e.g., 50% drug effect as in the 
right part of the picture).  A vertical section of the response surface yields to a dose response curve of one drug 
combined with a fixed concentration of the second drug.   
(Modified from Miller’s Anesthesia, 8th ed., Chapter 33, used with permission.) 
 
An extension of this method is a three dimensional graph wherein the drug concentrations 
are represented in the horizontal axes and the observed effect in the vertical axis.  It has the 
advantage that it offers the possibility to characterize the full concentration-response 
relation.  In fact isoboles are a horizontal section of the response surface.  Vertical sections 
parallel to one of the axes results in a dose response curve fore one drug combined with a 
constant concentration of the second drug.  Sections passing through the vertical axis and 
one of the horizontal axes describe the dose response curve for one of the drugs solely.  A 
vertical section through the origin of the coordinate system returns a dose response curve 
for one specific drug ratio.  Dose response curves from these different vertical sections can 
be described mathematically with a “Sigmoidal Emax model”.  Analogous to the technique of 
plotting multiple isobolograms in one graph, “multiple dose response curves” can be plotted.  
In that case several dose-response curves are plotted in the same graph, each with a 
different fixed concentration of the second drug.96,97  Vertical sections trough the origin 
result in a Hill-curve, illustrating the effect versus the dose of a certain drugratio.89,98   
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Although this model for representing drug interactions was first proposed in 1872 by Fraser 
reporting the antagonism between atropine and physostigmine, technical limitations and 
the fact that more complex mathematical approaches are advocated to generate a 3D 
surface yielded that the technique fell into disuse for several years.95,96,99  Despite its 
shortcomings, the intuitively attractive and in many circumstances easily usable 
isobologram, became very popular for many years.  In 1990, Greco induced a revival of the 
response surface and in the following ten years the response surface became the gold 
standard.10,11,89  Eight years later, Glass described an eminent paradigm shift of the definition 
of general anesthesia.4  He depicted the latter as a balance between a state of 
unconsciousness of the brain, mediated by hypnotics and on the other hand a form of 
inhibition of the noxious stimuli reaching the brain.  This inhibition can be mediated by the 
action of opioids at the opioid receptors situated in the spinal cord or by local anesthetics on 
periferal nerves.  With this idea in mind, a more physiological based concept, specifically 
mirroring the interaction between opioids and hypnotics, called the hierarchical model, was 
introduced in 2004.26   
 
 
32 Additivity, synergy and infra-additivity 
 
The concepts additive, synergistic and antagonistic interactions are intuitively easy to 
understand.  The knowledge of the effects evoked by the application of single drugs allows 
us to estimate the effect if two of those drugs are combined.  If the observed effect is more 
pronounced than expected it is called synergistic.  If the observed effect is equal to the 
estimation than it is termed additive.  In case of a less pronounced effect than expected 
from addition we name it antagonistic.  However, the problem is how to define “simple 
additivity”…  Moreover, the definition of “no interaction” is fundamental, since this will 
influence the nature of the interaction.100  Two commonly used concepts defining “no 
interaction” deserve a closer look : Loewe additivity and the Bliss independence.  Originally, 
both models were designed to describe simple enzyme reactions and both are equally logic, 
reasonable and theoretically underpinned.101,102   
 
 
321 Loewe additivity 
 
The concept of Loewe’s additivity is inseparable from the isobologram approach and is based 
on the idea that one drug cannot interact with itself.103  A straightforward way to clarify the 
concept of Loewe additivity is a sham experiment : presume that we administer a 
combination of drug A and drug B simultaneously, knowing that drug B is a dilution of drug 
A.  The effect evoked by the combination of drugs A and B will result in a straight line 
isobole, or the isobole defining “no interaction”, illustrating the basic principle : one agent 
cannot interact with itself.  This imaginary experiment also illustrates the limitations of the 
concept.  Drugs A and B could have different maximal effects or they could have different 
slopes in their dose-response relation making the isobole of “no interaction” a curved line.100  
Furthermore, in this concept, both drugs have the same site and mechanism of action.89,104   
Loewe additivity can be described mathematically by the following equation :  
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Equation 4 
ࡵ࢔࢚ࢋ࢘ࢇࢉ࢚࢏࢕࢔ ࡵ࢔ࢊࢋ࢞ =
ࢊ࡭
ࡰ࡭
+
ࢊ࡮
ࡰ࡮
 
 
In this equation dA and dB are the doses of drug A and B in a mixture evoking a specified 
effect (eg. 50 % of maximal effect).  DA and DB are, respectively, the doses of drug A and B, 
that evoke an equal effect when given alone.  If the interaction index equals 1 there is no 
interaction or there is an additive situation.  If the interaction index is less than 1, there is  
synergism and if the interaction index is more than 1 antagonism is noted.   
 
 
322 Bliss independence  
 
Bliss independence is based on probabilistic independence.  It implies that, if there is no 
interaction, two drugs behave completely independent from each other or they don’t 
cooperate biologically, chemically or physically.  This can be explained with the following 
example : assume that dose dA from drug A has an effect EA.  Similary, the response of drug B 
alone is EB.  Since the two drugs behave independently and the effects of drug A are already 
present, drug B can only elicit an effect on the remaining possible response : 1 – EA.  In case 
of an additive interaction the additional effect of drug B will be (1-EA) x EB.  Therefore the 
total effect due to the combination of drug A and drug B, presuming additive effect, will be 
EA + EB (1 – EA) which equals EA + EB – EA x EB .105  If the observed effect resulting from the 
combination of drug A and drug B, is more pronounced than the effect in case of Bliss 
independence, the interaction is called synergistic.  If, in contrast, the observed effect is less 
pronounced the interaction is called antagonistic.106  As for Loewe additivity, the maximal 
effect of both drugs has to be equal.  In contrast to the concept of Loewe additivity, Bliss 
independence is not consistent with an isobolographic approach.107   
 
 
33 Interaction models in anesthesiology 
 
The graphical representation of an interaction is the result of a mathematical model.  Today, 
several models have been proposed to describe hypnotic-opioid drug interaction.   
 
As described in the previous section, a vertical section of the response surfaces results in a 
so-called “Sigmoid Emax model”.  The Hill-equation (Equation 5) is widely used to describe the 
relationship between the effect (E) and the drug concentration (C).   
 
 
27 
 
Equation 5 
ࡱ = ࡱ࢓ࢇ࢞ ൬
࡯ࢽ
ࡱ࡯૞૙ࢽ + ࡯ࢽ
൰ 
 
 
EC50 is the drug concentration for which 50% of maximum effect is obtained and γ defines 
the slope and is called the “Hill coefficient of sigmoidicity”.87  Regarding the same effect, 
large differences in potency between various drugs can exist.  This can be overcome by using 
normalized concentrations : for two drugs with different potency the maximal effect 
corresponds with a normalized concentration equal to 1.  In mathematical terms the 
normalized concentration, U, is the concentration divided by the EC50.  This transforms 
Equation 5 into :  
 
Equation 6 
ࡱ = ࡱ࢓ࢇ࢞
ቀ ࡯ࡱ࡯૞૙
ቁ
ࢽ
૚ + ቀ ࡯ࡱ࡯૞૙
ቁ
ࢽ  = ࡱ࢓ࢇ࢞
ࢁࢽ
૚ +  ࢁࢽ
 
 
With little rearrangement of the formula the effect can be expressed as a percentage of the 
maximal effect or as a probability of no response for dichotomous data.   
 
Equation 7 
ࡼ = ࡱ/ࡱ࢓ࢇ࢞ =
ࢁࢽ
૚ + ࢁࢽ
 
 
If the probability or an extent of effect are predefined, U can be calculated from this 
formula.  In case of drug interaction U can be replaced by the appropriate equation, 
obtained from the interaction model.  Regarding interaction between opioids and hypnotics, 
different models have been proposed : the logistic regression model, the Greco model, the 
reduced Greco, the Minto model, the Hierarchical model and finally the modified 
Hierarchical model.   
 
 
331 The logistic regression model 
 
The logit is a term used in mathematics to describe the negative natural logarithm of the 
odds ratio.  Drug- response models of single drugs are frequently modelled using a logistic 
regression model using the logit as a linear function of drug concentration.  This responds in  
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Equation 8 
࢒࢕ࢍࢋ(࢕ࢊࢊ࢙ ࢘ࢇ࢚࢏࢕) = ࢒࢔ ൬
ࡼ
૚ − ࡼ
൰ = ࢼ૙ + ࢼ૚ ∙ (࡯) 
 
where P is the probability of effect and where β0 and β1 are modelled parameters.  After 
some algebra and substituting β0 with -γ∙ln(C50) and β1 with γ it results in Equation 7.  Several 
drug interactions have been modelled by making use of an extension of a logistic regression 
model for single drug responses.18,28,31  However, the multiple logistic regression approach 
has several shortcomings, advocating other modelling techniques, based on accepted 
pharmacodynamic principles.11   
 
 
332 The Greco model 
 
The Greco model is a response surface model based on an extrapolation of the equations 
describing the 50 % effect isobole of Loewe.10  It was designed with the objective to provide 
a quantitative assessment of drug interaction.   The model is characterized by an 
“interaction” or “non-additivity” parameter α, reflecting the type and magnitude of 
interaction :  
 
Equation 9 
૚ = ࢁ࡭ + ࢁ࡮ + ࢻ ࢁ࡭ ࢁ࡮ 
 
UA and UB are respectively the normalized effect site concentrations of drug A and B.  If α = 0 
there is additivity (or no interaction).  If α is positive, synergism exists and the isobole bends 
toward the origin.  If α is negative the interaction can be described as antagonistic.  Keeping 
the 50% effect in mind and applying this in Equation 7, U equal to 1, is obtained.  After 
extrapolation to the whole spectrum, U symbolizes the normalized effect site concentration 
of the drug combination yielding to :  
 
Equation 10 
ࢁ = ࢁ࡭ + ࢁ࡮ + ࢻ ࢁ࡭ ࢁ࡮ 
 
The Greco model has some constraints : Firstly, the Hill coefficient γ is a constant for all drug 
combinations of A and B.  Inherently the slope factor of the dose response curve for the 
single drugs should be similar.  Secondly, the maximal effect of both drugs should be 
identical.  Thirdly, the interaction parameter α is a constant for the entire range of effect and 
consequently does not allow different levels of interaction at different levels of effect.   
 
It is well known that opioids cannot reliably produce amnesia or hypnosis.108,109  This 
phenomenon will yield to unrealistic high estimations of the opioid EC50, making the 
assumption regarding the equal maximal effect, hard to accept.  In situations where one 
drug of the two drug combination has only a modulating effect on the other drug but no 
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effect by itself, Greco proposes a reduced, but fundamentally different form of his model.10  
This transforms Equation 10 to :  
 
Equation 11 
ࢁ = ࢁ࡭ + ࢻ ࢁ࡭ ࢁ࡮ 
 
In analogy with the pervious equation U is the normalized effect site concentration of the 
drug combination, UA, UB, are respectively the normalized effect site concentration of the 
hypnotic (UH) and the opioid (UO), α is the interaction parameter.  In this concept absence of 
a direct hypnotic effect of the opioids is postulated.  Consequently, the hypnotic effects of 
opioids are presumed a potentiation of the hypnotic drug.  However, circumventing this 
problem creates another : α and UO can never be estimated independently.97  With 
exception of the restriction concerning the maximal effect, it is clear that the reduced form 
of the model suffers from the same limitations as the original model.   
 
 
333 The Minto model 
 
The Minto model introduces a new parameter, θ, representing a concentration ratio of the 
studied drugs.11  Then for every θ, a classic Sigmoidal Emax model is made, resulting in a 
response surface.  In this concept every ratio of the studied drugs is considered as a new 
drug, for which a dose response curve is made.   
 
Equation 12 
ࣂ =  
࡮
࡭ + ࡮
 
 
After normalization of the drug concentration, Equation 12 becomes :  
 
Equation 13 
ࣂ =  
ࢁ࡮
ࢁ࡭ +  ࢁ࡮
 
 
As reflected by the formula θ is a dimensionless number between 0 (only drug A) and 1 (only 
drug B).  The drug concentration is equal to UA + UB.  If we apply this concept and combine it 
with Equation 6 the following formula emerges :  
 
Equation 14 
ࡱ = ࡱ૙ +  (ࡱ࢓ࢇ࢞ − ࡱ૙) 
൬ࢁ࡭ + ࢁ࡮ࢁ૞૙(ࣂ)
൰
ࢽ(ࣂ)
૚ + ൬ࢁ࡭ + ࢁ࡮ࢁ૞૙(ࣂ)
൰
ࢽ(ࣂ) 
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In this formula E0 is the baseline effect, Emax the peak effect, the drug concentration is equal 
to UA + UB and γ(θ) is the slope for that specific drug ratio θ.  The best description of the 
term U50(θ) is provided in Minto’s report : “U50(θ) is the potency of the drug combination at 
ratio θ relative to the normalized potency of each drug by itself.”11   
 
The true significance of this statement is easier to understand when it is illustrated with 
examples : suppose only drug B is present in a concentration evoking an effect equal to 50% 
of the maximal effect.  It is clear that the concentration of B is equal to C50,B.  Since drug A is 
absent, θ must be equal to 1.  Furthermore, UA must be 0 and UB must be 1, making the total 
drug concentration UA + UB equal to 1.  If we substitute the different parameters from 
Equation 14 with this data, it becomes clear that U50(θ), must be equal to 1.  If the same 
method of deduction is used with the assumption that only drug A is present in a 
concentration C50,A, then U50(θ) = 1 is found again.   
 
Now imagine a situation in which drug A and drug B are present in a concentration equal to 
½ C50 of that drug, being ½ C50,A and ½ C50,B.  In this case θ = 0,5, UA = 0,5, UB = 0,5 and the 
total concentration UA + UB = 1.  If the combination is additive they should elicit an effect 
equal to 50% of the maximal effect, since they are both present in exactly one half of the 
concentration that would evoke an effect of 50% in the case that they were administered 
alone.  In the case of additivity at θ = 0,5, U50(θ) is equal to 1.  However, if there is synergy at 
this drug ratio θ, the effect resulting of this concentration will be more than 50% of the 
maximal effect.  Stated another way : when drugs A and B are combined in ratio θ, lower 
concentrations of drugs A and B than the respective concentrations ½ C50,A and ½ C50,B will be 
sufficient to evoke 50 % of maximal effect.  This will result in U50(θ) < 1.  In summary : if the 
value of U50(θ) is equal to 1 the effect is additive at drug ratio θ, if the value of U50(θ) > 1 the 
effect is antagonistic at drug ratio θ and finally if U50(θ) < 1 the interaction is synergistic for 
drug combination θ.   
 
The basic principle of the Minto model is a θ for every drug combination and a 
corresponding sigmoidal Emax model for that θ.  Consequently there is an Emax, an U50, and an 
γ for every drug ratio θ.  Minto describes this parameters of the model using fourth-order 
polynomials.  Using the formulae (Equation 15), Emax(θ), U50(θ) or γ(θ) can be calculated for 
every θ, if f(θ) is replaced.  β0, β1, β2, β3, β4 are estimated from the data.   
 
Equation 15 
ࢌ(ࣂ) = ࢼ૙ +  ࢼ૚ ࣂ +  ࢼ૛ ࣂ૛  +  ࢼ૜ ࣂ૜ +  ࢼ૝ ࣂ૝ 
 
Fortunately, a lot of interactions can be described by a less complex quadratic function, 
resulting in a isobole with a simple inward or outward curvature and simplifying Equation 15 
to :  
 
Equation 16 
ࢌ(ࣂ) = ࢼ૙ +  ࢼ૚ ࣂ +  ࢼ૛ ࣂ૛ 
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It also needs only one coefficient to be estimated from the data.  This can be illustrated by 
applying Equation 16 for U50(θ).  When only drug A is present, and thus θ = 0, this will yield 
to U50(θ) = U50(0) = U50,A = β0.  When only drug B is present and consequently θ = 1, it will 
yield to U50(θ) = U50(1) = U50,B = β0 + β1 + β2 (cfr. Appendix 1 ).  Combining those equations 
results in  
 
Equation 17 
ࢁ૞૙(ࣂ) = ૚ − ࢼ૛,ࢁ૞૙ࣂ + ࢼ૛,ࢁ૞૙ࣂ
૛ 
 
Equation 17 states that if β2, U50 is 0, then U50(θ) = 1.  Applying this in Equation 14 makes 
clear that the interaction will be additive.  In case that β2, U50 is positive, U50(θ) must be less 
than one because θ is a number between 0 and 1.  Substituting this in Equation 14 reveals a 
greater effect than expected with U50(θ) equal to 1, and consequently synergy.  It is clear 
that if the data would yield to a negative β2, U50 the interaction is infra-additive.   
 
This model is very versatile, even allowing modeling of triple drug interaction.  In that case a 
θ for every drug can be defined as the proportion of each drug present.  Accordingly θA + θB 
+ θC = 1.  Like in the two drug model, for every fixed ratio of θA and θB, a sigmoidal relation 
between concentration and effect exists.  Equation 13 and Equation 14 can be rewritten as :  
 
Equation 18 
ࣂ࡭ =
ࢁ࡭
ࢁ࡭ + ࢁ࡮ + ࢁ࡯
 
 
Equation 19 
ࡱ = ࡱ૙ +  (ࡱ࢓ࢇ࢞ − ࡱ૙) 
൬ࢁ࡭ + ࢁ࡮ + ࢁ࡯ࢁ૞૙(ࣂ࡭, ࣂ࡮)
൰
ࢽ(ࣂ࡭,ࣂ࡮)
૚ + ൬ࢁ࡭ + ࢁ࡮ + ࢁ࡯ࢁ૞૙(ࣂ࡭, ࣂ࡮)
൰
ࢽ(ࣂ࡭,ࣂ࡮)
 
 
Despite the tremendous flexibility, the Minto model has limitations.  When the polynomials, 
describing the interaction, are a quadratic function, both drugs have to be able to exert the 
same maximum effect.  Furthermore the quadratic function tends to produce a “dip” in the 
isoboles estimated by the model.   
 
334 The Hierarchical model 
 
Greco already suggested a comprehensive mechanistic mathematical approach could be 
beneficial.  In 2004 Bouillon publishes the hierarchical model.26  The concept of the model is 
mainly based on the balance between a state of unconsciousness of the brain, mediated by 
hypnotics and on the other hand a form of inhibition of the noxious stimuli reaching the 
brain.  Hereby making use of the neuro-physiological insights in general anesthesia proposed 
by Glass.4   
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Analgetics are considered to have an effect on the spine, the midbrain and the thalamus, 
thereby attenuating the response of a noxious stimulus.  Hypnotics are supposed to 
generate cortical suppression resulting in a balance between ascending noxious stimuli and 
drug induced cortical suppression.  A graphical representation of the model resembles Figure 
7.   
 
 
Figure 7 
Hierarchical model of opioid–hypnotic drug interaction. Painful stimulus is first attenuated by the action of 
opioids.  The potency of the opioids in attenuating pain decreases (e.g., shifts to the right) with increasingly 
painful stimulation.  The attenuated signal then projects to the cortex, where hypnotics act to modulate the 
probability of response. Similar to opioids, the ability of the hypnotic to attenuate the response is shifted 
rightward with increasing stimulus.26   
 
 
 
The intensity of the stimulus will influence the concentration of the opioid needed to 
attenuate the stimulus.110  This is reflected in the following relation :  
 
Equation 20 
ࡼ࢕࢙࢚ࡻࡵ = ࡼ࢘ࢋࡻࡵ × ൬૚ −
ࡻࢽ
ࡻࢽ + (ࡻ૞૙  ×  ࡼ࢘ࢋࡻࡵ)ࢽ
൰ 
 
In this formula, PreOI represents the intensity of the afferent noxious stimulus, O is the 
opioid concentration and PostOI stands for postopioid intensity which is the intensity of the 
stimulus after attenuation of the stimulus due to the influence of opioids.  O50 is the 
concentration of opioids that results in a reduction of the postopioid intensity of 50%. γ is 
the steepness of the relation between the opioid concentration and the degree of 
attenuation of the stimulus.  By multiplying the preopioid intensity with the O50, the 
influence of the potency of the opioids to blunt responses and the influence of the stimulus 
intensity becomes apparent.   
 
 
 
33 
 
In the next hierarchical level the postopioid intensity is transferred to the cortex.  Here the 
central nervous depressant characteristics of the hypnotics counteract the incoming 
stimulus in an attempt to avoid arousal.  Mathematically this can be expressed as :  
 
Equation 21 
ࡼࡺࡾ =
ࡴ࣐
ࡴ࣐ + (ࡴ૞૙ × ࡼ࢕࢙࢚ࡻࡵ)࣐
 
 
Where PNR is the probability of non-responsiveness to a certain stimulus, H is the 
concentration of the hypnotic drug, H50 is the concentration resulting in a 50% PNR when the 
postopioid intensity is equal to 1, and φ is the slope of the relation between the 
concentration and the probability of non-responsiveness.  In this perspective, the O50 must 
be seen as opioid concentration resulting in a 50% reduction of the concentration of 
hypnotics compared with the concentration of the hypnotic without opioids, to obtain the 
same effect.   
 
In this concept, it is obvious that the postopioid intensity has to exceed 0, even in the 
unstimulated patient.  Furthermore, after some mathematics, it becomes clear that the only 
difference between a model for the probability of no response to shaking and shouting 
(Phypnosis) and a model for the probability of no response to laryngoscopy (Plaryngoscopy) is the 
estimate of the preopioid intensity of the stimulus (cfr. Equation 22, Appendix 2  
 
Equation 22 
ࢁ =
ࢁࡴ
ࡼ࢘ࢋࡻࡵ
ቆ૚ +
ࢁࡻࢽ
ࡼ࢘ࢋࡻࡵࢽ
ቇ 
 
If different stimuli result in an equal effect then U must be equal in the two conditions, 
consequently this results in different O50’s (or H50’s) for the different stimuli.  Or stated 
otherwise : the potency of opioids and hypnotics can be set in relation to the preopioid 
stimulus intensity.  This makes it possible to compare the intensities of different stimuli by 
comparing the respective C50’s.   
 
335 The Modified Hierarchical model  
 
In 2010, the hierarchical model was modified in order to increase parsimony and adopting 
the simplest formulation of the formulae, while retaining it’s essential features.27  The 
original and the modified hierarchal opioid-hypnotic interaction models are compared in 
Figure 8 (respectively part A and B).  Because unconscious anesthetized patients do not feel 
pain, these terms are replaced by “stimulus”.  Secondly, because the data of the original 
study26 estimated the slope factor almost equal to 1, the model was collapsed to a fractional 
Emax model.  Mathematically this can be expressed with the following formula :  
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Equation 23 
ࡼ࢕࢙࢚ࡻࡵ = ࡼ࢘ࢋࡻࡵ × ൬૚ −
ࡻ
ࡻ+ࡻ૞૙
൰ 
 
 
Where PostOI is the stimulus intensity after attenuation by the opioid, PreOI is the intensity 
of the incoming stimulus, O is the effect-site opioid concentration and O50 is the effect-site 
opioid concentration associated with a 50% reduction of preopioid intensity.  Therefore, the 
O50 does not represent the opioid concentrations associated with half maximal effect on the 
probability of tolerating the stimulus but it is the ability to increase the effectiveness of the 
hypnotic by altering the respective Ce50 of the hypnotic.   
 
Independent estimation of the preopioid intensities or C50’s for different intensities of 
stimuli is not possible with the hierarchical model.  If only one stimulus is investigated the 
preopioid intensity can be fixed to 1.  If more stimuli are investigated other preopioid 
intensities can be compared to a reference stimulus with the intensity of 1.   
 
In the original model, the multiplication of the C50 of the opioid with the preopioid pain 
intensity was believed to be necessary to account for the fact that higher opioid 
concentrations are needed to attenuate more severe pain.  Although not obvious, this 
behavior is also displayed by the modified model.  It is therefore the absolute value of 
postopioid intensity and the C50 of the hypnotic that determine the concentration of 
hypnotic needed to achieve a certain probability of non-responsiveness for a certain 
preopioid stimulus strength.   
 
The next hierarchical step in the modified model, the calculation of probability of tolerance 
to an incoming stimulus for a certain postopioid intensity, is unchanged compared to the 
original model (cfr. Equation 21).   
 
Under the assumption that the opioid potency (O50) is identical for fractional suppression of 
stimuli of different strength and secondly that preopioid intensity of the reference stimulus 
is 1, the ratio of the respective H50’s can be set in relation to the relative strength of the 
different stimuli.  This fixed opioid potency explains that the Modified Hierarchical model is 
sometimes called “the Fixed C50 model” in contrast to “the Scaled C50 model” or Hierarchical 
model.   
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Figure 8 
 
Comparison of the original and the modified hierarchal opioid– hypnotic interaction model.  The endpoint of 
the opioid–hypnotic interaction is the probability of response (Presponse, original model, A) or nonresponse to 
a stimulus (Pnonresponse, modified model,B).  The incoming stimulus is attenuated by the presence of an 
opioid.  Presponse or Pnonresponse is dependent on the strength of the attenuated stimulus, the hypnotic 
drug concentration, and the hypnotic drug concentration associated with a 50% probability of 
response/nonresponse (C50hypnotic).  In the original model (A), the incoming stimulus (“pain in”) of a 
strength-labeled preopioid intensity on the y-axis is attenuated by the opioid (on the x-axis) according to a 
negative Emax model resulting in an afferent stimulus with a strength that is a fraction of preopioid intensity.  
The pre-opioid stimulus intensity and the slope parameter of this Emax model are estimated from the data.  
The projected pain (“pain proj”) refers to the intensity of the attenuated stimulus transmitted to the central 
nervous system (also labeled as “afferent stimuli” in the original model).  Presponse is estimated from a 
negative Emax model.  In the modified model (B), the terms pain in and pain proj are replaced by “stimulus in” 
and “stimulus proj,” respectively because unconscious anesthetized patients do not feel pain.  Attenuation of 
preopioid intensity follows a fractional Emax model with a fixed slope constant of 1.  The C50opioid (dashed 
arrow) is the opioid concentration reducing the strength of preopioid intensity by 50%.  Pnonresponse is 
estimated with a positive Emax model, including the parameters postopioid intensity, current hypnotic drug 
concentration (x-axis), and the C50hypnotic (dotted arrow).27   
 
 
 
In summary the differences between the modified and the original hierarchical model are :  
- In the modified model the slope of the relation between postopioid intensity and 
opioids is equal to 1.   
- In the modified model the preopioid intensity has no influence on the O50 
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- In the modified model the preopioid intensity of the reference stimulus is equal 
to 1.   
 
 
The principle that different H50’s correspond with different strengths of stimuli has been the 
basis of the development of the Noxious Stimulation Response Index (NSRI).  This index is 
proposed to predict the likelihood of response to a noxious stimulus, and uses the modified 
hierarchical model to correlate the effect site concentrations of the hypnotics and opioids to 
correlate these with the probability of non-responsiveness to laryngoscopy.   
 
 
4 Developing models and response surfaces : efficient trial design 
 
Short and coworkers studied the influence of different study designs on the number of 
patients needed to describe an entire response surface adequately.  To do that, they 
created, depending on the study design, virtual plasma, effect-site concentrations and 
effects by applying different pharmacokinetic, pharmacodynamic and interaction models on 
data of virtual patients.12,111–113  A well-defined variability was added each step of the 
process to generate realistic data (as would be elicited in real patients).  The simulated data 
where then modelled, depending on the study design and secondly on the number of 
included virtual patients.  The models, best describing the simulated data, originating from 
different study designs and different numbers of included patients, were then compared 
with each other and with the known, predefined model.  By handling this way, the authors 
were able to select the design that resulted in the most robust model with the least patients 
needed to develop the model.   
 
In the crisscross design, drug A was held constant at a variety of steady state concentrations 
in half of the patients.  Simultaneous incremental doses of drug B were given up to 
maximum effect.  In the other half of the patients, drug B was held constant and the 
concentration of drug A was augmented up to maximum effect.  This approach seems to be 
the most efficient to determine the original response surface, using the least number of 
patients.  Furthermore, it had also some additional advantages : more than other study 
designs it mimics the way drugs are used clinically; concentrations of one drug are usually 
altered in response to clinical circumstances.  Compared to other designs, the crisscross 
design has the advantage that the data of each patient will frequently intersect parts of the 
surface covered by data originating from other patients, so outliers are less able to skew the 
surface.  The symmetrical design seems to be better able to discriminate a skewed surface 
accurately.   
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ABSTRACT 
 
Background: Various pharmacodynamic response surface models have been developed to 
quantitatively describe the relationship between two or more drug concentrations with their 
combined clinical effect.  We examined the interaction of remifentanil and sevoflurane on 
the probability of tolerance to shake and shout, tetanic stimulation, laryngeal mask airway 
insertion, and laryngoscopy in patients to compare the performance of five different 
response surface models.   
 
Methods: Forty patients preoperatively received different combined concentrations of 
remifentanil (0–12 ng/ml) and sevoflurane (0.5–3.5 vol.%) according to a criss-cross design 
(160 concentration pairs, four per patient).  After having reached pseudosteady state, the 
response to shake and shout tetanic stimulation, laryngeal mask airway insertion, and 
laryngoscopy was recorded.  For the analysis of the probability of tolerance, five different 
interaction models were tested : Greco, Reduced Greco, Minto, Scaled C50O Hierarchical, 
and Fixed C50O Hierarchical model.  All calculations were performed with NONMEM VI (Icon 
Development Solutions, Ellicott City, MD).   
 
Results: The pharmacodynamic interaction between sevoflurane and remifentanil was 
strongly synergistic for both the hypnotic and the analgesic components of anesthesia.  The 
Greco model did not result in plausible parameter estimates.  The Fixed C50O Hierarchical 
model performed slightly better than the Scaled C50O Hierarchical and Reduced Greco 
models, whereas the Minto model fitted less well.   
 
Conclusion: We showed the importance of exploring various surface model approaches 
when studying drug interactions.  The Fixed C50O Hierarchical model fits our data on 
sevoflurane remifentanil interaction best and appears to be an appropriate model for use in 
hypnotic-opioid drug interaction.   
 
This article is accompanied by an Editorial View.  Please see :  
Shafer SL : All models are wrong.  ANESTHESIOLOGY  2012; 116:240–1. 
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Pharmacodynamic response surface models are three or more dimensional structures that 
have been developed to quantitatively describe the relationship between two or more drug 
concentrations with their combined clinical effect.  Response surface models are powerful 
representations of drug interactions, because they combine information about any isobole 
and the concentration-response curve of any combination of the drugs involved.1,2  Using 
the mathematically defined response surface, the corresponding drug effect for any two or 
more drug concentrations of the interacting drugs can be predicted.1,3   
Various methodological approaches to response surface models are found in the 
literature.  Bol et al. further developed a previously published response surface model by 
Greco et al. to describe the interaction between dexmedetomidine and midazolam in rats.4,5  
The Greco model can be considered as the basic approach to describe quantal response 
surface models, since it is the original and most simple model for drug interaction.  As this 
model assumes identical slope factors and identical maximal effects for the single 
concentration effect courses of the interacting drugs, Minto et al. extended the Greco model 
to make the response surface modeling more flexible.  They defined a variable (originally 
called θ) as the proportion of one drug in the combination of two potentially interacting 
drugs.1  More recently, Bouillon et al. developed a novel mechanistic approach to the 
interaction between opioids and hypnotics.  Using the knowledge that analgesia represents a 
drug action on ascending neuropathways and that hypnosis is a cortical response that 
balances the ascending noxious stimulus against drug-induced cortical suppression, they 
quantified opioid-hypnotic drug interaction in a sequential (also called hierarchical) model.6  
As some of the authors of the original paper thought that the initial form of their hierarchical 
model was overparameterized,2 they designed a less complex form of the model, hereby 
called the Fixed C50O Hierarchical model,7 which is now applied in one of the commercially 
available drug interaction displays (Smart Pilot View, Drager, Lubeck, Germany).  In contrast 
to the Greco and Minto models, the Scaled C50O and Fixed C50O Hierarchical models 
approach comes more close to the clinical pharmacological and physiologic reality.   
To characterize the interaction between sevoflurane and remifentanil in blunting 
responses to verbal (Observer’s Assessment of Alertness/Sedation scale) and painful stimuli 
(pressure algometry, electrical tetanic stimulus, and thermal stimulation), Manyam et al. 
constructed a response surface for each pharmacodynamic response using a Logit model 
approach and found synergy between sevoflurane and remifentanil for all responses.8  As 
this study suffered from nonsteady-state conditions at the moment of measurements, the 
authors reevaluated their data using effect-site sevoflurane concentrations and a Greco 
model instead of a Logit approach.9  Accounting for the lag time between sevoflurane effect-
site concentration and end-tidal concentration improved the predictions of responsiveness 
during anesthesia but had no effect on predicting a response to a noxious stimulus in the 
recovery room.  They concluded that models may be useful in predicting events of clinical 
interest but largescale evaluations with numerous patients are needed to better characterize 
model performance.  Also, they did not test if other response surface models would describe 
the data more accurately.   
The aim of this study was to quantify the pharmacodynamic interaction between 
sevoflurane and remifentanil in patients and to investigate the performance of different 
interaction models to predict the likelihood of response.  Quantal responses to different 
clinically relevant hypnotic and noxious stimuli were studied.   
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1 Materials and Methods 
This study used a similar study design as our previously published report.10   
11 Subjects 
After obtaining Institutional Review Board approval (Ghent University Hospital Ethics 
Committee, Gent, Belgium) and prospective trial registration at ClinicalTrials.gov 
(NCT00522587), as well as written informed consent, 40 American Society of 
Anesthesiologists status I or II patients, aged 18 to 60 yr, and scheduled to undergo surgery 
requiring general anesthesia, were included.  Patients were allowed to take their usual 
medication.  Exclusion criteria were weight less than 70% or more than 130% of ideal body 
weight, neurologic disorder, diseases involving the cardiovascular system (hypertension, 
coronary artery disease, prior acute myocardial infarction, any valvular and/or myocardial 
disease involving decrease in ejection fraction, arrhythmias, which are either symptomatic or 
require continuous medication/pacemaker/automatic internal cardioverter defibrillator), 
pulmonary diseases, gastric diseases, endocrinologic diseases, and recent use of 
psychoactive medication or more than 20 g of alcohol daily.  The complete study was 
executed in a quiet operation room before the start of the surgical procedure.   
12 Study Design 
This study was performed as a randomized, prospective, open-label study.  After the 
unpremedicated patients arrived in the operating room, standard monitors 
(electrocardiogram, noninvasive blood pressure, SpO2), M-entropy using a Datex S/5 
Anesthesia Monitor (GE Healthcare, Helsinki, Finland) and bispectral index using a Aspect A-
2000 monitor (Covidien, Norwood, MA) were connected, and a large forearm vein was 
cannulated.  Thereafter, the patients were preoxygenated with 6 l/min O2 at a FI  1.0 for 5 
min, using a tight-fitting facemask, which also served to sample exhaled air for end-tidal 
carbon dioxide measurement.  All medical devices are approved for the purposes applied in 
the study.  All drugs and the way of administration, either alone or in combination, are 
approved for clinical use under the studied conditions.  No “off label” drug applications were 
used (European situation).  Vital signs as well as end-tidal sevoflurane concentrations, 
respiratory data (tidal volume, minute volume, end-tidal carbon dioxide), and infusion 
related data (predicted concentrations, amounts infused) were continuously recorded on a 
computer hard disk using RUGLOOP II data recording software (Demed, Temse, Belgium).   
13 Drug Administration 
131 Technical Aspects.  
Remifentanil was administered by using a target-controlled infusion technique based on a 
three-compartment model and an effect-site compartment as published by Minto et al.11,12  
Remifentanil infusion was administered by using an Alaris Asena pump (Carefusion, 
Basingstoke, United Kingdom).  RUGLOOP II TCI driver (Demed) controlled the pump at 
infusion rates between 0 and 1,200 ml/h via an RS-232 interface.  Sevoflurane was 
administered in 50% O2 and 50% air by using a standard out of circle vaporizer and a 
standard breathing circuit of an ADU anesthesia workstation (Datex/Ohmeda, GE 
Healthcare).  In all steps, the sevoflurane vaporizer was set to maximum until 80% of the 
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target concentration was reached, then it was turned down to the target setting. A fresh gas 
flow above minute ventilation was used throughout the study.   
132 Dosing Regimen.  
The study design was a modification of the criss-cross design proposed by Short et al.3  The 
choice of the sevoflurane/remifentanil concentrations pairs were based on the sevoflurane 
Ce50 (Ce50sevo) to suppress the response to skin incision (minimal anesthetic concentration, 
MAC) of 1.85%13 and a remifentanil Ce50 (remifentanil concentration reducing the MACSEVO 
by 50%) of 1.5 ng/ml14 :  
opioid effect = CeREMI/(Ce50REMI  + CeREMI) 
CeSEVO(norm) = (CeSEVO/Ce50SEVO)/(1 - opioid effect) 
 
where opioid effect is the relative effect of remifentanil on Ce50SEVO, CeREMI is the effect-site 
concentration of remifentanil, CeSEVO is the effect-site concentration of sevoflurane, and 
CeSEVO(norm) is the effect-site concentration of sevoflurane normalized to MAC, taking into 
account the opioid effect.   
We randomized 40 patients to receive specific combinations of sevoflurane and 
remifentanil as simulated and described in the next paragraph.  Before induction the 
subjects were randomly assigned to receive four prespecified pairs of sevoflurane and 
remifentanil concentrations.  In half of the patients, remifentanil was held constant, and 
sevoflurane was stepwise increased; in the other half, sevoflurane was held constant and 
remifentanil was stepwise increased (table 1).  For each of the 10 escalating combinations, 
three patients were included.  To study the boundaries of the response surface (single drug 
without interaction), five patients were given sevoflurane only (0.7 to 3.5 vol.%) and five 
were given remifentanil (2–12 ng/ml) during the study period.  The maximum CeSEVO was set 
at 3.5 vol.%, and maximum CeREMI was set at 12 ng/ml.  A maximum of four steps was used to 
explore a single slice of the response surface.  No other drugs were given, except for a 
possible 0.1 mg bolus of phenylephrine if mean arterial blood pressure dropped below 50 
mmHg.   
14 Assessment of Clinical Response 
For each concentration step, the clinical response was assessed 12 min after reaching the 
target concentrations to allow for plasma effect-site equilibration.  The patient was exposed 
to the following series of stimuli with increasing intensity: (1) verbal and nonpainful tactile 
stimuli according to the Observer’s Assessment of Alertness/Sedation (OAA/S score)15 (an 
OAA/S score less than 2 was considered as tolerant); (2) a tetanic stimulus of the ulnar nerve 
for 5 s by using the standard neurostimulator used in the clinical setting to test the level of 
muscle relaxation (100 Hz, 60 mA, Tristim NS3A peripheral nerve stimulator; Life Tech, 
Houston, TX); (3) insertion of a laryngeal mask airway (LMA size 3 for women and 4 for men, 
LMA Unique®, The Surgical Company, Amersfoort, The Netherlands); (4) laryngoscopy aiming 
at full visualization of the vocal chords by using a size-3 curved Macintosh-type blade (HEINE 
Optotechnik GmbH & Co KG, Herrsching, Germany).  Verbal response, eye opening, 
grimacing, coughing, withdrawal, or any other purposeful or nonpurposeful movement, 
including jaw clenching and bucking after a stimulus, were defined as a response.  Absence 
of a response implied tolerance of the stimulus and was labeled 0, and presence of a 
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response implied no tolerance of the stimulus and was labeled 1 in the case report form.  All 
assessments were performed by one investigator to minimize interobserver variability.  If 
there was no response to the first stimulus, the next stimulus was applied 1 min after the 
response assessment of the first.  The assessment at each drug concentration level was 
stopped as soon as a response was observed or the patient tolerated laryngoscopy.  If there 
was no response to laryngoscopy at the highest predefined drug combination, data 
acquisition was stopped, and the patient’s trachea was intubated after the administration of 
0.9 mg/kg rocuronium.   
Table 1. Concentration Grid of Study Design   
   
MAC 
Multiples  
Patients Remifentanil Sevoflurane (Minimum– 
(n) (ng/ml) (vol.%) Maximum) 
5 0 0.7, 1.5, 2.5, 3.5 0.4–1.9 
3 1 0.7, 1.5, 2.5, 3.5 0.6–3.2 
3 2 0.5, 1.5, 2.5, 3.5 0.6–4.4 
3 3 0.5, 1.0, 1.5, 2.5 0.8–4.1 
3 4 0.5, 1.0, 1.5, 2.5 1.0–5.0 
3 6 0.5, 0.75, 1.0, 1.5 1.4–4.1 
   MAC 
Multiples  
Patients Sevoflurane* Remifentanil (Minimum– 
(n) (vol.%) (ng/ml) Maximum) 
5 0.5 2, 4, 8, 12 0.6–2.4 
3 0.75 0, 4, 8, 12 0.4–3.6 
3 1.0 0, 1, 4,10 0.5–4.1 
3 1.5 0, 1, 3, 6 0.8–4.1 
3 2.0 0, 1, 2, 4 1.1–4.0 
3 2.5 0, 1, 2, 4 1.4–5.0 
* A 0 vol.% sevoflurane group has been omitted for ethical reasons; with 
0.5 vol.% sevoflurane, a minimum of 1 ng/ml remifentanil is administered. 
MAC = minimal anesthetic concentration  
 
15 Pharmacodynamic Analysis of Quantal Responses 
The four quantal responses, defined as tolerance to shaking and shouting, tolerance to a 5 s 
tetanic stimulus, tolerance to LMA insertion, and tolerance to laryngoscopy were modeled 
using five interaction models: Greco model,4,5 Reduced Greco model,2,16 Minto model,1 
Scaled C50O Hierarchical model,6 and Fixed C50O Hierarchical model.2,7  Details of the models 
can be found in the appendix.   
An OAA/S score of 0–1 was considered as tolerant to shaking and shouting, and a 
score of 2–5 as responsive.   
For remifentanil, the targeted effect-site concentration after 12 min of equilibration 
was considered as the steady-state concentration taking into account the reported11,12 age-
dependent equilibration half-time of 0.94, 1.32, and 2.20 min for 20, 50, and 80 yr, 
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respectively, and was used as the remifentanil effect-site concentration (CeREMI) in the 
analysis.  For sevoflurane, the alveolar concentration measured by the S5 Anesthesia 
Monitor (GE Healthcare) via end-expiratory measurement after 12 min of equilibration was 
considered as the steady state concentration, and was used as sevoflurane effect-site 
concentration (CeSEVO) in the analysis.  To reduce data noise in CeREMI and CeSEVO, the median 
value of 11 measurements at 5 s intervals during 1 min preceding the assessment of the 
OAA/S score were used.  The duration of equilibration of 12 min was five times the reported 
equilibration half-life for sevoflurane of 2.4 min.17   
In the current data set it was observed in several cases that the patient was tolerant 
to a stimulus, whereas the same patient was responsive to the preceding, a priori considered 
less intense stimulus.  Therefore the approach described by Bouillon et al.6 and by 
Schumacher et al.,10 combining the observed responses to the four stimuli into a single 
value, could not be applied.  Instead the observed response to each stimulus was compared 
to the probability of that response according to the model, irrespective of the response to 
the other stimuli.   
16 Parameter Estimation 
The model parameters were estimated using NONMEM VI version 2.0 (Icon Development 
Solutions, Ellicott City, MD), using FOCE LAPLACE and LIKELIHOOD options.   
Platform was Windows XP (Microsoft, Redmond, WA) and compiler was G95.  For all 
parameters interindividual variability was either assumed to be absent, or to have a log-
normal distribution.  A single value for the individual deviation from the typical value (η in 
NONMEM) was used for Ce50 of sevoflurane and remifentanil for all stimuli, in accordance 
with the assumption that this value reflects the sensitivity of that individual for hypnotic and 
opioid drugs.   
Model building was performed starting with the simplest form of each model, and 
expanding the model with interaction terms and interindividual variability until the decrease 
of the objective function value (OFV) was not statistically significant using the chi-square 
test.  The best fitting model was selected using Akaike Information Criterion, calculated as 
OFV + 2p, where p is the number of parameters in the model.  The NONMEM analysis was 
performed with various values for initial estimates and boundary values.  The results were 
accepted as valid only if both minimization and covariance step were successful, unless 
stated otherwise.   
To evaluate the final model a bootstrap analysis was performed, based on 1,000 sets 
of 40 patients each, randomly selected from the available 40 patients, using a custom 
program written in C.  Results were analyzed in Excel (Microsoft).  In addition, log-likelihood 
profiles were calculated for each population parameter, and the 95% CIs were obtained from 
these data assuming a chi-square distribution with one degree of freedom and P = 0.025, 
resulting in a critical difference of 5.02 in the OFV.   
Several performance measures were calculated from the prediction errors, i.e., the 
difference between the predicted probability of tolerance minus the observed response (0 
for responsive, 1 for tolerant): mean prediction error, mean absolute prediction error, and 
root mean squared error. In addition, the prediction error score was calculated as the 
percentage of mispredicted responses, i.e., if tolerant, P < 0.5, or if responsive, P > 0.5.   
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17 Statistical Analysis 
All model parameters are reported as typical values with relative standard errors in % within 
parentheses, and clinical data are given as mean and SD or as median and range, when 
appropriate. 
 
2 Results 
In total, 40 patients (26 females, 14 males) were included in this study.  The demographics 
are as follows: body weight : 66 ± 11 kg, height : 172 ± 8 cm, age : 30 ± 11 yr.  All patients 
were classified as American Society of Anesthesiologists status I.   
21 Data 
In total, the data sets contained 159 periods of testing (40 patients with 4 periods per 
patient, minus 1 missing period where no stimulus was given).  According to the protocol 
escalating stimulus intensity was assumed in the order of shaking and shouting, tetanic 
stimulation, LMA insertion, and laryngoscopy.  In 74 cases a stimulus was not applied for 
ethical reasons, because the patient was responsive to the preceding less intense stimulus at 
the same concentrations of sevoflurane and remifentanil.  The patient was then considered a 
responder to more intense stimuli for data analysis.  In 14 other cases a stimulus was not 
given for other reasons (such as severe hemodynamic changes), although the patient was 
tolerant to the preceding stimulus.  In the data analysis these data were treated as missing 
values.   
22 Model Selection 
The Greco model did not result in plausible parameter estimates; both Ce50REMI and α 
became very large, whereas the OFV was higher than for the Reduced Greco model (data not 
shown).  If the parameters were allowed to take very large values, the OFV approached that 
of the Reduced Greco model, and the ratio Ce50REMI/α approached Ce50REMI of the Reduced 
Greco model.  Therefore the original Greco model was not further considered.  The Akaike 
Information Criterion of the Minto model was markedly higher than for the other models, 
and the estimated Ce50REMI was above the highest remifentanil concentration applied.  
Compared with the other models, the Akaike Information Criterion of the Fixed C50O 
Hierarchical model was the lowest, indicating the best-fitting model.   
Allowing variation of the Ce50REMI and the slope parameters among the different 
stimuli in the modeling process did not significantly reduce the OFV.  Even estimating a 
different Ce50REMI for the nonnoxious shaking and shouting compared with the Ce50REMI for 
tetanic stimulation, LMA insertion, and laryngoscopy did not result in a significant 
improvement of the OFV.  In the final model a common Ce50REMI and common slope 
parameters for all stimuli were obtained, whereas the Ce50SEVO was stimulus specific (table 
2).   
Inclusion of interindividual variability in each parameter was tested either alone or in 
combinations.  In all cases interindividual variability was the same for each stimulus.  The 
results have been summarized in table 2.  For all models, inclusion of interindividual 
variability in Ce50SEVO significantly improved the OFV (P < 0.01); but not interindividual 
variability of other parameters.  We performed a covariate analysis on patient weight,  
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Table 2. Comparison of OFV, AIC, Parameter Values, and Measures of Performance between the Models, Including 
Interindividual Variability 
       Scaled C50O  Fixed C50O 
 Reduced Greco  Minto  Hierarchical  Hierarchical 
— — %SE   — %SE   — %SE   — %SE 
OFV 285.285 —  311.035 —  280.925 —  276.789 — 
Number of parameters 7 —  8 —  8 —  8 — 
ΔAIC$ 6.496 —  34.246 —  4.136 —  0 — 
C50O (ng/ml) 2.28 14%  14.3 12%  — —  1.69 21% 
C50O _TOSS (ng/ml) — —  — —  1.47 21%  — — 
C50O _TTET (ng/ml) — —  — —  1.46* —  — — 
C50O _TLMA (ng/ml) — —  — —  1.90§ —  — — 
C50O _TLAR (ng/ml) — —  — —  1.81¶ —  — — 
C50H _TOSS (vol%) 1.40 8%  1.31 9%  1.55 7%  1.47 7% 
C50H _TTET (vol%) 1.41 8%  1.40 9%  1.54 7%  1.48 7% 
C50H _TLMA (vol%) 2.02 8%  1.91 9%  2.00 7%  2.09 8% 
C50H _TLAR (vol%) 1.93 8%  1.89 9%  1.91 7%  2.00 8% 
γ0 — —  — —  0.704 12%  0.718 12% 
γ 6.94 11%  9.32 11%  7.28 11%  7.41 12% 
βC50 — —  1.47 15%  — —  — — 
IIV(C50H) 21% 37%  26% 38%  19% 38%  20% 38% 
MPE (%) 0.1 —  0.2 —  0.1 —  0.1 — 
MAPE (%) 11.2 —  11.8 —  11.3 —  11.0 — 
RMSE(%) 22.7 —  23.2 —  23.0 —  22.6 — 
PES (%) 6.9 —   6.6 —   7.7 —   7.6 — 
* Calculated from C50H _TTET * C50O _TOSS/C50H _TOSS. § Calculated from C50H _TLMA * C50O _TOSS/C50H _TOSS. ¶ 
Calculated from C50H _TLAR * C50O _TOSS/C50H _TOSS. $ Difference between AIC of the model and AIC of the best model 
(Fixed C50O Hierarchical model). 
γO = model parameter reflecting the steepness of the concentration-effect relationship for the opioid; γ = model parameter 
reflecting the steepness of the concentration-effect relationship;βC50 = model parameter reflecting the interaction in the Minto 
model; %SE = the standard error expressed in % of the typical value; AIC = Akaike’s information criterion; C50H = effect-site 
concentration of the hypnotic with 50% effect to tolerance to shaking and shouting (TOSS), tolerance to tetanic stimulation (TTET), 
tolerance to laryngeal mask airway insertion (TLMA), and tolerance to laryngoscopy (TLAR); C50O = effect-site concentration of 
the opioid with 50% effect; IIV = interindividual variability, calculated as the square root of interindividual variance, multiplied by 
100%; MAPE = mean absolute prediction error, MPE = mean prediction error; OFV = objective function value; PES = prediction 
error score, or the percentage of mispredicted responses; RMSE = root mean squared error.   
 
height, age, gender, and order of administration of remifentanil and sevoflurane.  None of 
these covariates did improve the fit significantly.   
The Reduced Greco model is identical with the Fixed C50O Hierarchical model if γO is 
fixed to 1, and therefore both models may be compared using the likelihood ratio.  Given the 
reduction of 8.5 in OFV it can be concluded that the Fixed C50O Hierarchical model fits 
significantly better to the data than the Reduced Greco model.  The Scaled C50O and Fixed 
C50O Hierarchical models cannot be compared using the likelihood ratio, because both 
models have the same number of parameters.  However, the reduction of 4.1 in the OFV 
indicates that the Fixed C50O Hierarchical model fits better to the data.   
The differences between the four models with respect to the performance measures 
were rather small (table 2).   
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Table 3. Median and 95% Nonparametric CIs of Parameters for the Fixed C50O Hierarchical Model with 
Interindividual Variability Obtained by Bootstrap Analysis (Using 1,000 Replicate Datasets) and from Log-likelihood 
Profiles 
— 
C50O C50H  C50H  C50H  C50H  
γO γ 
IIV 
(ng/ml) TOSS (vol%) 
TTET 
(vol%) 
TLMA 
(vol%) 
TLAR 
(vol%) C50H 
NONMEM 
1.69 1.47 1.48 2.09 2.00 0.718 7.41 20% Typical value 
Bootstrap analysis 
Median 1.67 1.47 1.49 2.09 2.00 0.713 7.65 19% 
2.5% 0.80 1.29 1.25 1.76 1.69 0.464 6.14 11% 
97.5% 2.55 1.70 1.78 2.51 2.37 0.981 10.70 26% 
Log-likelihood profiles 
0.99 1.25 1.26 1.77 1.69 0.543 5.81 12% 2.5% 
97.5% 2.59 1.73 1.75 2.48 2.37 0.925 9.54 30% 
γO = model parameter reflecting the steepness of the concentration-effect relationship for the opioid; γ = model parameter 
reflecting the steepness of the concentration-effect relationship; C50H = effect-site concentration of the hypnotic with 50% effect 
to tolerance to shaking and shouting (TOSS), tolerance to tetanic stimulation (TTET), tolerance to laryngeal mask airway 
insertion (TLMA), and tolerance to laryngoscopy (TLAR); C50O = effect-site concentration of the opioid with 50% effect; IIV = 
interindividual variability, calculated as the square root of interindividual variance, multiplied by 100%. 
 
The results of the final model, i.e., Fixed C50O Hierarchical model with interindividual 
variability in Ce50SEVO, were checked by performing a bootstrap analysis, based on 1,000 
sets; 994 sets resulted in a successful minimization, and 983 sets gave a successful 
covariance step.  The results of the bootstrap analysis were in good agreement with the 
NONMEM results (table 3).  Also, the CIs estimated from the bootstrap analysis and from the 
log-likelihood profiles were comparable (table 3).  The log-likelihood profiles for the 
parameters of the Fixed C50O Hierarchical model are depicted in figure 1.   
 
23 Response Surface and Isoboles 
The response surfaces for the probabilities of tolerance to each stimulus are shown in figure 
2.  Figure 3 compares the isoboles for 50% probability of tolerance to the four stimuli for the 
four models.  Figure 4 shows the isoboles for 50% probability of tolerance to the four stimuli 
for the Fixed C50O Hierarchical model and the observed responses.  Figure5 compares the 
isoboles for 50% probability of tolerance to the four stimuli for the four models.  In figure 6, 
the isoboles for 5%, 50%, and 95% probability of tolerance to the four stimuli for the Fixed 
C50O Hierarchical model are shown.  Figure 7 shows the isoboles for 95% probability of 
tolerance to laryngoscopy for the four models, illustrating the clinical significant difference 
between the Minto model and the three other models.   
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Fig. 1. Log-likelihood profiles for the 
parameters of the Fixed C50O 
Hierarchical model, expressed as a 
percentage of the estimated value. The 
horizontal line represents the 
significance level on a chi-square 
distribution (P  0.025). Note that the 
profiles of the C50H for the four stimuli 
are almost the same. IIV  interindividual 
variability; TLAR  tolerance to 
laryngoscopy; TLMA  tolerance to 
laryngeal mask airway insertion; TOSS  
tolerance to shaking and shouting; TTET  
tolerance to tetanic stimulation. 
 
 
 
 
 
3 Discussion 
As expected, the pharmacodynamic interaction between sevoflurane and remifentanil was 
strongly synergistic for both the hypnotic and the analgesic components of anesthesia, as 
illustrated by tolerance to shake and shout, tetanic stimulation, LMA insertion, and 
laryngoscopy.2,6,7  The main finding of this study is the validity of the Fixed C50O Hierarchical 
model2,7 assuming an identical Ce50 and slope parameter for the opioid and an identical 
slope parameter of the hypnotic for different stimuli, but keeping different Ce50hypnotic for 
different stimuli.  The model is thus validated not only for the propofol-remifentanil but also 
for the sevoflurane-remifentanil combination.  The flexibility of the Fixed C50O Hierarchical 
model where only the Ce50opioid, the Ce50hypnotic and slope parameters for the opioid and 
hypnotic are needed as input parameters, is of importance for the parsimonious description 
of the interaction and therefore very useful in the context of anesthesia drug displays.   
The Minto model with a Ce50REMI of 14.3 ng/ml was statistically inferior, whereas the 
original Greco model did not even support a reliable estimation of the Ce50REMI (estimated 
values above 50 ng/ml).  This is in agreement with the clinical experience that in the absence 
of a hypnotic drug opioids do not suppress the response to stimulation, at least at clinically 
reasonable opioid concentrations.  The Hierarchical models are semi-mechanistic models 
that have been developed to detect synergism for the combination of an analgesic and a 
hypnotic drug using a simple reconstruction of neuropathic pathways, as opposed to other 
more generalistic models.  These Hierarchical models, as well as the Reduced Greco model, 
assume no relevant opioid effect if given alone, and therefore these models fitted better to 
the data than the Greco and Minto models.  The differences between the Reduced Greco 
model, Scaled C50O Hierarchical model, and Fixed C50O Hierarchical model were rather small, 
and each of these three models fitted reasonably well to the data. However, the OFV and 
Akaike Information Criterion unequivocally showed that the Fixed C50O Hierarchical model 
fit best to our data.   
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Fig. 2. Response surface for probability of tolerance to shaking and shouting, tetanic stimulation, laryngeal mask airway 
insertion, and laryngoscopy for the Fixed C50O Hierarchical model. The solid lines at probability 0.5 represents the 50% 
isoboles.  TLAR = tolerance to laryngoscopy; TLMA = tolerance to laryngeal mask airway insertion; TOSS = tolerance to 
shaking and shouting; TTET = tolerance to tetanic stimulation.   
 
Fig. 3. Isoboles for 50% probability of tolerance to shaking and shouting, tetanic stimulation, laryngeal mask airway insertion, 
and laryngoscopy for four models (dashed line = Reduced Greco, thin solid line = Minto, dotted line = Scaled C50O Hierarchical, 
thick solid line  Fixed C50O Hierarchical).  Note that the isoboles of shaking and shouting and tetanic stimulation are almost the 
same for the Scaled C50O and Fixed C50O Hierarchical models, and that the isobole of the Scaled C50O Hierarchical model is 
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obscured by that of the Fixed C50O Hierarchical model.  TLAR = tolerance to laryngoscopy; TLMA = tolerance to laryngeal mask 
airway insertion; TOSS = tolerance to shaking and shouting; TTET = tolerance to tetanic stimulation. 
 
 
Fig. 4. Isoboles for 50% probability of tolerance to shaking and shouting, tetanic stimulation, laryngeal mask airway insertion, 
and laryngoscopy for the Fixed C50O Hierarchical model, with observed responses (open circles = responsive, closed squares = 
tolerant).  TLAR = tolerance to laryngoscopy; TLMA = tolerance to laryngeal mask airway insertion; TOSS = tolerance to 
shaking and shouting; TTET = tolerance to tetanic stimulation.   
 
Fig. 5. Isoboles for 50% probability of tolerance to shaking and shouting (thick solid line), tetanic stimulation (dotted line), 
laryngeal mask airway insertion (thin solid line), and laryngoscopy (dashed line) for the Reduced Greco model, Minto model, 
Scaled C50O Hierarchical model, and Fixed C50O Hierarchical model.  Note that the isoboles of tolerance to shaking and 
shouting and tetanic stimulation are almost the same for the Reduced Greco, Scaled C50O Hierarchical, and Fixed C50O 
Hierarchical models, and that the isoboles of tolerance to laryngeal mask airway insertion and laryngoscopy are almost the 
same for the Minto model.   
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The conclusions with respect to the best fitting model should not be translated to 
interactions of different classes of drugs.  Each of these models is an empirical model that 
needs to be validated for each application.  The Reduced Greco and both Hierarchical 
models are applicable when one of the drugs does not exert an effect when given alone, as 
is the case for the sevoflurane-remifentanil combination studied in this investigation.  For 
other drug combinations where both drugs can exert a full effect, the original Greco model 
and the Minto model may be appropriate.  For combinations where one of the drugs can 
only exert a partial effect, a modified version of the Minto model seems appropriate.   
To evaluate the clinical relevance of the observed differences between the models, 
the isoboles for 95% probability of tolerance to laryngoscopy for the four models are shown 
in figure 7.  At a fixed remifentanil concentration of 3 ng/ml, the sevoflurane concentration 
predicted by the Minto, Reduced Greco, Scaled C50O Hierarchical, and Fixed C50O 
Hierarchical model is 1.59, 1.27, 1.08, and 1.19 vol.%, respectively.  This illustrates the 
deviating characteristics of the Minto model, and the relatively small differences between 
the Reduced Greco and both Hierarchical models.  Clinicians aim at titrating their drugs 
during anesthesia at least at a level of 95% probability of tolerance, so at a specific 
remifentanil concentration, applying the Minto model would result in the use of a clinically 
relevant higher sevoflurane concentration than when using the other models.   
 
 
Fig. 6. Isoboles for 5% (dotted line), 50% (thick solid line), and 95% (dashed line) probability of tolerance to shaking and 
shouting, tetanic stimulation, laryngeal mask airway insertion, and laryngoscopy for the Fixed C50O Hierarchical model.  TLAR = 
tolerance to laryngoscopy; TLMA = tolerance to laryngeal mask airway insertion; TOSS = tolerance to shaking and shouting; 
TTET = tolerance to tetanic stimulation.   
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Fig. 7. Isoboles for 95% probability of tolerance to 
laryngoscopy for four models (dashed line = 
Reduced Greco, thin solid line = Minto, dotted line = 
Scaled C50O Hierarchical, thick solid line = Fixed 
C50O Hierarchical). TLAR = tolerance to 
laryngoscopy.   
 
 
 
 
 
 
 
Response surfaces or interaction isoboles are used in anesthetic drug displays as 
reference to interpret the current effect-site concentrations estimated in the patient.  The 
parameter estimates of the model are therefore crucial.  According to the Fixed C50O 
Hierarchical model, the Ce50s of the hypnotic are used to rank different stimuli according to 
their intensity.  The Ce50SEVO for tolerance of shaking and shouting (nonnoxious) and tetanic 
stimulation (noxious) were similar.  The Ce50SEVO for tolerance of LMA insertion and for 
laryngoscopy were also similar but substantially higher.  In the previous study on the 
interaction of sevoflurane and propofol performed with the same stimuli by the same 
investigators,10 the Ce50 values for sevoflurane for tolerance to shake and shout, tetanic 
stimulation, LMA insertion, and laryngoscopy were 1.03, 2.11, 2.55, and 2.83 vol.% 
respectively, which is markedly different from that found in the present study (1.47, 1.48, 
2.09, and 2.00 vol.%, respectively).  Furthermore, the slope reported by Schumacher et al. 
was 17.6, whereas in the present study it was 7.41.  To elucidate the cause of these 
differences, the data points of the previous and the current study where sevoflurane was 
given alone were reanalyzed (table 4).  The parameter estimates obtained from the 
“sevoflurane alone” data of the two studies still differ, although the difference is smaller and 
the order of the Ce50s was similar in both studies.  We can only speculate why the Ce50SEVO 
for tolerance to shake and shout was lower and the Ce50SEVO for tolerance to laryngoscopy 
was higher in the previous compared to the current study.  Age, weight, and height were 
similar in the two studies.  Classification of the subjects in responders and nonresponders 
was similar (a response was assumed if there was an observed response to a given stimulus, 
and if there was a response to a lower intensity stimulus and when the subsequent higher 
intensity stimulus was not applied).  The pattern and current intensity of the electrical 
stimulus was also the same.  The individual airway anatomy of the patients may affect the 
force to be applied during LMA insertion and the pressure applied with the laryngoscope to 
visualize the vocal cords.  This may explain in part the difference between the Ce50s for 
tolerance to LMA insertion and laryngoscopy but not the difference between Ce50s for 
tolerance to shake and shout and tetanic stimulation.   
A synergistic interaction between sevoflurane and remifentanil for both the hypnotic 
and analgesic stimuli using surface modeling was also found previously.8,9  However, their 
parameter estimates differ markedly from those of the current study.  Several reasons may 
explain this discrepancy: Whereas Manyam et al. used a logistic regression model, Johnson 
used the Greco model in his reanalysis of the same data.  In the study of Manyam et al. the 
stimuli were given 5 min after achieving a stable end-tidal sevoflurane concentration, 
whereas in our study the equilibration was allowed for 12 min, which is five times the 
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reported equilibration half-life for sevoflurane of 2.4 min.17  To compensate for this 
disequilibrium, Johnson et al.9 used an estimated effect-site concentration to describe the 
hysteresis with the end-tidal concentration.  The Ce50REMI for OAA/S1 during emergence (no 
return of consciousness) reported by Johnson et al. was 50.9 ng/ml, which is far above the 
investigated concentration range applied and may thus not be reliable, although it reflects 
the weak hypnotic potency of opioids.  The Ce50REMI for tolerance of tibial pressure was 1.3 
ng/ml, which is in the range of the common Ce50REMI in the current study as well as in the 
previous studies.2,6,7  In our study the Ce50REMI estimated with the Reduced Greco model was 
2.28 ng/ml for OAAS1 (table 2), which is lower than the value calculated from the ratio 
Ce50/reported by Johnson et al. (50.9/9.4  5.4 ng/ml).   
 
Table 4. Comparison of Results from Data in the Absence of Remifentanil and Propofol in the Present Study (19 Patients 
with 34 Observations for Each Stimulus) and Schumacher Study (28 Patients with 45 Observations for Each Stimulus), 
without and with Interindividual Variability in C50H 
 Present Study  Present Study  Schumacher  Schumacher 
— without IIV  with IIV  without IIV  with IIV 
— Typical Value %SE   Typical Value %SE   Typical Value %SE   Typical Value %SE 
C50H _TOSS (vol%) 1.25 10%  1.32 9%  0.955 9%  1.00 ** 
C50H _TTET (vol%) 1.57 9%  1.61 9%  2.17 6%  2.26 ** 
C50H _TLMA (vol%) 2.00 9%  2.01 9%  2.37 6%  2.55 ** 
C50H _TLAR (vol%) 2.09 9%  2.11 9%  2.52 6%  2.85 ** 
γ 5.96 17%  10.0 27%  7.96 18%  49.5* ** 
IIV (C50H) — —   22% 54%   — —   32% ** 
* Value reached boundary. ** Covariance matrix not calculated. 
γ = model parameter reflecting the steepness of the concentration-effect relationship; %SE = the standard error expressed in % of the 
typical value; C50H = effect-site concentration of the hypnotic with 50% effect to tolerance to shaking and shouting (TOSS), tolerance to 
tetanic stimulation (TTET), tolerance to laryngeal mask airway insertion (TLMA), and tolerance to laryngoscopy (TLAR); IIV = 
interindividual variability, calculated as the square root of interindividual variance, multiplied by 100%. 
 
Whereas Johnson et al. reported a different slope for OAAS1 (5.2) and tolerance of 
tibial pressure (2.7), we did not find a significant difference between the slopes for the 
different stimuli, and in our final model the common slope was 7.4.  It seems that the data 
from Manyam, reanalyzed by Johnson and our data are difficult to compare because of the 
different methodology and the different endpoints used.   
Our data are in line with the previous data on MAC reduction for various inhaled 
anesthetics in the presence of opioids.13,14,18–21  Whereas studies using multiple stimuli and 
several combinations of a hypnotic and an opioid in a criss-cross design6,10 only one stimulus 
(skin incision) at one randomly assigned combination of the two drugs in one patient was 
applied in the traditional MAC depression studies.  The advantage of the former is a 
reduction of the number of subjects while maintaining a sufficient number of data points for 
parameter estimation.   
Current interaction displays use two different stimuli and the related interaction 
models as reference to quantify the anesthetic potency of a given combination of a hypnotic 
(propofol or volatile) and an opioid.  The Fixed C50O Hierarchical model appears to be the 
most appropriate to define the reference lines or numbers to guide the clinician in rational 
dosing.  The two stimuli used in interaction displays as reference must be clearly different in 
 
60 
 
intensity, i.e., significantly differ in their Ce50hypnotic.  According to the present and previous 
data, “shaking and shouting” and “laryngoscopy” with their clearly distinct Ce50s, are 
therefore reasonable reference stimuli representing a superficial (near loss of consciousness) 
and a deeper state of anesthesia needed for surgery.   
In conclusion, we confirmed that the pharmacodynamic interaction between 
sevoflurane and remifentanil was strongly synergistic for both the hypnotic and the analgesic 
components of anesthesia.  We illustrated the importance of exploring the various surface 
modeling approaches when studying pharmacodynamic drug interactions as model selection 
might influence the results.  In this particular investigation, the Fixed C50O Hierarchical 
model best fits our data on sevoflurane remifentanil interaction and it appears to be an 
appropriate model for use in hypnotic-opioid drug interaction displays.  However, the 
prediction performance was not essentially different between the Reduced Greco, Scaled 
C50O Hierarchical, and Fixed C50O Hierarchical models.   
 
4 Appendix: Binary Response Models 
The probability of tolerance, P, to a certain stimulus can be expressed as 
 
ࡼ =
ࢁࢽ
૚ + ࢁࢽ
 
(A1) 
 
where U represents the normalized combined potency of one or more drugs and is a 
function of the drug effect-site concentrations and model parameters, reflecting the relative 
drug concentration, and γ is the slope parameter reflecting the steepness of the 
concentration-effect relationship.  Different interaction models differ with respect to the 
functional form of U and γ, as described below.   
Eq. A1 is the general form of all binary response models described below, and is used 
in earlier publications, either explicitly or implicitly, in some cases using different symbols for 
U and γ (e.g., in Luginbuhl,7 N and φ, respectively). 
We focus here on models describing the interaction of an opioid (O) and a hypnotic 
(H) on the probability of tolerance. For each drug we normalize the effect-site 
concentrations to the related C50, using 
 
ࢁࡻ =
࡯ࡻ
࡯૞૙ࡻ
 
(A2) 
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ࢁࡴ =
࡯ࡴ
࡯૞૙ࡴ
 
(A3) 
 
where UO and UH are the normalized opioid and hypnotic effect-site concentrations, CO is the 
effect-site concentration of the opioid, CH is the effect-site concentration of the hypnotic, 
C50O is the effect-site concentration of the opioid that results in P = 0.5 in the absence of the 
hypnotic, and C50H is the effect-site concentration of the hypnotic that results in P = 0.5 in 
the absence of opioid.   
In the case of multiple stimuli, the parameters for each stimulus may be different.  
Usually, however, one or more parameters are chosen identical for each stimulus, to allow 
reliable estimation of parameters from a limited number of observations.   
 
41 Greco Model 
The Greco model is a simplification of the original Greco model, and is an extrapolation from 
the 50% effect isobole2,4,5: 
 
ࢁ = ࢁࡻ + ࢁࡴ + ࢻ ∙ ࢁࡻ ∙ ࢁࡴ 
(A4) 
 
where U is the total potency, α is a dimensionless interaction parameter (α = 0: additive; α < 
0: infraadditive; α > 0: supraadditive), and UH and UO are the normalized concentrations of 
the hypnotic and opioid respectively.   
The model has four parameters: C50O, C50H, γ and α.  In the case of multiple (N) 
stimuli, there are 4.N model parameters; assuming equal values for γ and α for each 
stimulus, there are 2.N + 2 parameters (C50O and C50H for each additional stimulus).  The 
model can be further reduced by assuming a common value for C50O for each stimulus; in 
this case there are N + 3 parameters (one additional parameter for each stimulus).   
 
42 Reduced Greco Model without Effect of the Opioid Alone 
In the case of the interaction of opioids with hypnotics, the effect of the opioid alone on P 
may be too small to accurately assess the C50O (i.e., the actual value of C50O is very high).  
The Greco model can then be easily modified by leaving out the term UO from Eq. A4, 
creating  
 
ࢁ = ࢁࡴ + ࢻ ∙ ࢁࡻ  ∙ ࢁࡴ 
(A5) 
 
which may be written after rearrangement and replacement of UO according to Eq. A2:  
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ࢁ = ࢁࡴ ∙ ൬૚ + ࢻ ∙
࡯ࡻ
࡯૞૙ࡻ
൰ 
(A6) 
 
The parameters C50O and α cannot be estimated independently, since only their ratio 
α/C50O appears in Eq. A6.  Therefore Bouillon2 replaced the term α/C50O by a single 
parameter α’, resulting in A7:  
 
ࢁ = ࢁࡴ + ൫૚ + ࢻ′ ∙ ࡯ࡻ൯ 
(A7) 
 
Alternatively, may be fixed to 1, resulting in A8, which is equal to A9,  
 
ࢁ = ࢁࡴ + ൬૚ +
࡯ࡻ
࡯૞૙ࡻ
൰ 
(A8) 
 
ࢁ = ࢁࡴ + (૚ +  ࢁࡻ) 
(A9) 
 
C50O may now be interpreted as the concentration of the opioid that decreases C50H by 
50%: If CO = C50O (UO = 1), U = 2 x UH, i.e., the concentration of the hypnotic required to 
achieve a certain potency U, and thus a certain probability of tolerance P, is reduced by a 
factor 2, compared to the concentration in the absence of the opioid.   
Both methods are equivalent and produce identical results.  Fixing the term to 1 
instead of introducing another term α’ has the advantage that the observed value of C50O 
can be directly interpreted as the concentration that decreases C50H by 50%, whereas the 
meaning of the term in the Bouillon method is more difficult to explain.   
There are three model parameters to be estimated in the Reduced Greco model: 
C50H, γ and α’ in the Bouillon method, and C50O, C50H, and γ in the second method.  In the 
case of multiple (N) stimuli, there are 3.N model parameters; assuming an equal value γ for 
each stimulus, there are 2.N + 1 parameters. The model can be further reduced by assuming 
a common value for C50O for each stimulus; in this case there are N + 2 parameters. 
 
43 Minto Model 
The Minto model1 may be described by the following equations, A10,  
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ࣂ =  
ࢁࡴ
ࢁࡻ + ࢁࡴ
 
(A10) 
 
where θ is the fraction of the potency of one drug (in this case the hypnotic) to the total 
potency of both drugs (not to be confounded with the term θ in NONMEM).  The value of θ 
is between 0 and 1 according to the relative contribution of the two drugs to the total 
potency UH plus UO.  Equation A11,  
 
ࢁ૞૙(ࣂ) = ૚ − ࢼࢁ૞૙ ∙ ࣂ ∙ (૚ − ࣂ) 
(A11) 
 
where U50 is the potency of two drugs in the combination yielding half maximal effect, and 
βU50 is a dimensionless interaction coefficient relating θ (fraction of hypnotic) and 1-θ 
(fraction of opioid) to U50 (higher-order functions of θ may be used to accommodate more 
complex shapes of interaction).  Equation A12,  
 
ࢁ =  
ࢁࡻ + ࢁࡴ
ࢁ૞૙
 
(A12) 
 
where U is the potency of the two drugs normalized to U50.   
The steepness parameter γ is a model parameter, or a function of the ratio of the 
drug concentrations (θ) and model parameters (C50O, C50H, γO, γH, βγ), and may be written 
as a linear interpolation between γH, and γO, and an interaction term analogous to Eq. A11 
(higher-order functions of θ may be used to accommodate more complex shapes of 
interaction): A13,  
 
ࢽ = ࢽࡴ ∙ ࣂ + ࢽࡻ ∙ (૚ − ࣂ) − ࢼࢽ ∙ ࣂ ∙ (૚ − ࣂ) 
(A13) 
 
Note that Eqs. A11 and A13 have been rearranged from the corresponding equations in the 
original paper of the Minto model,1 to clarify the interaction.   
There are four model parameters: C50O, C50H, γ, and βU50, or six model parameters: 
C50O, C50H, γO, γH, βU50, and βγ.  In the case of multiple (N) stimuli, there are 4.N (or 6.N) 
model parameters; assuming an equal value for γ’s and β’s for each stimulus, there are 2.N + 
2 (or 2.N + 4) parameters.  The model can be further reduced by assuming a common value 
for C50O for each stimulus; in this case there are N + 3 (or N + 5) parameters.  In the current 
implementation using Eq. A1 the Minto model implies that both drugs on their own may 
yield the maximal effect.   
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44 Hierarchical Model 
The original Hierarchical model6,7 may be written as A14,  
 
ࡼ =
࡯ࡴࢽ
(࡯૞૙ࡴ ∙ ࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟)ࢽ + ࡯ࡴࢽ
 
(A14) 
And A15,  
 
࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
= ࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
∙ ቆ૚ −
࡯ࡻࢽࡻ
(࡯૞૙ࡻ ∙ ࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟)ࢽࡻ + ࡯ࡻࢽࡻ
ቇ 
(A14) 
 
where postopioid_intensity is the stimulus intensity after attenuation by the opioid, and 
preopioid_intensity is the intensity of the stimulus in the absence of opioid.   
Eq. A14 corresponds to the general Eq. A1 if 
 
ࢁ =  
ࢁࡴ
࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
 
(A16) 
 
Eqs. A15 and A16 may be combined to eliminate the term postopioid_intensity with A17,  
 
ࢁ =
ࢁࡴ
࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
∙ ቆ૚ + ൬
ࢁࡻ
࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
൰
ࢽࡻ
ቇ 
(A17) 
 
The original Hierarchical model6 was considered overparameterized.2  The parameters 
preopioid_intensity, C50H, and C50O cannot be estimated uniquely, since the values of C50H, 
and C50O can always be adjusted to offset any value of preopioid_intensity.   
In the case of a single stimulus, the overparametrization can be solved by fixing 
preopioid_intensity to 1, reducing Eq. A17 to A18,  
 
ࢁ = ࢁࡴ ∙ (૚ + ࢁࡻࢽࡻ) 
(A17) 
 
Eq. A18 demonstrates that, for single stimulus, the Hierarchical model is a simple extension 
of the Reduced Greco model, i.e., by adding an exponent γO to UO in Eq. A9, yielding Eq. A18.   
 
65 
 
In the case of multiple stimuli, the overparametrization can be solved in various ways, 
leading to different models: the Scaled C50O and the Fixed C50O Hierarchical model. 
 
45 Scaled C50O Hierarchical Model 
This approach is consistent with the concept described by Bouillon et al.,6 where the C50o is 
multiplied by preopioid intensity to reflect the decreasing potency of opioids in attenuating 
pain as the intensity of the pain increases.   
The Scaled C50O Hierarchical model constrains C50Oi and C50Hi for i > 1 to:  
C50Oi = C50O1 * preopioid_intensityi 
C50Hi = C50H1 * preopioid_intensityi 
In short, the characteristic feature of the Scaled C50O Hierarchical model is that the 
stimulus intensity is a factor by which the C50s of both drugs are multiplied.   
There are four model parameters: C50O, C50H, γ and γO.  In the case of multiple (N) 
stimuli, there are 4.N model parameters; the constraints on C50Oi and C50Hi reduce the 
number of free parameters to 3.N + 1; assuming that γ and γO are not affected by the type 
and intensity of the stimulus, there are N + 3 parameters (C50O1, γ, γO, and N values of C50Hi; 
values of C50Oi for i more than 1 follow from the constraints).   
 
46 Fixed C50O Hierarchical Model 
The modified Hierarchical model proposed by Bouillon2 introduced a different constraint on 
C50Oi that is also reasonable and testable: C50O is the same for all stimuli. Therefore this 
model is referred to as ’Fixed C50O Hierarchical model’, constraining C50Oi and C50Hi for i  1 
to: 
C50Oi = C50O1 
C50Hi = C50H1 * preopioid_intensityi 
This constraint is identical to omitting preopioid_intensity from the denominator of Eq. A15.  
From these constraints and Eq. A18 it follows that the Fixed C50O Hierarchical model is an 
extension of the Reduced Greco model, i.e., by adding an exponent γO to UO in Eq. A9 and 
with a common parameter C50O for all stimuli.  Note that in the Fixed C50O Hierarchical 
model proposed by Bouillon2 γO was assumed to be 1 (equation on page 481 of that paper), 
making the model identical to the Reduced Greco model.  The number of model parameter 
is identical to that of the Scaled C50O Hierarchical model (C50O, γ, γO, and N values for C50Hi).   
 
47 Relationships between Models 
The characteristics and relationships between the models can be summarized as follows:  
The Greco model and the Minto model as commonly implemented assume an effect 
of the opioid given alone, whereas the other models assume that the opioid alone has no 
effect on the response to a stimulus; 
The Reduced Greco model is a reduction of the Greco model; the models are 
identical if the parameters C50O and α of the Greco model are infinitely large, and their ratio 
(C50O/α) is equal to C50O of the Reduced Greco model; 
The Reduced Greco model with a common parameter C50O for all stimuli and the 
Fixed C50O Hierarchical model are identical if the parameter γO is fixed to 1; 
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The Scaled C50O Hierarchical model assumes that the C50 of opioid (C50O) and 
hypnotic (C50H) are multiplied by a common factor representing the intensity of the 
stimulus, i.e., the ratio C50O/C50H are the same for each stimulus; 
The Fixed C50O Hierarchical model assumes a common C50O for each stimulus; 
For a single stimulus the Fixed C50O Hierarchical model is identical to the Scaled C50O 
Hierarchical model. 
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Chapter 4 A Response Surface Model Approach for 
Continuous Measures of Hypnotic and Analgesic Effect during 
Sevoflurane–Remifentanil Interaction data.   
 
Quantifying the Pharmacodynamic Shift Evoked by Stimulation 
 
Bjorn Heyse, M.D.,Johannes H. Proost, Pharm.D., Ph.D., Laura N. Hannivoort, M.D., 
Douglas J. Eleveld, Ph.D., Martin Luginbühl, M.D., Ph.D., Michel M. R. F. Struys, M.D., 
Ph.D., Hugo E. M. Vereecke, M.D., Ph.D.  
 
Anesthesiology 2014; 120:1390-9 
 
 
ABSTRACT 
 
Background: The authors studied the interaction between sevoflurane and remifentanil on 
bispectral index (BIS), state entropy (SE), response entropy (RE), Composite Variability Index, 
and Surgical Pleth Index, by using a response surface methodology.  The authors also studied 
the influence of stimulation on this interaction.   
 
Methods: Forty patients received combined concentrations of remifentanil (0 to 12 ng/ml) 
and sevoflurane (0.5 to 3.5 vol%) according to a crisscross design (160 concentration pairs). 
During pseudo–steady-state anesthesia, the pharmacodynamic measures were obtained 
before and after a series of noxious and nonnoxious stimulations.  For the “prestimulation” 
and “poststimulation” BIS, SE, RE, Composite Variability Index, and Surgical Pleth Index, 
interaction models were applied to find the best fit, by using NONMEM 7.2.0. (Icon 
Development Solutions, Hanover, MD).   
 
Results: The authors found an additive interaction between sevoflurane and remifentanil on 
BIS, SE, and RE. For Composite Variability Index, a moderate synergism was found.  The 
comparison of pre- and poststimulation data revealed a shift of C50SEVO for BIS, SE, and RE, 
with a consistent increase of 0.3 vol%.  The Surgical Pleth Index data did not result in 
plausible parameter estimates, neither before nor after stimulation.   
 
Conclusions: By combining pre- and poststimulation data, interaction models for BIS, SE, and 
RE demonstrate a consistent influence of “stimulation” on the pharmacodynamic 
relationship between sevoflurane and remifentanil.  Significant population variability exists 
for Composite Variability Index and Surgical Pleth Index.   
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Bern, Bern, Switzerland (M.L.). 
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Two important components of general anesthesia are hypnosis and analgesia: The hypnotic 
component may be defined as probability of tolerance to a nonnoxious stimulus (e.g., name 
calling or shake and shout), whereas the analgesic component (also called: the balance 
between nociception and antinociception) may be considered as the probability of tolerance 
to a noxious stimulus.1  Tolerance means “the absence of a response” being either a somatic 
response (e.g., movement, sweating, eye opening), a hemodynamic response (increase in 
heart rate or blood pressure), or an arousal on the electroencephalogram of the frontal 
cortex, which is a reflection of a decreased cerebral hypnotic drug effect due to an 
insufficient analgesic effect.  This “component” definition is based on the notion that 
tolerance to verbal and noxious stimulation will be mediated through different neuronal 
networks, which are located in the higher cortical versus subcortical structures of the brain, 
respectively.1  These networks are independently affected by the interaction between a 
hypnotic and an analgesic drug.  As an example of this, Heyse et al.2 showed different 
response surface models for tolerance to nonnoxious and noxious stimulation.   
In addition to the dichotomous observations of tolerance to stimulation, several 
neurophysiology-derived measures of anesthesia effect have been developed to monitor the 
anesthesia state of the patient in a continuous way. Electroencephalographic measures, such 
as bispectral index (BIS; Covidien, Boulder, CO), state entropy (SE), and response entropy 
(RE) (M-Entropy; GE Healthcare, Helsinki, Finland), have a stronger correlation with the 
hypnotic component than with the analgesic component of anesthesia.3  More recently, new 
continuous measures with different neurophysiological background, such as the Surgical 
Pleth Index (SPI; GE Healthcare) and the Composite Variability Index (CVI; Covidien), attempt 
to quantify the balance between nociception and antinociception.4,5  All these continuous 
surrogate measures of hypnotic or analgesic effect are influenced by the interaction 
between hypnotic and analgesic drugs and should therefore be studied with this multidrug 
reality in mind.  Eventually, the ultimate goal of continuous monitoring is to effectively 
counter deviating measurements with an adequate change in the balance between opioids 
and hypnotics so that better clinical results are obtained.  This performance can only be 
expected if a well-described dose-response relationship exists between the measurements 
and the applied drug combinations.   
To depict this dose-response relationship in the presence of multiple drugs, it is common 
to use population-derived response surface interaction models.2  For BIS, SE, RE, CVI, and 
SPI, the interaction between sevoflurane and remifentanil on continuous measures has not 
yet been described.   
Therefore, the primary goal of this study was to develop response surface models that 
best describe the dose-response relationship between the combined administration of 
sevoflurane and remifentanil versus BIS, SE, RE, CVI, and SPI.  Overall, we hypothesized that 
the nature of the various interactions should be synergistic for the continuous measures as 
this is in concordance with the interaction on dichotomous clinical endpoints as described by 
Heyse et al.2  The secondary goal of the study was to investigate whether noxious 
stimulation significantly affects the model structure or the model parameters.   
 
 
1 Materials and Methods 
The data presented in this article were collected during a previous study as published by 
Heyse et al.2  This study presents the results of a secondary analysis focusing on the 
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continuous measurements of drug effect, whereas the previous study focused on 
dichotomous endpoints of anesthetic effect (clinical signs of responsiveness).  The studied 
patients, the crisscross study design, and drug administration methods applied in this study 
have been described elsewhere in detail.2   
 
11 Subjects 
After obtaining Institutional Review Board (Ghent U niversity Hospital Ethics Committee, 
Gent, Belgium) approval and prospective trial registration at ClinicalTrials.gov 
(NCT00522587) and after obtaining written informed consent, 40 patients with American 
Society of Anesthesiologists status I or II, aged 18 to 60 yr, and scheduled to undergo surgery 
requiring general anesthesia were included.  Exclusion criteria were weight less than 70% or 
more than 130% of ideal body weight, neurological disorders, diseases involving the 
cardiovascular system, pulmonary diseases, gastric diseases, endocrine diseases, and recent 
use of psychoactive medication or use of more than 20 g of alcohol daily.  The complete 
study was executed in a quiet operating room before the start of the surgical procedure.   
 
12 Study Design 
This study was performed as a randomized, prospective, open-label study. No participant of 
the study received premedication.  After the patients arrived in the operating room, 
standard monitors (electrocardiogram, noninvasive blood pressure, and hemoglobin oxygen 
saturation), M-Entropy using a Datex S/5 Anesthesia Monitor (GE Healthcare), and BIS using 
an Aspect A-2000 monitor (Covidien) were connected, and a large forearm vein was 
cannulated.  Thereafter, the patients were preoxygenated with 6 l/min of O2 at an FI = 1.0 for 
5 min using a tightfitting face mask, which also served to sample exhaled air for end-tidal 
carbon dioxide measurement.  Vital signs and end-tidal sevoflurane concentrations, 
respiratory data (tidal volume, minute volume, and end-tidal carbon dioxide), and infusion-
related data (predicted concentrations and infused volumes) were continuously recorded on 
a computer hard disk using RUGLOOP II data-recording software (Demed, Temse, Belgium).   
 
13 Drug Administration 
131 Technical Aspects.  
Remifentanil was administered by a target-controlled infusion technique by using  RUGLOOP 
II TCI software (Demed) based on a three-compartment model with an effect-site 
compartment as published by Minto et al.6,7  Sevoflurane was administered in 50% O2 and 
50% air by using a standard out-of-circle vaporizer and a standard breathing circuit of an 
ADU anesthesia workstation (Datex/Ohmeda; GE Healthcare).   
132 Dosing Regimen.  
We randomized 40 patients to receive four prespecified combinations of sevoflurane (0.5 to 
3.5 vol%) and remifentanil (0 to 12 ng/ml) according to a modification of the crisscross 
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design proposed by Short et al.8 In half of the patients, remifentanil was held constant, and 
sevoflurane was stepwise increased; in the other half, sevoflurane was held constant and 
remifentanil was stepwise increased. The dosing schedule is shown in table 1 in the study by 
Heyse et al.2 No muscle relaxants were administered throughout the study. 
 
14 Assessment of Clinical Response 
For each concentration step, the clinical response was assessed 12 min after reaching the 
target concentrations to allow for plasma effect-site equilibration.  The patient was exposed 
to the following series of stimuli, with increasing intensity: (1) verbal and nonpainful tactile 
stimuli according to the Modified Observer’s Assessment of Alertness/ Sedation (OAA/S) 
score9; (2) a tetanic stimulus of the ulnar nerve for 5 s by using the standard 
neurostimulator; (3) insertion of a laryngeal mask airway (size 3 for women and 4 for men, 
LMA Unique® [The Surgical Company, Amersfoort, The Netherlands]); and (4) laryngoscopy 
aiming at full visualization of the vocal cords by using a size-3 curved Macintosh-type blade 
(HEINE Optotechnik GmbH & Co KG, Herrsching, Germany).  All stimuli— including 
laryngoscopy—were performed by a single anesthesiologist (B.H.) to minimize 
interindividual variability in stimulation.  Between each stimulus, a 1-min delay was 
maintained to evaluate the somatic responsiveness on each stimulus.  If there was no 
response to a stimulus, the next stimulus was applied 1 min after the response assessment 
of the previous stimulus.   
In this study, we only compared data before OAA/S score (unstimulated state) with data 
after laryngoscopy (stimulated state).  For the data that were obtained in between stimuli, 
we did not estimate separate models.  We could not exclude a bias evoked by influences of 
the preceding stimulus on the next one.  However, by performing simultaneous model 
estimations on data before and after the sequence of four clinically relevant stimulations, we 
explore pharmacodynamic differences between a generally “unstimulated” versus a 
“stimulated” anesthesia state.   
 
15 Data Acquisition and Management 
151 BIS, SE, and RE.  
The spectral entropy monitor (M-Entropy; GE Healthcare) calculated SE and RE. BIS was 
simultaneously derived from the frontal electroencephalogram (At-Fpzt) by using a quatro 
BIS™ sensor with four electrodes (Covidien).  The smoothing time of the BIS monitor was set 
at 15 s.  All data were recorded electronically using RUGLOOP II software (Demed) with a 5-s 
time interval.   
The median of the recorded values during 1 min before the assessment of the OAA/S 
score was used for the analysis of the BIS, SE, and RE data.   
152 CVI.  
The raw electroencephalographic signal was captured by the BIS™ monitor with a 128-Hz 
sample rate and allowed post hoc calculation of CVI.  The calculation of CVI has been 
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described by Mathews et al.5  The CVI is a composite index that combines the variability in 
BIS with frontal electromyographic changes over time.  A high CVI reflects activation of the 
frontal electromyography and increased input of sensory information from deep brain 
structures to the cortex.  A low CVI reflects an adequate inhibition of this sensory input and 
adequate analgesia.  The CVI was calculated with a 5-s time interval.  The median of the 
recorded values during 1 min before the assessment of the OAA/S score was used for the 
analysis.  In the case that one or more values were missing during the last minute before the 
assessment of OAA/S score due to a technical reason, the CVI was regarded as a missing 
value and was not taken into account in the analysis.   
153 SPI.  
The SPI is derived from plethysmographic pulse wave characteristics combined with heart 
rate variability and is a surrogate measure of the orthosympathetic and parasympathetic 
nervous system response to noxious stimulation.  The calculation of SPI has been described 
by Huiku et al.4 The SPI was calculated with a 1-s time interval.  The median of the recorded 
values during 1 min before the assessment of the OAA/S score was used for the analysis. In 
the case that there were less than seven values during the last minute before the 
assessment of OAA/S score, the SPI was regarded as a missing value and was not taken into 
account in the analysis.   
154 Data after Stimulation.  
A moving median technique was applied on the raw data measured during 1 min after 
laryngoscopy.  For the NONMEM analysis, the highest value of the moving median over 
several consecutive values was used.  By doing so, the effect of single outlier values on the 
average behavior of each measurement was minimized without losing sensitivity for 
detecting a relevant response on BIS, SE, RE, CVI, and SPI after stimulation.  For 
measurements that were logged every 5 s (BIS, SE, RE, and CVI), or every second (SPI), we 
performed the moving median technique over a sequence of respectively five or seven 
consecutive values.  In the case that there were less than five or seven consecutive values 
during 1 min after application of laryngoscopy, or if laryngoscopy was not applied because 
the patient was responsive to a previous stimulus (see the study by Heyse et al.2), the 
measurement was considered as missing and was not taken into account in the analysis.   
155 Pharmacodynamic Analysis of the Continuous Variables  
For the continuous data, a negative sigmoid Emax model was used10: 
ࡱࢌࢌࢋࢉ࢚ = ࡱ૙ − (ࡱ૙ − ࡾࡱࡿࢀ) ∙ ൬
ࢁࢽ
૚ + ࢁࢽ
൰ 
(1) 
where E0 is the baseline value in the absence of drug, REST is a nonsuppressible effect (the 
lowest possible value of the effect variable), U represents the normalized combined potency 
of one or more drugs, and γ is the slope parameter reflecting the steepness of the 
concentration–effect relationship.   
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The normalized combined potency U is a function of the drug effect-site concentrations 
and model parameters, as described in detail in the appendix in the study by Heyse et al.2  
The following models were tested:  
a. Greco model 
ࢁ =
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
+
࡯ࡾࡱࡹࡵ
࡯૞૙ࡾࡱࡹࡵ
+ ࢻ ∙
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
∙
࡯ࡾࡱࡹࡵ
࡯૞૙ࡾࡱࡹࡵ
 
(2) 
 
where CSEVO is the effect-site concentration of sevoflurane, CREMI is the effect-site 
concentration of remifentanil, C50SEVO is the effect-site concentration of sevoflurane with 
50% effect, C50REMI is the effect-site concentration of remifentanil with 50% effect, and α is a 
dimensionless interaction parameter.   
b. Reduced Greco model without effect of the opioid alone 
ࢁ =
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
∙ ൬૚ +
࡯ࡾࡱࡹࡵ
࡯૞૙ࡾࡱࡹࡵ
൰ 
(3) 
 
c. Minto model11 
ࢁ =
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
+ ࡯ࡾࡱࡹࡵ࡯૞૙ࡾࡱࡹࡵ
૚ − ࢼࢁ૞૙ ∙ ࣂ ∙ (૚ − ࣂ)
 
(4) 
 
where βU50 is a dimensionless interaction parameter, and θ is defined by:  
ࣂ =
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
+ ࡯ࡾࡱࡹࡵ࡯૞૙ࡾࡱࡹࡵ
 
(5) 
 
d. Hierarchical model 
ࢁ =
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
∙ ቆ૚ + ൬
࡯ࡾࡱࡹࡵ
࡯૞૙ࡾࡱࡹࡵ
൰
ࢽ૙
ቇ 
(6) 
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where γO is the slope parameter reflecting the steepness of the concentration–effect 
relationship for remifentanil.   
Because each pharmacodynamic endpoint was analyzed separately, the Scaled C50O and 
Fixed C50O Hierarchical models are identical.2.. 
For BIS, SE, and RE, it was assumed that the measure approaches zero for high 
concentrations of sevoflurane or remifentanil, so REST is zero, reducing the model to a 
fractional Emax model.10  For CVI and SPI, the nonsuppressible effect REST was modeled as a 
function of the drug concentrations according to the procedure described by Minto et al.11: 
ࡾࡱࡿࢀ = ࡾࡱࡿࢀࡿࡱࢂࡻ ∙ ࣂ + ࡾࡱࡿࢀࡾࡱࡹࡵ ∙ (૚ − ࣂ) − ࢼࡾࡱࡿࢀ ∙ ࣂ ∙ (૚ − ࣂ) 
(7) 
 
where RESTSEVO, RESTREMI, and βREST are model parameters.   
 
16 Parameter Estimation 
The model parameters were estimated using NONMEM 7.2.0 (Icon Development Solutions, 
Hanover, MD), using first-order conditional estimation.  Platform was Windows XP 
(Microsoft, Redmond, WA) and compiler was G95.  For all parameters, interindividual 
variability was assumed either to be absent or to have a lognormal distribution.  It was 
tested whether a single value for the individual deviation from the typical value (eta in 
NONMEM) could be used for C50 of sevoflurane and remifentanil, in accordance with the 
assumption that this value reflects the sensitivity of that individual for hypnotic and opioid 
drugs.  Residual intraindividual variability of the continuous variables was modeled using 
standard additive or proportional error models.   
Parameters were tested for significance by comparing the objective function which is 
minus two times log-likelihood (−2LL).  Significance level for hypothesis tests was 0.01 (chi-
square test), or a 6.84 difference in the −2LL adding one parameter for nested models.  The 
goodness-of-fit for the models was also assessed by visual inspection of the predicted versus 
observed plots and the distribution of residuals for each of the continuous endpoints.   
Model building was performed starting with the simplest form of each model and 
expanding the model with parameters and interindividual variability until the decrease of the 
objective function value was not statistically significant using the chi-square test.  In 
addition, model building was started with the most complex model, reducing the model by 
fixing parameters to zero.  The NONMEM analysis was performed with various values for 
initial estimates and boundary values.  The results were accepted as valid only if both 
minimization and covariance steps were successful, unless stated otherwise.   
To evaluate the final model, a bootstrap analysis was performed, based on 2,000 sets of 
40 patients each, randomly selected from the available 40 patients, using a custom program 
written in c.  Results were analyzed in Excel (Microsoft) to obtain nonparametric 95% CIs.   
The poststimulation data after laryngoscopy were analyzed by using an identical modeling 
approach as applied on the prestimulation data.  To investigate the effect of the stimulations 
on the model parameters, we performed a simultaneous fitting of the data before OAA/S (= 
unstimulated anesthesia state) and after laryngoscopy (= stimulated anesthesia state) in a 
stepwise model-building process, starting with fixed common parameters for both data sets, 
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followed by testing the addition of parameters for the difference between before OAA/S and 
after laryngoscopy.   
17 Statistical Analysis 
All model parameters are reported as typical values with relative standard error (in % of the 
typical value) within parentheses, and clinical data are given as mean and SD or as median 
and range, when appropriate.   
 
2 Results 
In total, 40 patients (26 women and 14 men) were included in this study. The demographics 
are as follows: body weight, 66 ± 11 kg; height, 172 ± 8 cm; and age, 30 ± 11 yr. All patients 
were classified as American Society of Anesthesiologists status I.   
 
21 Data 
In total, the data sets contained 159 periods of testing (40 patients with 4 periods per 
patient minus 1 missing period where no stimulus was given). 
 
22 Model Development for BIS 
Initially, BIS data were analyzed using the Greco, Reduced Greco, Minto, and Hierarchical 
models, using a fractional Emax model (REST = 0).  For both the Greco model and the Minto 
model, the interaction term for C50 did not differ significantly from zero.  Similarly, the 
interaction term for γ in the Minto model did not differ significantly from zero.  
Consequently, both models yield identical results.  The objective function value for the Greco 
model (808.5) was markedly lower than that for the Reduced Greco model (823.0) and 
Hierarchical model (822.2), and therefore, the Greco model was considered as the most 
appropriate method.  The additional error model fitted better to the data than the 
proportional error model, as concluded from the objective function value and diagnostic 
plots of residuals.   
 
23 Final Model for BIS 
The final results for this model are shown in table 1.  In the final model, interindividual 
variability was included in C50REMI and C50SEVO with a common eta.  The value for C50 for 
remifentanil (27.3 ng/ml) exceeds the upper range of concentrations in the study (12 ng/ml), 
but its precision was satisfactory (relative standard error 12%).  The response surface of the 
final model is shown in figure 1. Figure 2 depicts the observed BIS values (filled symbols) and 
predicted BIS (solid line) versus the normalized combined potency UBIS, which has a 
sigmoidal Emax relationship.   
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24 Model Development for SE and RE 
The Greco model was found to be the most appropriate model for SE and RE, in accordance 
with the best model for BIS. 
 
25 Final Models for SE and RE 
The results of the final models are summarized in table 1.  The variability in SE and RE is 
larger than for the BIS data, as reflected in larger relative standard errors, larger 
interindividual variability, and larger residual SD.   
The response surfaces of the final models for SE and RE are shown in figure 1. Figures 3 
and 4 depict the observed (filled symbols) and predicted (solid line) SE and RE versus the 
normalized combined potencies USE and URE, respectively, which also have a sigmoidal Emax 
relationship.   
Table 1. Population Model Estimates for BIS, SE, RE, and CVI   
  BIS SE RE CVI 
Interaction Model Greco/Minto Greco/Minto Greco/Minto Reduced Greco 
C50REMI (ng/ml) 
27.3 (13%) 16.2 (19%) 18.2 (21%) 7.56 (32%) 
(20.4–37.7) (11.0–27.9) (12.6–31.9) (4.01–17.7) 
C50SEVO (vol%) 
1.99 (6%) 1.82 (8%) 1.88 (7%) 1.09 (97%) 
(1.68–2.23) (1.49–2.11) (1.58–2.14) (0.08–3.28) 
  γ 
1.88 (10%) 1.87 (9%) 2.08 (8%) 1.16 (29%) 
(1.53–2.27) (1.54–2.26) (1.76–2.40) (0.77–2.15) 
  E0 
89.5 (4%) 97.1 (5%) 103 (4%)  4.32 (57%) 
(83.5–99.1) (84.3–110) (95–113) (2.35–19.9) 
IIV(C50REMI) 20% (14%)  59% (19%)  67% (19%)  0* 
 (14–25%) (33–86%) (43–99%)  
IIV(C50SEVO) 20%† 22% (22%)  25% (19%)  18% (24%)  
  (8–30%) (13–34%) (0–26%) 
Residual SD 6.2‡ (9%)  9.5‡ (10%)  9.6‡ (10%)  27%§ (11%)  
 (5.0–7.2) (7.5–11.1) (7.5–11.2) (22–33%) 
∆C50SEVO (vol%) 
0.30 (18%) 0.31 (22%) 0.36 (20%) II 
(0.20–0.41) (0.18–0.46) (0.23–0.52)   
Values are typical values, relative standard error (% of the typical value) and 95% CI obtained by bootstrapping. 
* Not significantly different from zero; † Common value for remifentanil and sevoflurane; ‡ Additive error; § Proportional error; 
II Could not be estimated (for details, see text).  
BIS = bispectral index; CVI = Composite Variability Index; C50REMI = effect-site concentration of remifentanil with 50% effect; 
C50SEVO = effect-site concentration of sevoflurane with 50% effect; ΔC50SEVO = increase of C50SEVO after laryngoscopy, as 
obtained in a separate analysis (see text); E0 = baseline value in the absence of drugs; γ = model parameter reflecting the 
steepness of the concentration–effect relationship; IIV(C50REMI) and IIV(C50SEVO) = interindividual variability for C50REMI and 
C50SEVO, respectively (calculated as the square root of interindividual variance, multiplied by 100%); Residual SD = SD of the 
differences between the observed and predicted responses (calculated as the square root of the residual variance); RE = 
response entropy; SE = state entropy. 
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26 Model Development for CVI 
In four patients, the CVI could not be calculated due to missing data.  In 17 patients, the CVI 
could not be calculated from the available electroencephalogram registration in one or more 
periods.  In total, 122 CVI values in 36 patients were available.   
For CVI, the objective function value of the Reduced Greco model was lower than for 
the Greco model and Minto model.  The proportional error model fitted better to the data 
than the additional error model, as concluded from the objective function value and 
diagnostic plots of residuals.  Using the Hierarchical model, the slope factor γ for 
remifentanil (0.289) and C50SEVO (0.266 vol.%) was very low, E0 (10.2) was much higher than 
the highest observed CVI value, and standard errors were high; therefore, this model was 
not accepted as a valid model.   
 
Fig. 1. Response surface for electroencephalographic endpoints before stimulation (A, C, E, G) and after stimulation (B, D, F, H) 
was applied: Bispectral index (BIS), state entropy (SE), response entropy (RE), and Composite Variability Index (CVI), as a 
function of the end-tidal steady-state sevoflurane concentration and the predicted remifentanil effect-site concentration, 
calculated from the data listed in table 1.  Measured values above the surface are shown as filled circles and below the surface 
as open circles.   
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Fig. 2. Relationship between the normalized combined 
potency UBIS according to the Greco model and the 
observed bispectral index (BIS) (squares, n = 159) and 
predicted BIS (solid line; calculated from the data listed in 
table 1) for unstimulated (filled symbols) and stimulated 
(open symbols).   
Fig. 3. Relationship between the normalized combined 
potency USE according to the Greco model and the 
observed state entropy (SE) (squares, n = 159) and 
predicted SE (solid line; calculated from the data listed in 
table 1) for unstimulated (filled symbols) and stimulated 
(open symbols).   
 
27 Final Model for CVI 
The results for the final Reduced Greco model are shown in table 1.  The residual error of 
27% is large and the CIs for the model parameters are wide, reflecting the poor fit.   
The response surface of the final model for CVI is shown in figure 1. Figure 5 depicts the 
observed (filled symbols) and predicted CVI values (solid line) versus the normalized 
combined potency UCVI.  The CVI has a sigmoidal Emax relationship with UCVI, which is 
comparable in behavior to BIS, SE, and RE.   
 
28 Model Development for SPI 
In two patients, the SPI could not be calculated due to missing data.  In four patients, the SPI 
could not be calculated from the available plethysmography data in one or more periods.  In 
total, SPI data from 145 periods in 38 patients were available.   
Modeling of the SPI data did not result in reliable results.  Plotting the SPI data against the 
sevoflurane or remifentanil concentration revealed that the SPI value is hardly affected by 
sevoflurane or remifentanil, in contrast to the BIS, SE, RE, and CVI (data not shown).   
 
Fig. 4. Relationship between the normalized combined 
potency URE according to the Greco model and the 
observed response entropy (RE) (squares, n = 159) and 
predicted RE (solid line; calculated from the data listed in 
table 1) for unstimulated (filled symbols) and stimulated 
(open symbols).   
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29 Data after Stimulation 
The data after stimulation were first analyzed using an identical modeling approach as 
applied on the unstimulated data.  For BIS, SE, and RE, the number of data points was 114 (in 
45 periods, laryngoscopy was not applied for ethical or other reasons).  The optimal models 
were identical and the parameters were broadly comparable with the results before the 
assessment of OAA/S, except for C50SEVO, which was consistently higher after the series of 
stimulation (data not shown).   
Next, to investigate this effect of stimulation on the model parameters, we 
performed a simultaneous fitting of the data before OAA/S (= unstimulated anesthesia state) 
and after laryngoscopy in a model-building process (= stimulated anesthesia state), starting 
with fixed common parameters for both data sets, followed by adding parameters for the 
difference between before OAA/S and after laryngoscopy.  This analysis revealed that 
C50SEVO was significantly higher after laryngoscopy for BIS, SE, and RE, with an average 
increase of 0.3 vol% sevoflurane (table 1), whereas the other parameters did not change.  
The response surfaces of the final models for BIS, SE, and RE are shown in figure 1.  Figures 
2–4 depict the observed values (open symbols) and predicted values (solid line) versus the 
normalized combined potency U for BIS, SE, and SE, respectively.  Because the baseline 
values, maximal effect and steepness of the model are not affected by the stimulation, the 
relationship between U and predicted value is not affected, and the solid line is identical for 
unstimulated and stimulated conditions.  For each combination of sevoflurane and 
remifentanil, the value UBIS (similar for USE and URE) after stimulation is lower compared 
with the unstimulated state as a result of the higher C50SEVO.  Consequently, the predicted 
BIS after stimulation will be higher than in the unstimulated state, reflecting a reduction of 
the combined drug effect.  In other words, stimulation moves UBIS to the left, and the 
predicted BIS upwards along the solid lines of figures 2–4.   
 
 
Fig. 5. Relationship between the normalized combined 
potency UCVI according to the Reduced Greco model and 
the observed Composite Variability Index (CVI) (squares, n 
= 122) and predicted CVI (lines; calculated from the data 
listed in table 1) for unstimulated (filled symbols, solid line) 
and stimulated (open symbols, dashed line).   
 
 
 
 
 
In contrast, simultaneous analysis of the CVI data before OAA/S and after laryngoscopy, 
with parameters fixed to the values from the analysis of the data before OAA/S alone (table 
1), resulted in a lower value for C50REMI (3.09 ng/ml; CI, 1.78 to 4.68 ng/ml), a higher value 
for γ (1.62; CI, 1.28 to 1.79), and E0 (13.1; CI, 9.4 to 17.2).  Also, the residual SD (46%; CI, 37 
to 53%) after stimulation was higher, indicating an even larger variability in the dose–
response relationship of CVI compared with the unstimulated condition.  Figure 5 depicts the 
observed values (open symbols) and predicted CVI (dashed line) versus the normalized 
combined potency UCVI, respectively.  Figure 5 also shows the shift in dose–response 
relationship of CVI versus UCVI between the unstimulated (solid line) and stimulated 
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condition (dashed line).  Because the baseline and steepness are affected by the stimulation, 
the relationship between UCVI and predicted value is different for the unstimulated and 
stimulated data.  The response surface for CVI after stimulation is shown in figure 1.   
The SPI data after stimulation (104 valid SPI values) were analyzed using the same 
approaches.  Similar to the unstimulated data, the SPI values after stimulation were hardly 
affected by sevoflurane or remifentanil, and modeling did not result in reliable results (data 
not shown).   
 
210 Isoboles 
In figure 6, the isoboles of BIS values from 10 to 80 are depicted for the unstimulated (solid 
lines) and stimulated (dashed lines) condition.  The additive nature of the interaction results 
in linear isoboles for the complete range of BIS values.  The isoboles are shifted upwards 
after stimulation, reflecting the increase in C50SEVO.   
In figure 7, the isoboles of CVI values from 0.5 to 3 are depicted for the unstimulated 
(solid lines) and stimulated (dashed lines) condition, showing a synergistic nature of the 
interaction, as reflected by the Reduced Greco model.  For low CVI values, the isoboles of 
the stimulated condition intersect the isoboles of the unstimulated condition.   
For SPI, no isoboles could be depicted, as we could not fit an appropriate response 
surface model to the data.   
 
 
Fig. 6. Isoboles for bispectral index values of 10, 20, 30, 40, 
50, 60, 70, and 80 for the unstimulated (solid lines) and 
stimu-lated (dashed lines) data, as a function of the end-
tidal sevoflurane concentration and the predicted 
remifentanil effect-site concentration, calculated from the 
data listed in table 1.   
 
Fig. 7. Isoboles for Composite Variability Index values of 
0.5, 1, 1.5, 2, 2.5, and 3 for the unstimulated (solid lines) 
and stimulated (dashed lines) data, as a function of the end-
tidal sevoflurane concentration and the predicted 
remifentanil effect-site concentration, calculated from the 
data listed in table 1.   
 
3 Discussion  
 
We describe the interaction between sevoflurane and remifentanil on BIS, SE, RE, CVI, and 
SPI.  Although opioids have a rather weak effect on the electroencephalogram, we found an 
additive effect of remifentanil on reduction of BIS, SE, and RE by sevoflurane.  The effect on 
CVI was synergistic.  The SPI was not affected by sevoflurane or remifentanil.  The Greco 
model provided the best fit of the data for BIS, SE, and RE, whereas the reduced Greco 
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model best described CVI.  Interestingly, the structural interaction model was not affected 
by noxious stimulation, but noxious stimulation did increase the C50SEVO for BIS, SE, and RE 
by 20%, whereas the C50REMI did not change.  In contrast, for CVI all model parameters 
changed except C50SEVO.   
The findings on (unstimulated) BIS, SE, and RE are in agreement with that reported in 
previous literature.  Nieuwenhuijs et al.12 presented an interaction model during 
sevoflurane–alfentanil anesthesia, suggesting additivity for BIS.  During propofol anesthesia, 
Vanluchene et al.3 found that remifentanil evoked an increase in the threshold for loss of 
consciousness on BIS, SE, and RE in a dose-dependent way, but no conclusion was drawn on 
the nature of this interaction.  Bouillon et al.13 found additivity for BIS during propofol–
remifentanil anesthesia.  Schumacher et al.10 found an additive interaction on BIS for 
combined propofol and sevoflurane.  Conversely, the interaction of sevoflurane and 
remifentanil on clinical endpoints of effect, as published by Heyse et al.,2 was not additive 
but synergistic.  Also, C50REMI was 10-fold higher for BIS, SE, and RE compared with C50REMI 
for dichotomous endpoints.2  Apparently, the opioid effect on the electroencephalogram is 
weak, despite a strong effect on patient responsiveness.  This may explain why 
electroencephalographic variables are poor predictors of responsiveness to noxious stimuli.   
According to the parameter estimates (table 1), BIS is least opioid sensitive, followed 
by SE, RE, and CVI, whereas BIS, SE, and RE are equally sensitive to sevoflurane, but less than 
CVI.  The slope of the response surfaces is similar for BIS, SE, and RE, but steeper than the 
slope for CVI (fig. 5).  The interaction model for BIS is characterized by the lowest 
interindividual (table 1: IIV [C50REMI]) and residual variability.   
Interaction models not only define combined effects of sevoflurane and remifentanil 
as a response surface but also allow expression of the potency of a combination of drugs as 
one dimensionless number.  For this purpose, we introduced “U” being units of combined 
potency related to each of the investigated effects variables.  For example, UBIS is the sum of 
the sevoflurane and remifentanil concentration both normalized to the respective C50’s of 
the BIS dose–response curve (equations 2 and 4).  The potency UBIS = 1 can be achieved by 
1.99 vol% of sevoflurane (=C50SEVO) or (e.g.) by 1.49 vol% of sevoflurane (=0.75 × C50SEVO) 
plus 6.8ng/ml of remifentanil (=0.25 × C50REMI). As C50 is specific for each 
electroencephalographic variable, one given sevoflurane and remifentanil concentration 
does not yield identical values of “U” for BIS, SE, RE, or CVI.  According to the final models 
(table 1), 1.5 vol% of sevoflurane combined with 5ng/ml of remifentanil yields a UBIS, USE, 
URE, and UCVI of 0.94, 1.13, 1.07, and 2.29, respectively.   
In concordance with Minto et al.,11 we consider the combination of two drugs as a 
virtual new drug. “U” can be used as if it was a drug concentration of that virtual new drug 
on the x-axis of a two-dimensional concentration–response curve (figs. 2–5).  With the 
selected interaction models, the combined potency “U” predicted the effect on BIS, SE, and 
RE with an error of approximately 10%, which is comparable to that reported in the previous 
studies.13   
“U” as a number represents potency of a combination of sevoflurane and 
remifentanil to suppress the electroencephalographic variable and has similarities with the 
Noxious Stimulation Response Index.14  The Noxious Stimulation Response Index is based on 
the suppression of a response to laryngoscopy, using the Hierarchical interaction model.  The 
C50REMI (1.16ng/ml) in this model is much lower than the C50REMI in the current study (7.5 to 
27.3ng/ml, depending on the type of electroencephalographic variable).  This makes Noxious 
 
83 
 
Stimulation Response Index much more opioid sensitive compared with “U,” which is in 
agreement with the fact that hypnotics have a stronger effect on electroencephalogram 
than the effects of opioids on electroencephalogram.  The clinical utility of any of the “U”s or 
Noxious Stimulation Response Index to titrate opioids and hypnotics remains to be 
determined.   
The CVI as a potential indicator of nociception behaved similar as dichotomous 
endpoints in the previous study2: the interaction was synergistic.  The best fit was found with 
the reduced Greco model.  As expected, the concentration–response curve of CVI was 
affected by noxious stimulation (figs. 5 and 7), especially due to a substantial increase in 
baseline effect (E0), probably due to an increase in electromyographic activity.  The dose–
response curve was rather flat, and a ceiling effect was observed at the level of a CVI of 
approximately 1 (fig. 5).  This explains why a larger increase of the sevoflurane concentration 
is needed to lower CVI from 1 to 0.5 than that required to lower CVI from 3 to 2.5 (fig. 7).  
Although noxious stimulation and opioids evoke a greater effect on CVI than on BIS, SE, and 
RE, CVI may offer lower discriminating capacity compared with BIS, SE, and RE.  Even in our 
best-fitted model, the differences between estimated and observed CVI were high, 
especially after noxious stimulation (figs. 1 and 5).   
The poststimulation data set represents a population that is in a pharmacological 
pseudosteady state (at similar drug concentrations as before stimulation), where the applied 
stimuli may have disrupted the balance between drug concentrations and effect variables.  
Assuming that noxious stimulation might induce an arousal response on the 
electroencephalographic variables, we hypothesized that the parameter estimates from the 
poststimulation data could be different from those of the prestimulation data.  We expected 
larger differences in model estimates for CVI and SPI compared with BIS, SE, and RE, as the 
arousal response in BIS is already suppressed by rather low remifentanil concentrations.15   
For all poststimulation response surface models, the structural model with the lowest 
objective function was identical to the prestimulation model.  For BIS, SE, and RE, the model 
parameters hardly changed, except for C50SEVO (consistently 0.3 vol% higher after 
laryngoscopy).  This pharmacodynamic shift is consistent for BIS and entropy and it is only 
little smaller than the difference between C50SEVO for tolerance of shake and shout and 
laryngoscopy, found in the previous article (0.53 vol%).2  Typical accuracy for measuring 
sevoflurane end-tidal concentrations is ±0.15 vol% + 5% of reading.  The time between 
nonstimulation and poststimulation sampling did not exceed 6min and therefore was 
assumed to be constant.  Therefore, we consider 0.3 vol% (or 14% of 1 minimal alveolar 
concentration) as clinically relevant.  The sevoflurane and remifentanil concentrations 
mentioned above (1.5 vol% and 5 ng/ml) yield a poststimulation U for BIS, SE, and RE which 
is approximately 10% lower than the prestimulation U.  Therefore, both single-model 
parameters (e.g., C50s) and combined potency U could be used as surrogate measures of 
stimulus intensity.   
For CVI, the changes in the poststimulation model are complex. C50REMI decreased to 
3.09 ng/ml.  Gamma and the baseline effect (E0) increased.  The increased steepness of the 
dose–response curve and the larger difference between baseline and maximal effect suggest 
an improved descriptive capacity for CVI in stimulated compared with unstimulated 
conditions.  However, the residual SD and the standard errors of the parameters indicate a 
larger variability in the dose–response relationship compared with the unstimulated 
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condition.  Our finding is in agreement with the notion that a noxious stimulus is mandatory 
to measure the balance between nociception and antinociception accurately.   
For SPI, we were not able to extract plausible parameter estimates from our data, 
neither from prestimulation nor from poststimulation observations.  Either SPI is hardly 
affected by sevoflurane and remifentanil or the inter- and intraindividual variability of SPI 
hides a minimal dose– response relationship.  The sympathetic and parasympathetic nerve 
system may be affected by many confounding factors apart from noxious stimulation and 
anesthetic drug dosages.  The inability to detect any dose–response relationship in steady-
state conditions, both with or without noxious stimulation, lowers the expectations for SPI 
as a guide for titrating sevoflurane and remifentanil anesthesia.   
In conclusion, sevoflurane and remifentanil are additive on BIS and entropy, but they 
act synergistic on CVI.  SPI is not correlated to drug concentrations.  Noxious stimulation did 
not change structural models but increased the C50 of sevoflurane related to BIS and 
entropy, whereas a more complex parameter shift was found for CVI.   
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ABSTRACT 
 
Background: The interaction of sevoflurane and opioids can be described by response 
surface modeling using the hierarchical model.  We expanded this for combined 
administration of sevoflurane, opioids, and 66 vol.% nitrous oxide (N2O), using historical data 
on the motor and hemodynamic responsiveness to incision, the minimal alveolar 
concentration, and minimal alveolar concentration to block autonomic reflexes to 
nociceptive stimuli, respectively.   
 
Methods: Four potential actions of 66 vol.% N2O were postulated: (1) N2O is equivalent to A 
ng/ml of fentanyl (additive); (2) N2O reduces C50 of fentanyl by factor B; (3) N2O is 
equivalent to X vol.% of sevoflurane (additive); (4) N2O reduces C50 of sevoflurane by factor 
Y.  These four actions, and all combinations, were fitted on the data using NONMEM 
(version VI, Icon Development Solutions, Ellicott City, MD), assuming identical interaction 
parameters (A, B, X, Y) for movement and sympathetic responses.   
 
Results: Sixty-six volume percentage nitrous oxide evokes an additive effect corresponding 
to 0.27 ng/ml fentanyl (A) with an additive effect corresponding to 0.54 vol.% sevoflurane 
(X).  Parameters B and Y did not improve the fit.   
Conclusion: The effect of nitrous oxide can be incorporated into the hierarchical interaction 
model with a simple extension.  The model can be used to predict the probability of 
movement and sympathetic responses during sevoflurane anesthesia taking into account 
interactions with opioids and 66 vol.% N2O.   
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Katoh et al.1 described the reduction of minimal alveolar concentration (MAC) and MAC to 
block autonomic reflexes to nociceptive stimuli (MAC-BAR) of sevoflurane by fentanyl.  MAC 
and MAC-BAR are the minimal alveolar anesthetic concentrations that evoke respectively 
“immobility” or “hemodynamic stability” after surgical incision in 50% of subjects.  Nitrous 
oxide (N2O) is combined with inhaled anesthetics in anesthesia for its potentiating effects. 
For this reason, Katoh et al.1 also tested the MAC reduction evoked by nitrous oxide.   
The classical MAC reduction studies use a logistic regression approach.2  The logistic 
regression approach as applied by Katoh et al. does not provide unique parameters 
describing the influence of nitrous oxide, independent of the type of response (movement 
or hemodynamic), thus not allowing to apply the results to other responses.  Because the 
article of Katoh et al. does not provide the model parameters of the logistic regression 
analysis, it does not allow a flexible calculation of the probability of response at any drug 
level.   
Currently, nonlinear mixed effect modeling is considered to be the definitive 
standard for modeling three dimensional response surfaces on interaction datasets.3  One of 
the advantages of the response surface approach is that a single formula describes the full 
range of effect for any combination of drugs.2,3  Recently, Heyse et al.4 reviewed several 
equations that have been proposed as structural model for response surface modeling and 
found that the hierarchical model (with fixed C50 of opioids) performed best to predict the 
response to multiple noxious and non-noxious stimuli during a sevoflurane–remifentanil 
anesthesia.  In contrast to the logistic regression approach, the hierarchical model is a 
mechanism-based model in which every parameter represents a pharmacologic endpoint, 
which has clinical meaning (e.g., potency of the opioid, potency of the hypnotic, steepness 
of the dose–response relationship).  The parameters of the logistic regression are 
mathematical constants that have no physiological or pharmacologic correlate.   
A response surface model that describes the effects of nitrous oxide has not yet been 
described.  We hypothesized that the hierarchical model could be expanded further to allow 
flexible inclusion of the effects of 66 vol.% N2O in the interaction between opioids and 
sevoflurane.   
The methodology for response surface modeling demands high numbers of 
observations in volunteers or patients, considerable costs, and manpower.  Fortunately, we 
had the opportunity to reuse the historical dataset of Katoh et al.1  Contemporary analyzing 
methods can extract more information from this data compared with the classical MAC 
reduction approach.  The data from Katoh et al.1 contain large numbers of observations with 
sufficient numbers of responders and nonresponders and a wide range of drug doses.   
The purpose of the current study was to develop a response surface model for the 
combination of sevoflurane, nitrous oxide, and fentanyl using this dataset.   
 
1 Materials and Methods 
11 Data 
The study by Katoh et al.1 was performed after approval from the District Ethics Committee 
of Hamamatsu University Hospital (Hamamatsu, Japan), and individual informed consent had 
been obtained from all patients.  We reanalyzed the raw data from Katoh et al.1 on the 
sevoflurane MAC and MAC-BAR reduction by fentanyl in the presence (n = 86 patients) or 
absence (n = 96 patients) of 66 vol.% N2O.  Patients were randomly assigned to receive 
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nitrous oxide or not.  Patients of both sexes, between 20 and 50 years, were classified as 
American Society of Anesthesiologists physical status I and were scheduled for elective 
surgery of the abdomen, extremities, or body surface.   
 
12 Anesthetic Management 
The anesthetic management and data collection were described in detail in the original 
article.1  In short, all patients fasted for at least 8 h before anesthesia and received no 
premedication.  A target-controlled infusion of fentanyl (using the pharmacokinetic model 
published by Shafer et al.5) was initiated in all patients, according to a randomization list.  
Fentanyl plasma concentration targets ranged between 0 and 8 ng/ml.  Inhaled induction 
was performed with sevoflurane 8% in 100% oxygen (control group) or sevoflurane 8% in 
oxygen with 66 vol.% N2O group.  After loss of consciousness and precurarization with 0.02 
mg/kg vecuronium, 1.5 mg/kg succinylcholine was administered and tracheal intubation was 
performed to secure the airway for the remainder of the study.  Ventilation was adjusted to 
maintain normocapnia.  An end-tidal concentration of sevoflurane was targeted according to 
a randomization list, between 0 and 4.5 vol.%.  N2O was administered at an end-tidal 
concentration of 66 vol.%.  End-tidal concentrations of sevoflurane, nitrous oxide, and 
carbon dioxide were measured continuously using an infrared multigas anesthetic analyzer 
(Capnomac Ultima, Datex, Helsinki, Finland), which was calibrated before anesthesia for 
each patient using a standard gas mixture.  Gas samples were collected via a catheter placed 
at the tracheal end of the endotracheal tube.   
After intubation and setting the drug targets for maintenance, a 20-min delay was 
respected to allow equilibration between the effect-site concentration and the end-tidal 
vapor pressure of sevoflurane and the plasma concentration of fentanyl, respectively.  As 
such, all observations of the responses were performed during a pharmacologic pseudo 
steady state.  This was confirmed by analysis of venous blood samples taken 5 min before 
and within 30 s after incision.  Patients with a difference in measured plasma fentanyl 
concentration of more than 35% between samples were excluded from further analysis.  The 
delay of 20 min also allowed recovery from the neuromuscular blocking agents, which was 
confirmed by monitoring the recovery.   
Twenty minutes after intubation, the surgeon made an abdominal incision and 
somatic or hemodynamic responses were observed.  Positive response was defined as a 
somatic or hemodynamic change within 60 s after incision.  Coughing, chewing, or 
swallowing was not considered a purposeful movement.  Hemodynamic response was 
defined as an increase in heart rate or systolic blood pressure of more than 15% over the 
preincision baseline value.   
 
13 Interaction Model  
 The probability of tolerance, P, to a certain stimulus ( e.g. , incision) can be expressed as  
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ࡼ =
ࢁࢽ
૚ + ࢁࢽ
 
(1) 
 
where U represents the normalized potency of a single drug or a combination of drugs.  U is 
a function of the drug effect-site concentrations and model parameters, reflecting the 
relative drug concentration, and γ is the slope parameter reflecting the steepness of the 
concentration–effect relationship.4,6   
The hierarchical model (equation 2) can be incorporated in equation 1 for calculating 
all levels of probability of response.6   
 
ࢁ = ࢁࡿࡱࢂࡻ ∙ (૚ + ࢁࡻࢽࡻ) 
(2) 
where  
ࢁࡻ =
࡯ࡻ
࡯૞૙ࡻ
 
(3) 
and  
ࢁࡿࡱࢂ =
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
 
(4) 
 
UO and USEVO are the normalized opioid and sevoflurane effect-site concentrations, CO is the 
effect-site concentration of the opioid, CSEVO is the sevoflurane effect-site concentration, 
C50O is the effect-site concentration of the opioid that decreases C50SEVO by 50%, C50SEVO is 
the sevoflurane effect-site concentration that results in P = 0.5 in the absence of opioid, and 
γO is the slope parameter reflecting the steepness of the concentration-effect relationship of 
the opioid.   
The hierarchical model resulted in the best fit during sevoflurane–remifentanil 
interactions.4  We first used the same structural model to fit the interaction in the control 
group (sevoflurane, fentanyl, without N 2 O) of the study by Katoh et al.1   
The data of the study by Katoh et al. did not allow a full response surface modeling of 
the three drugs (sevoflurane, fentanyl, N2O) because N2O was applied at a single 
concentration level (66 vol.%) only.  Therefore, the influence of N2O was treated as a 
covariate in the hierarchical model of sevoflurane and opioids.  For this purpose, we 
postulated that N2O interacts with sevoflurane and/or fentanyl as expressed below.   
 
1. Fentanyl: 
a. N2O is equivalent to a concentration of A ng/ml of fentanyl (additive 
interaction) 
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b. N2O reduces the C50 of fentanyl by a factor B (potentiation, nonadditive 
interaction) 
2. Sevoflurane: 
a. N2O is equivalent to a concentration of X vol.% of sevoflurane (additive 
interaction) 
b. N2O reduces the C50 of sevoflurane by a factor Y (potentiation, nonadditive 
interaction) 
To incorporate these assumptions into the hierarchical model, parameter A, B, X, and Y were 
added to equations 3 and 4, as shown in equations 5 and 6:  
 
ࢁࡻ =
࡯ࡻ + ࡭
࡯૞૙ࡻ ∙ ࡮
 
(5) 
ࢁࡿࡱࢂ =
࡯ࡿࡱࢂࡻ + ࢄ
࡯૞૙ࡿࡱࢂࡻ ∙ ࢅ
 
(6) 
 
Using equations 5 and 6 as a structural model, each of the postulated actions of N2O and any 
of the combinations of A, B, X, and Y were fitted simultaneously to all data for model 
parameter estimation.   
 
14 Parameter Estimation  
The model parameters were estimated using NONMEM VI version 2.0 (Icon Development 
Solutions, Ellicott City, MD), using FOCE LAPLACE and LIKELIHOOD options.  Platform was 
Windows XP (Microsoft, Redmond, WA) and compiler was G95.  For all parameters, the 
interindividual variability was either assumed to be absent or to have a lognormal 
distribution.  Model building was performed starting with the simplest form of each model 
and expanding the model with interaction terms and interindividual variability, until the 
decrease of the objective function value (OFV) was no longer statistically significant using 
the chi-square test.  For each added parameter, a difference of 3.84 units in OFV was 
considered statistical significant at P < 0.05.   
The NONMEM analysis was performed with various values for initial estimates and 
boundary values.  The results were accepted as valid only if both minimization and 
covariance step were successful, unless stated otherwise.   
To evaluate the uncertainty in the parameters of the final model, nonparametric 95% 
CIs of the model parameters were obtained from a bootstrap analysis, based on 500 sets of 
177 patients each, randomly selected from the available 177 patients, using a custom 
program written in C.  Results were analyzed in Microsoft Excel version 2010.  In addition, 
log-likelihood profiles were calculated for each population parameter, and the 
nonparametric 95% CIs were obtained assuming a chi-square distribution with one degree of 
freedom and P = 0.025, resulting in a critical difference of 5.02 in the OFV.   
Several performance measures were calculated from the prediction errors, i.e., the 
difference between the predicted probability of tolerance minus the observed response (0 
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for responsive, 1 for tolerant): Mean Prediction Error, Mean Absolute Prediction Error, and 
Root Mean Squared Error.  In addition, the Prediction Error Score was calculated as the 
percentage of mispredicted responses, i.e. , if tolerant, the probability of tolerance was less 
than 0.5, or if responsive, the probability of tolerance was more than 0.5.   
 
15 Statistical Analysis 
All model parameters are reported as typical values with standard errors (expressed in % of 
the typical value) within parentheses, and clinical data are given as mean and SD.   
 
2 Results 
Of the 96 patients not receiving nitrous oxide, two patients were excluded because of 
hypotension and the administration of ephedrine before the incision, and three patients 
were excluded because they were judged as being awake just before skin incision.  
Therefore, our analysis was performed on the remaining 177 patients of which 86 did 
receive nitrous oxide and 91 did not.  Demographic data can be found in the original article.1  
The measured drug concentration of fentanyl before incision ranged between 0 and 10 
ng/ml.  The measured end-tidal partial pressure of sevoflurane at the time of observation 
ranged between 0 and 4 vol.%.   
 
Table 1. The Objective Function Value (OFV), No. of Parameters, Parameter Estimations, and Measures  of 
Performance for the Hierarchical Model Derived from the Control Group (without Nitrous Oxide) and for Three 
Competing Models (Sevoflurane-Additivity Model, Sevoflurane/Opioid-Additivity Model, and Sevoflurane-
Additivity/Potentiation Model) Derived from the Total Dataset 
     Sevoflurane/  Sevoflurane-  
  Control Group  Sevoflurane-  Opioid- Additivity/  
 Units  (Without Nitrous  Additivity   Additivity   Potentiation 
    Oxide) Model (X) Model (XA) Model (XY) 
OFV — * 209.0 200.8 199.5 
No. of parameters — 6 7 8 8 
Model parameters 
ng/ml 2.07 (22) 2.46 (16) 2.07 (19) 2.13 (16)  C50O-movement 
 C50O-hemodynamic ng/ml 0.43 (41) 0.71 (19) 0.47 (33) 0.62 (20) 
 C50SEVO-movement vol.% 1.73 (8) 1.59 (6) 1.68 (7) 1.71 (6) 
 C50SEVO-hemodynamic vol.% 4.60 (18) 3.59 (8) 4.63 (17) 4.18 (11) 
 γO — 0.931 (12) 0.941 (9) 0.907 (10) 0.982 (9) 
 γ — 6.40 (17) 6.92 (12) 7.09 (12) 6.70 (13) 
 X vol.% — 0.64 (9) 0.54 (11) 0.35 (22) 
 Y — — — — 0.70 (11) 
 A ng/ml — — 0.27 (43) — 
Model performance 
— 
 
0.0 0.0 0.0  MPE (%) 
 MAPE (%) —  19.1 18.2 18.1 
 RMSE (%) —  31.2 30.4 30.3 
 Prediction error score (%)  —   14.7 12.1 12.4 
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Typical values (standard error, in % of the typical value). 
* Obtained from data without nitrous oxide; therefore, OFV is not comparable to other models. γ = steepness of concentration–
effect relationship of sevoflurane; γO = steepness of concentration–effect relationship of opioid; MAPE = mean absolute prediction 
error; MPE = mean prediction error; OFV = objective function value; RMSE = root mean squared error; prediction error score = 
percentage of mispredicted responses; X, Y, A = interaction parameters for nitrous oxide, identical for movement and 
hemodynamic responses,  
 
Fig. 1. Observed somatic responses to incision in the control group (A) and in the nitrous oxide (N2O) group (B).  Minimal 
alveolar concentration (MAC) that evokes 50% tolerance to incision (MAC).  MAC that evokes 95% tolerance to incision. 
(MAC95) MAC and MAC95 calculated with the sevoflurane/opioid-additivity model (XA). 
 
To identify the model for the interaction of sevoflurane and fentanyl, the data from 
patients not receiving nitrous oxide (control group) were analyzed using the hierarchical 
model with separate, unconstrained values for C50O for movement and sympathetic 
responses.4,6  Using the fixed C50O and the scaled C50O approach resulted in an increase of 
OFV by 29 and 37, respectively.  Therefore, the model with separate values for C50O was 
considered the appropriate model for the interaction of sevoflurane and fentanyl for 
movement and sympathetic responses.  Parameter estimations are listed in table 1.   
For the simultaneous analysis of all data, the hierarchical model with different values of C50O 
and C50SEVO for movement and sympathetic responses was expanded by one of the factors 
X, Y, A, or B, resulting in a decrease of the OFV by 123, 54, 35, and 57, respectively, showing 
that factor X (called the sevoflurane-additivity model [X]) is the most influential factor in the 
model.  Using different values of X for movement and for sympathetic responses in the 
sevoflurane-additivity model (X) did not result in a significant difference of OFV (–0.6).   
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Fig. 2. Observed hemodynamic responses to incision in the control group (A) and in the nitrous oxide (N2O) group (B).  Minimal 
alveolar concentration to block autonomic reflexes to nociceptive stimuli in 50% of patients (MAC-BAR) and 95% of patients 
(MAC-BAR95) using the sevoflurane/opioid-additivity model (XA).   
 
In a second step, we expanded the sevoflurane-additivity model (X) further by 
including factors A or B in the equation.  Inclusion of factor A in combination with factor X 
(sevoflurane/opioid-additivity model [XA]) resulted in a significant decrease of the OFV by 
8.2 units.  Using separate values of X and A for movement and sympathetic responses did  
not result in a significant drop of the OFV.  Combining factor B with factor X did not result in 
a significant decrease of OFV (–1.5).   
In a third step, we combined factor X with factor Y (sevoflurane-
additivity/potentiation model [XY]), which resulted in a decrease of the OFV of –9.5 units 
compared with the sevoflurane-additivity model (X).  This model mathematically combines 
an additive (X) and nonadditive (Y) interaction of nitrous oxide with sevoflurane.  This model 
does not support an independent interaction of nitrous oxide with fentanyl.  The difference 
between the OFV of the sevoflurane/opioid-additivity (XA) and sevoflurane -
additivity/potentiation (XY) models is not significant.   
Finally, the combinations of three or four factors, including X (XYA, XYB, XAB, XYAB), 
did not result in lower OFV.  In addition, the inclusion of intraindividual variability in any 
parameter did not result in a significant reduction of OFV for any model.   
The final results of the parameter estimations for three adequately fitting models are 
listed in table 1.  In all models, the values for X, Y, and A are identical for movement and 
sympathetic responses.  Figures 1 and 2 show the observed somatic (fig. 1) and 
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hemodynamic (fig. 2) responses to incision in the control group (fig. 2A) and in the nitrous 
oxide group (fig. 2B), and MAC and MAC95 (fig. 1) and MAC-BAR and MAC-BAR95 (fig. 2) for 
the sevoflurane/opioid-additivity model (XA).  Figure 3 shows the three-dimensional 
response surface as predicted by this model for movement (fig. 3, A and C) and 
hemodynamic responses (fig. 3, B and D) after incision in the control group (fig. 3, A and B) 
and in the nitrous oxide group (fig. 3, C and D).  MAC, MAC-BAR, MAC95, and MAC-BAR95 
estimations for sevoflurane in the absence and presence of nitrous oxide and fentanyl for 
the sevoflurane/opioid-additivity model (XA) are also listed in table 2.  The values are within 
comparable range of the results of Katoh et al.1 (table 3).  The differences between the 
sevoflurane/opioid-additivity (XA) and sevoflurane-additivity/ potentiation (XY) models with 
respect to the measures of “goodness-of-prediction” were rather small (table 1).   
The results of the final sevoflurane/opioid-additivity model (XA) were checked by 
performing a bootstrap analysis.  The median parameters of the bootstrap analysis were in 
reasonable agreement with the NONMEM results.  The 95% CI for the parameters X (0.54 
vol.% sevoflurane) and A (0.27 ng/ ml fentanyl) were 0.41–0.67 vol.% and 0.07–0.62 ng/ml, 
respectively.  The 95% CI obtained from the log-likelihood profiles was 0.42–0.68 vol.% for X 
and 0.05–0.58 ng/ml for A.   
 
3 Discussion 
In this reanalysis of previously published data, we present new information on the 
interaction between opioids, sevoflurane, and nitrous oxide compared with the original 
work.1  We found that a simple extension of the hierarchical model (equations 2–6) 
integrates the additional effect of 66 vol.% N2O to the interaction of fentanyl and 
sevoflurane using a response surface modeling approach.   
Although the opioid used was fentanyl, we often do refer to it using the more 
general term “opioid.”  This is a deliberate choice because the model may be applicable for 
other opioids also, provided that equipotent doses of the other opioids are given.7   
The major difference between our analysis (using the hierarchical model) and the original 
analysis by Katoh et al. (using logistic regression) is that our analysis was performed on all 
data simultaneously, i.e., a single analysis with parameters common for the groups 
(movement and sympathetic response, without and with nitrous oxide) where appropriate, 
rather than on all four groups of data separately.  In principle, both approaches are equally 
valid, and we confirmed that the MAC and MAC-BAR values for both approaches are 
comparable.  However, the separate logistic analysis does not provide unique parameters 
describing the influence of nitrous oxide, in contrast to the simultaneous response surface 
approach providing these parameters (A, B, X, Y).  The unique parameters allow to apply the 
results to other responses to noxious stimuli, e.g., tolerance to laryngoscopy, taking into 
account the difference in intensity of the noxious stimuli.  Once the interaction of  
sevoflurane and opioids has been adequately described by the hierarchical model, the 
interaction with nitrous oxide can be modeled by adding parameters A, B, X, and/or Y of the 
nitrous oxide interaction according to equations 5 and 6.   
We used the hierarchical model in our analysis, because this model was found to 
describe the interaction between sevoflurane and remifentanil best.4  For comparison, we 
also tested the Greco model, reduced Greco model, and the logistic model using the 
simultaneous approach.  For each of the tested models, and for each model for the nitrous  
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Fig. 3. Three-dimensional response surfaces as predicted by the sevoflurane/opioid-additivity model (XA). A and B, Response 
surface for, respectively, movement and hemodynamic responses after incision in the control group (fentanyl, sevoflurane, no 
nitrous oxide). C and D, Response surface for, respectively, movement and hemodynamic responses after incision in the nitrous 
oxide (N2O) group (fentanyl, sevoflurane, 66 vol.% nitrous oxide). 
 
oxide effect (X, XY, XA), the OFV values and model parameters were close to that of the 
hierarchical model.  From a clinical point of view, the hierarchical model reflects the 
physiologic sequence of the opioid and hypnotic drug effect : Opioids reduce the afferent  
nociceptive transmission to medulla, thalamus, and cortex and thus the arousal response to 
the nociceptive stimulus and thus the hypnotic drug concentration to keep the patient 
asleep or unresponsive.   
The process of minimizing the OFV is presented in separate stages because each 
stage represents a logical sequence where we tested a hypothesis on the interaction 
mechanisms that may explain the observed data.   
In the first stage of modeling, the sevoflurane-additivity model (X) fitted the data 
best, supporting the hypothesis that an additive interaction of nitrous oxide with sevoflurane 
contributes strongly to the leftward shift of the isoboles.  Model Y (potentiation of 
sevoflurane) was by far inferior to the sevoflurane-additivity model (X), which suggests that 
a reduction of C50SEVO by nitrous oxide is less likely than an additive effect.  This finding is in 
concordance with the MAC additivity principle.   
The second stage explored whether the fit on the data can be improved by modeling 
the analgesic potency of nitrous oxide.  The flexibility of the structural model increases by 
assuming an additional interaction between nitrous oxide and fentanyl (in an additive (A) or 
nonadditive (B) way, respectively).  We found that 66 vol.% N2O corresponds simultaneously 
to 0.27 ng/ml of fentanyl (A) and 0.54 vol.% of sevoflurane (X).   
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Table 2. MAC, MAC-BAR, MAC95, and MAC-BAR95 Values for Sevoflurane (vol.%) Calculated for the 
Sevoflurane/Opioid-Additivity Model (XA) in the Absence and Presence of 66 vol.% Nitrous Oxide (N2O) and 
Fentanyl (1, 3, or 6 ng/ml) 
  No Fentanyl 1 ng/ml Fentanyl 3 ng/ml Fentanyl 6 ng/ml Fentanyl 
MAC 1.68 1.11 0.70 0.46 
+N2O 0.91 0.48 0.13 0* 
Reduction by 66 vol.% N2O 46% 56% 82% 100% 
MAC-BAR 4.63 1.56 0.73 0.42 
+N2O 2.37 0.81 0.15 0 * 
Reduction by 66 vol.% N2O 49% 48% 80% 100% 
MAC95 2.54 1.68 1.06 0.70 
+N2O 1.66 1.01 0.47 0.14 
Reduction by 66 vol.% N2O 35% 40% 55% 80% 
MAC-BAR95 7.02 2.36 1.11 0.64 
+N2O 3.87 1.50 0.50 0.08 
Reduction by 66 vol.% N2O 45% 36% 55% 88% 
* No response in more than 50% of patients in the absence of sevoflurane.   
MAC = concentration of sevoflurane (vol.%) required to avoid moving in 50% of patients; MAC-BAR = concentration of sevoflurane 
(vol.%) required to avoid hemodynamic response in 50% of patients; MAC95 = concentration of sevoflurane (vol.%) required to 
avoid moving in 95% of patients; MAC-BAR95 = concentration of sevoflurane (vol.%) required to avoid hemodynamic response in 
95% of patients 
Table 3. MAC, MAC-BAR, MAC95, and MAC-BAR95 Values for Sevoflurane (vol.%) as Reported by 
Katoh  et al.1 in the Absence and Presence of 66 vol.% Nitrous Oxide (N2O) and Fentanyl (1, 3, or 6 
ng/ml) 
  No  Fentanyl 
1 ng/ml  
Fentanyl 
3 ng/ml 
Fentanyl 
6 ng/ml  
Fentanyl 
MAC 1.85 1.16 0.72 0.48 
+N2O 0.79 * * * 
MAC-BAR 4.15 1.78 0.71 0.33 
+N2O 2.52 * * * 
MAC95 2.28 * * * 
+N2O 1.10 * * * 
MAC-BAR95 6.26 * * * 
+N2O 2.98 * * * 
* Data not reported in the original publication.     
MAC = concentration of sevoflurane (vol.%) required to avoid moving in 50% of patients; MAC-BAR = concentration 
of sevoflurane (vol.%) required to avoid hemodynamic response in 50% of patients; MAC95 = concentration of 
sevoflurane (vol.%) required to avoid moving in 95% of patients; MAC-BAR95 = concentration of sevoflurane (vol.%) 
required to avoid hemodynamic response in 95% of patients. 
 
 
The parameter estimates of sevoflurane MAC and MAC-BAR presented in table 2 are 
consistent with the results of the original article for the sevoflurane/opioid-additivity model 
(table 3).  The reduction of sevoflurane MAC by 66 vol.% N2O in the absence of fentanyl is 54 
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and 57% in the current and original study, respectively.  The C50 of fentanyl is 2.07 ng/ml in 
the current study and 1.8 ng/ml in the original study.  The small differences are presumably 
related to the differences in method of analysis.  Stevens et al.8 reported a reduction of the 
isoflurane MAC in the presence of 70% N2O by 68%.  Fragen and Dunn9 reported a reduction 
of the sevoflurane MAC in the presence of 65% N2O by 50%, whereas Rampil et al.10 
reported a 50% reduction for desflurane in the presence of 60% N2O.   
In the final stage of modeling, we tested several—more complex—combinations of 
interactions.  Only the combination of parameters X and Y resulted in a comparably low OFV 
(but without significant difference with the sevoflurane/opioid additivity model [XA]).  The 
sevoflurane-additivity/potentiation model (XY) is less consistent with current pharmacologic 
concepts because it describes the interaction between nitrous oxide and sevoflurane as a 
combined additive and nonadditive interaction with sevoflurane.  In addition, no 
independent analgesic effect of nitrous oxide is included in this model.  In addition, the C50 
values of the sevoflurane/opioid-additivity model (XA) are closer to the C50 values in 
conditions without nitrous oxide (control group) compared with that of the sevoflurane 
additivity/potentiation (XY) model (table 1).  For these reasons, we consider the 
sevoflurane/opioid-additivity model (XA) to be a better suited structural model to estimate 
responsiveness during opioid, sevoflurane, and nitrous oxide interaction.   
A potential limitation of this study is based on the fact that data were derived from 
only one particular population (Asian).  Even though MAC has limited variability within a 
population, interpopulation (ethnic) differences exist.11  Therefore, the validity of the 
proposed response surface model must be tested prospectively in a population with wider 
ethnic variation.   
Our response surface model only applies to the clinical endpoint of a somatic or 
hemodynamic response to a noxious stimulus, MAC and MAC-BAR, respectively.  For the 
response to stimuli that test the hypnotic state of the patient, such as “shake and shout,” 
“MACawake,” “name calling,” “the observer’s assessment of alertness and sedation score,” 
and the “isolated forearm technique,” we were not able to model a response surface 
because these endpoints were not included in our dataset.  Moreover, the available 
literature suggests that the nature of the interaction for hypnotic endpoints of anesthesia 
might be different compared with somatic responsiveness to noxious stimuli.  Data from 
Katoh et al. suggest the interaction between sevoflurane and nitrous oxide for MACawake to 
be infra-additive and so is the effect on learning.12–14  This has also been confirmed with 
thiopental and ethanol.15,16  This differential characteristic of the interaction for responses 
on noxious and non-noxious stimuli is probably evoked through differential balance of the N-
methyl-D-aspartate and γ-aminobutyric acid receptor type A receptor inhibition in the neural 
networks, especially in the unstimulated patient.12  In addition, several 
electroencephalographic-derived measures of cerebral hypnotic drug effect do not detect 
the addition of nitrous oxide both during intravenous and inhalational anesthesia in 
unstimulated patients.17  In conclusion, our final model currently is only applicable for 
responses to a noxious stimulus and does not allow extrapolation to hypnotic endpoints of 
anesthesia.   
Another important limitation of the dataset used in this analysis is that only one 
concentration of nitrous oxide has been tested and that data for other concentrations of 
nitrous oxide are currently lacking.  However, if we assume that lower concentrations of 
nitrous oxide (< 66vol.%) reduce the two interaction parameters X and  A in a proportional 
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way, the proposed the sevoflurane/opioid-additivity model (XA) can be generalized for 
different concentrations of nitrous oxide (CN2O) according to equations 7 and 8:  
 
ࢄ = ૙. ૞૝ ∗ ࡯ࡺ૛ࡻ/૟૟ 
(7) 
࡭ = ૙. ૛ૠ ∗ ࡯ࡺ૛ࡻ/૟૟ 
(8) 
 
Because equations 7 and 8 cannot be verified from our data, but are based on one 
assumption of linearity in the interaction between 0 and 66 vol.% N2O, the clinical 
performance of this proposed solution needs to be prospectively validated.   
The final response surface equation presented in this study can easily be applied in 
advisory systems that provide bedside pharmacokinetic – dynamic information based on the 
demographics of the patient and the administered drug doses.  Such devices are currently 
being commercialized for clinical practice; however, prospective validation is still mandatory 
to evaluate the population-based reference as a tool for the clinician to target desired levels 
of responsiveness in an individual case.11   
 
4 Conclusion  
The influence of 66 vol.% N2O was best described by a combination of an additive effect 
corresponding to 0.27ng/ ml fentanyl (A) and an additive effect corresponding to 0.54 vol.% 
sevoflurane (X).  With a simple extension, the effect of 66 vol.% N2O can be incorporated in 
the hierarchical interaction model of sevoflurane and opioids and allows to model the triple 
interaction in a response surface.   
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Chapter 6  Noxious Stimulation Response Index 
 
A Novel Anesthetic State Index Based on Hypnotic–Opioid 
Interaction 
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M.D., Hugo Vereecke, M.D., Ph.D., Björn Heyse, M.D., Thomas W. Bouillon, PD Dr. med., 
Michel M.R.F. Struys, M.D., Ph.D. 
 
Anesthesiology 2010; 112:872–80 
 
 
ABSTRACT 
 
Background: The noxious stimulation response index (NSRI) is a novel anesthetic depth index 
ranging between 100 and 0, computed from hypnotic and opioid effect-site concentrations 
using a hierarchical interaction model.  The authors validated the NSRI on previously 
published data.   
 
Methods: The data encompassed 44 women, American Society of Anesthesiology class I, 
randomly allocated to three groups receiving remifentanil infusions targeting 0, 2, and 4 
ng/ml Propofol was given at stepwise increasing effect-site target concentrations.  At each 
concentration, the observer assessment of alertness and sedation score, the response to 
eyelash and tetanic stimulation of the forearm, the bispectral index (BIS), and the acoustic 
evoked potential index (AAI) were recorded.  The authors computed the NSRI for each 
stimulation and calculated the prediction probabilities (PKs) using a bootstrap technique.  
The PKs of the different predictors were compared with multiple pairwise comparisons with 
Bonferroni correction.   
 
Results: The median (95% CI) PK of the NSRI, BIS, and AAI for loss of response to tetanic 
stimulation was 0.87 (0.75–0.96), 0.73 (0.58–0.85), and 0.70 (0.54–0.84), respectively.  The 
PK of effect-site propofol concentration, BIS, and AAI for observer assessment of alertness 
and sedation score and loss of eyelash reflex were between 0.86 (0.80–0.92) and 0.92 (0.83–
0.99), whereas the PKs of NSRI were 0.77 (0.68–0.85) and 0.82 (0.68–0.92).  The PK of the 
NSRI for BIS and AAI was 0.66 (0.58–0.73) and 0.63 (0.55–0.70), respectively.   
 
Conclusion: The NSRI conveys information that better predicts the analgesic component of 
anesthesia than AAI, BIS, or predicted propofol or remifentanil concentrations.  Prospective 
validation studies in the clinical setting are needed.   
 
Presented at the Best Abstracts of the Meeting Session of the American Society of Anesthesiologists Annual Meeting, 
October 19, 2009.   
Supplemental digital content is available for this article.  Direct URL citations appear in the printed text and are available in 
both the HTML and PDF versions of this article.  Links to the digital files are provided in the HTML text of this article on the 
Journals Web site (www.anesthesiology.org). 
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The cerebral effect of hypnotic drugs is frequently measured using processed 
electroencephalography with and without stimulation.  During general anesthesia, opioids 
are administered according to response to clinical stimuli mostly in terms of arterial pressure 
or heart rate increase.  Several indices measuring the balance between nociception and 
antinociception during general anesthesia are under investigation, but no “analgesic state 
index” is available predicting responsiveness to noxious stimulation during combined 
administration of an analgesic and a hypnotic.   
In an attempt to develop an analgesic state monitor during anesthesia, we have 
investigated pulse wave and heart rate variation in response to a standardized electrical 
stimulus on the ulnar nerve as surrogate variable.1–3  These variables were not related to 
predicted remifentanil effect-site concentrations.  Conversely, the predicted remifentanil 
effect-site concentration combined with the bispectral index (BIS) was a significant predictor 
of a relevant hemodynamic response to tracheal intubation.2  The prediction was not 
improved by adding the pulse wave response to electrical ulnar nerve stimulation.2  Given 
the close correlation of the effect-site propofol concentration and the BIS,4 we believe that 
the predicted effect-site propofol concentrations together with the predicted effect-site 
opioid concentrations and an appropriate interaction model provide sufficient information 
to predict the responsiveness of an anesthetized patient to noxious stimulation.   
Bouillon et al.5 have described a response surface model for propofol and 
remifentanil in 2004.  The model is the basis for a two-dimensional concentration domain 
interaction display in which predicted hypnotic and opioid concentrations are related to 
interaction isoboles such as the 50 and 90% tolerance of laryngoscopy isobole.  To present 
the same information in a time-domain display, Schumacher et al.6 have defined the noxious 
stimulation response index (NSRI, see Methods section) based on the modified hierarchical 
interaction model by Bouillon.7  Generally speaking, the NSRI is a univariate index calculated 
from the weighted propofol and remifentanil concentrations corrected for interaction and 
normalized to a range between 0 and 100, where 100 reflects 100% probability and values 
approaching 0 reflect close to 0% probability of responding to laryngoscopy.   
The aim of this study was to compare the NSRI with predicted remifentanil and 
propofol effect-site concentrations, BIS, and A-Line autoregressive index (acoustic evoked 
potential index [AAI], A-Line AEP monitor, Danmeter A/S, Odense, Denmark) in terms of 
prediction probability (PK) of the hypnotic state and the responsiveness to a noxious stimulus 
in anesthetized patients, using a previously published data set.4   
 
1 Materials and Methods 
11 Patients and Protocol of the Previous Study 
In the previous study by Struys et al.,4 45 American Society of Anesthesiologists physical 
status 1 patients scheduled for ambulatory gynecologic surgery were enrolled and 
randomized to three treatment groups.  Approval and written informed consent was granted 
for the original study by Institutional Ethics Committee of the Ghent University Hospital, 
Ghent, Belgium.  The mean (SD) age in the three groups was 33 (5)–34 (4), and the mean 
weight and height were 63 (10)–66 (11) kg and 167 (6)–168 (6) cm, respectively.  Propofol 
was infused in all groups according to a staircase protocol starting with effect-site target 
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concentrations of 1.5 g/ml in group 1 (no remifentanil) and 1.0 g/ml in groups 2 and 3, in 
which remifentanil was added at effect-site target concentrations of 2.0 or 4.0 ng/ml, 
respectively.  The infusion pumps were controlled by Rugloop II software (Demed, Temse, 
Belgium) using the pharmacokinetic parameter sets and effect-site equilibration constant 
(ke0) reported by Schnider et al.8,9 for propofol and Minto et al.10,11 for remifentanil.   
Propofol concentration was increased in steps of 0.5 g/ml every 4 min.  After an 
effect-site equilibration time of 4 min, that is, immediately before the next increase of the 
propofol target concentration, the eyelash reflex, the observer assessment of alertness and 
sedation score (OAAS), the BIS (Version 3.4, calculated by the A-2000 BIS® monitor, Aspect 
Medical Systems, Newton, MA), the AAI, and the propofol effect-site concentration were 
recorded.  Thereafter, the presence or absence of a motor response to a 2-s tetanic stimulus 
(100 Hz, 50 mA) applied on the volar forearm was recorded.  In the raw data set, the 
predicted propofol and remifentanil effect-site concentrations and the related eyelash reflex 
(present or absent), OAAS score, BIS, AAI, and response to tetanic stimulation were 
available.   
 
12 The Hierarchical Propofol–Remifentanil Interaction Model 
The NSRI is based on the hierarchical interaction model by Bouillon et al.5 in 2004.  The 
originally reported model was modified to increase parsimony while retaining its essential 
features (appendix).7  On the basis of this modified model, the combination of predicted 
propofol and remifentanil concentrations can be expressed as probability to tolerate a 
certain reference stimulus, for example, tolerance of “shaking and shouting”, as indicator of 
deep hypnosis.  The original and the modified model are illustrated in figure 1.   
 
1.  Reduction of the incoming stimulus intensity:  
 
࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟ = ࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟ ቆ૚ −
࡯ࢋ࢕࢖࢏࢕࢏ࢊ
࡯ࢋ૞૙࢕࢖࢏࢕࢏ࢊ + ࡯ࢋ࢕࢖࢏࢕࢏ࢊ
ቇ 
(1) 
 
 
where postopioid_intensity = stimulus intensity after attenuation by the opioid, 
preopioid_intensity = intensity of the incoming stimulus, Ceopioid  = effect-site opioid 
concentration, and Ce50opioid  = effect-site opioid concentration associated with a 50% 
reduction of preopioid_intensity.  Therefore, the Ce50opioid does not represent the opioid 
concentrations associated with half maximal effect on the probability of tolerating the 
stimulus but it is the ability to increase the effectiveness of the hypnotic by altering the 
respective Ce50 of the hypnotic (Ce50hyp, see Eq. 2).  For a single stimulus, 
preopioid_intensity must be set to 1 to identify the C50 of the hypnotic (see Eq. 2).  In this 
case, the postopioid_intensity is always a dimensionless number between 0 and 1, 
depending on the opioid concentration.   
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Fig. 1. Comparison of the original 
and the modified hierarchal opioid– 
hypnotic interaction model.  The 
endpoint of the opioid–hypnotic 
interaction is the probability of 
response (Presponse, original model, A) 
or nonresponse to a stimulus 
(Pnonresponse, modified model, B).  The 
incoming stimulus is attenuated by 
the presence of an opioid.  Presponse or 
Pnonresponse is dependent on the 
strength of the attenuated stimulus, 
the hypnotic drug concentration, 
and the hypnotic drug concentration 
associated with a 50% probability of 
response/nonresponse (C50hypnotic).  
In the original model (A), the 
incoming stimulus (“pain in”) of a 
strength-labeled preopioid_intensity 
on the y-axis is attenuated by the 
opioid (on the x-axis) according to a 
negative Emax model resulting in an afferent stimulus with a strength that is a fraction of preopioid_intensity.  
The preopioid stimulus intensity and the slope parameter of this Emax model are estimated from the data.  The 
projected pain (“pain proj”) refers to the intensity of the attenuated stimulus transmitted to the central 
nervous system (also labeled as “afferent stimuli” in the original model).  Presponse is estimated from a negative 
Emax model.  In the modified model (B), the terms “pain in” and “pain proj” are replaced by “stimulus in” and 
“stimulus proj”, respectively because unconscious anesthetized patients do not feel pain.  Attenuation of 
preopioid_intensity follows a fractional Emax model with a fixed slope constant of 1.  The C50opioid (dashed 
arrow) is the opioid concentration reducing the strength of preopioid_intensity by 50%.  Pnonresponse is estimated 
with a positive Emax model, including the parameters postopioid_intensity, current hypnotic drug 
concentration (x-axis), and the C50hypnotic (dotted arrow).  Supplemental Digital Content 1 illustrates the 
behavior of the modified model, http://links.lww.com/ALN/A578 (for further information refer to the 
appendix).   
 
2.  Calculation of probability of tolerance to an incoming stimulus: the 
postopioid_intensity modifies the Ce50hyp representing the hypnotic concentration that 
corresponds to a 50% probability of tolerance of a stimulus with preopioid_intensity in the 
absence of opioid.   
 
 
 
ࡼ࢔࢕ି࢘ࢋ࢙࢖࢕࢔࢙ࢋ =
൬
࡯ࢋࢎ࢟࢖
࡯ࢋࢎ࢟࢖ ∙ ࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
൰
ࣘ
૚ + ൬
࡯ࢋࢎ࢟࢖
࡯ࢋࢎ࢟࢖ ∙ ࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
൰
ࣘ 
(2) 
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where Pno-response = probability of nonresponse to a stimulus, Cehyp = effect-site concentration 
of hypnotic, and φ = slope parameter.   
In summary, the model expresses the probability of nonresponse to a stimulus as a 
function of the stimulus strength (as incorporated in postopioid_intensity) and the opioid 
and hypnotic drug concentrations.  The modified model is depicted in figure 1B (for further 
details see the appendix).  The mechanistic behavior of the model is further illustrated in 
Supplemental Digital Content 1, which contains an interactive excel worksheet for model 
simulation, http://links.lww.com/ALN/A578.   
 
3.  Extension to stimuli of differing intensity: Under the assumption that the opioid 
potency (C50opioid) is identical for fractional suppression of stimuli of differing strength, only 
one parameter has to be added per additional stimulus, either “preopioid_intensity of 
stimulusn” (n suffix for the nth stimulus) or, alternatively, the model can be parameterized 
with “C50hyp n” (n suffix for the C50hyp related to the nth stimulus).  If the second 
parameterization is chosen, the ratio of the respective C50s yields the relative strength of 
the stimuli.  The second parameterization was chosen with “shake and shout” as reference 
stimulus with a preopioid_intensity of 1.  The relative intensity of laryngoscopy then 
corresponds to the ratio of the propofol Ce50TOSS and the Ce50TOL (Eq. 3).   
 
ࡾ࢒ࢇ࢘ =
࡯ࢋ૞૙ࢎ࢟࢖ࢀࡻࡸ
࡯ࢋ૞૙ࢎ࢟࢖ࢀࡻࡿࡿ
 
(3) 
 
 
Where Rlar = intensity ratio of laryngoscopy to the calibration stimulus shaking and shouting, 
Ce50hypTOL and Ce50hypTOSS = effect-site hypnotic concentrations associated with 50% 
probability of tolerating laryngoscopy and shake and shout, respectively.  The parameter 
estimates (SE) for Ce50hypTOL and Ce50hypTOSS according to the modified model were 8.46 
(1.98) and 2.99 (0.75) g/ml-1, respectively.5  Intensity ratios compared with shake and shout 
can be computed for any other stimulus, provided the respective Ce50hyp is known.   
 
121 Transformation of Probabilities of Tolerance into NSRI Units. 
1. The combined potency of an opioid and a hypnotic for suppression of a stimulus of 
defined strength (N) can be expressed as : 
 
ࡺ =
࡯ࢋࢎ࢟࢖
࡯ࢋ૞૙ࢎ࢟࢖ × ࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
 
(4) 
 
Therefore, equation 2 can be generalized according to equation 5. 
ࡼ࢔࢕ି࢘ࢋ࢙࢖࢕࢔࢙ࢋ =
ࡺࣘ
૚ + ࡺࣘ
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(5) 
 
2. The probability of no-response to laryngoscopy (PTOL) can be computed according to 
equations 3 and 5.   
 
ࡼࢀࡻࡸ =
ቀࡺ ࡾ࢒ࢇ࢘ൗ ቁ
ࣘ
૚ + ቀࡺ ࡾ࢒ࢇ࢘ൗ ቁ
ࣘ 
(6) 
 
3. Normalization to a scale from 0 to 100 and calibration: for ergonomic reasons 
(conformity with standard electroencephalographic monitoring), the increasing probability 
of tolerating laryngoscopy (scale from 0 to 1) with increasing drug concentrations was 
transformed into a decreasing value from 100 (probability of no-response to laryngoscopy 0) 
to 0 (probability of no-response to laryngoscopy asymptotically approaching 1) by 
transformation and by modifying the slope parameter of equation 6.  The NSRI value can 
therefore decrease near 0 but never be exactly 0.  By using the same structural model as for 
the probability of no-response to laryngoscopy, the NSRI is defined as follows.   
 
ࡺࡿࡾࡵ = ૚૙૙ × ൮૚ −
ቀࡺ ࡾ࢒ࢇ࢘ൗ ቁ
࢙࢒
૚ + ቀࡺ ࡾ࢒ࢇ࢘ൗ ቁ
࢙࢒൲ 
(7) 
 
 
where slope factor sl is an empirically calibrated scalar and not an estimated model 
parameter or a mathematical transformation of the slope parameter.  Regardless of the 
value of sl, a PTOL of 0.5 corresponds to a NSRI of 50.  The slope factor sl was calibrated to 
transform a PTOL of 0.9 to an NSRI of 20, yielding sl = 2.18.  The NSRI has the same underlying 
structural model but is not a direct mathematical transformation of PTOL.  The relationship 
between the NSRI and the probability of tolerance of laryngoscopy is depicted in figure 2.   
 
 
 
 
109 
 
Fig. 2. The relation of the probability to tolerate 
laryngoscopy and noxious stimulation response index 
(NSRI).  The NSRI is calculated using the same 
structural model as the probability to tolerate 
laryngoscopy (PTOL) but with a modified slope 
constant.  The figure related the PTOL to corresponding 
NSRI values.  An NSRI of 50 and 20 corresponds to 
50% and 90% probability of tolerating laryngoscopy, 
respectively.  The shape of the curve is dependent on 
the slope constant.   
 
 
 
13 Data Evaluation and Statistics 
The predicted propofol and remifentanil effect-site concentrations from the previous study4 
were used to compute the related NSRI according to equations 1, 4, and 7.   
For comparison, PTOL was calculated according to equations 1 and 2.  Primary 
independent variables (predictors) were the NSRI and the predicted propofol and 
remifentanil effect-site concentrations.  Primary dependent variables were the modified 
OAAS (full scale, table 1), the presence or absence of the eyelash reflex, and the presence or 
absence of a motor response to electrical tetanic stimulation of the forearm (dichotomous), 
BIS, and AAI values (continuous data).  The BIS and the AAI were also used as predictors of 
OAAS and response to eyelash and tetanic stimulation.  A similar analysis was performed for 
PTOL.   
 
 
Score Responsiveness 
5 Responds readily to name spoken in normal tone 
4 Lethargic response to name spoken in normal 
tone 
3 Responds only after name is called loudly an/or 
repeatedly 
2 Responds only after mild prodding or shaking 
1 Responds only after painful trapezius squeeze 
0 No response after painful trapezius squeeze 
 
 
For all predictors, the PKs for all variables to be predicted were calculated.  The 
prediction probability macro (PKMACRO; Excel spreadsheet) developed by Smith et al.,12 
which was used for data evaluation in the previous article,4 is designed for analysis of 
independent data.  Because the data were not independent, we applied a bootstrap 
technique with 1,000 random samples of the 263 data points for each dependent variable 
for PK calculation using Matlab (The Mathworks Inc., Natick, MA).  Each sample included one 
random data point per patient, that is, 44 data points.  The PK value was then calculated for 
each sample using the PKMACRO functionality within Matlab.  With this modification, the 
Table 1. Modified Observer Assessment 
of Alertness and Sedation Score as 
Applied by Struys et al.4   
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assumption of independence of the data was not violated.  Because the PK values were not 
normally distributed, they are presented in box plots.  To avoid assumptions on the 
distribution of the bootstrap samples, the 2.5–97.5 percentile range of the 1,000 PK was 
calculated to approximate the 95% CI of the resampled PKs.  The differences between a 
median PKs of a given predictor (e.g., NSRI) and another predictor (e.g., BIS) in predicting the 
same variable (e.g., OAAS) were considered statistically significant if the median PK of the 
first was outside the 95% CI of the second predictor, corresponding to an [alpha] of 0.05.  
Because statistical testing with calculation of P values might be affected by the bootstrap 
distribution and the number of resamplings, we restrict our PK comparison to this rather 
crude and conservative method and do not present the calculated P values.   
To get a rough estimate of the intensity of the 2-s tetanic stimulation, the NSRI 
associated with a 50% probability of loss or response to tetanic stimulation was calculated 
using a simple logistic regression analysis in NONMEM (Version V, Globomax LLC, Hanover, 
MD).  The naïve pooled data method was applied for parameter estimation.  Patient 
identifier, NSRI, dependent variable (0 or 1),and missing dependent variable (0 or 1) were 
the input data.  No further model building steps were performed, and no covariates were 
evaluated.   
 
2 Results 
The data of one patient were incomplete; hence, 263 data sets of 44 patients were available 
for our reanalysis.   
The dependent variables loss of eyelash reflex, BIS, and AAI reflect the hypnotic state, 
whereas loss of response to tetanic stimulation reflects the analgesic state.  The OAAS is 
mostly used as a clinical measure of the hypnotic state and dominated by hypnotic surrogate 
endpoints; however, the discrimination between levels 1 and 0 is based on the response to a 
painful stimulus (trapezius squeeze).  The results of the PK analysis are presented in figure 3.   
The PK values (95% CI) for prediction of OAAS by the effect-site propofol 
concentration, the BIS, the AAI, and the NSRI were 0.88 (0.81–0.93), 0.88 (0.82–0.93), 0.86 
(0.80–0.92), and 0.77 (0.68–0.85), respectively.   
The PK values of NSRI, effect-site propofol concentration, BIS, and AAI for prediction of loss 
of response to tetanic stimulation were 0.87 (0.75–0.96), 0.68 (0.54–0.81), 0.73 (0.58–0.85), 
and 0.70(0.54–0.84), respectively, whereas the corresponding PK of the remifentanil effect-
site concentration was 0.66 (0.50–0.80).  The reason for the median propofol PK being 
slightly higher than the remifentanil PK might be explained by the study design including only 
two remifentanil concentrations.   
The PKs of the remifentanil effect-site concentration to predict OAAS, loss of eyelash 
reflex, BIS, and AAI were (0.32–0.54), 0.41 (0.26–0.59), 0.36 (0.29–0.45), and 0.38 (0.30–
0.46), respectively, which indicates a slight reverse prediction, most likely caused by study 
design (in groups with remifentanil, the propofol concentrations were lower).4   
The PK for PTOL was similar to NSRI (fig. 3B) because the NSRI is the transformed and rescaled 
PTOL.  The NSRI (SE of the estimate) associated with a 50% probability of loss of response to 
tetanic stimulation was 61 (SE, 3.8) (fig. 4).   
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Fig. 3. Prediction probabilities (PKs) of different predictors and predicted variables.  The PK values according to 
Smith et al.12 were estimated from 1,000 random samples of 263 data points from 44 patients, with 1 data 
point per patient in each sample.  The data are presented as box plots with median values depicted as 
horizontal lines and the interquartile range (lower and upper limits of the boxes).  The error bars represent the 
10 and 90 percentiles, and the black circles the 5 and 95 percentiles.  Pairwise comparison of the PK values by 
comparing the median PK of one predictor with the 2.5–97.5 percentile range of another predictor 
(corresponding to the 95% confidence interval).  If the median PK of the first is outside this percentile range, it is 
considered significantly different.  A: observer assessment of alertness and sedation score (OAAS), B: loss of 
eyelash reflex, C: loss of motor response tetanic stimulation, D: bispectral index (BIS), and E: acoustic evoked 
potential index (AAI).*  Significantly different compared with noxious stimulation response index (NSRI), 
probability to tolerate laryngoscopy (PTOL), and effect-site remifentanil concentration (Remi); #  Significantly 
different compared with effect-site propofol concentration (Prop), BIS, AAI, and Remi.   
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Fig. 4. The NSRI50 for tolerance of 2-s tetanic 
stimulus: A logistic regression analysis with 
the naïve pooled data method (non-linear 
mixed effects modeling naïve pooled 
analysis) for dependent variables was 
performed to estimate the noxious 
stimulation response index (NSRI) value 
associated with a 50% probability to tolerate 
tetanic stimulation of the forearm ( NSRI50).  
PLORT  probability of tolerance of tetanic 
stimulation; black diamonds individual 
response to tetanic stimulation (1 response 
and 0 no response); prediction (black line) 
predicted probability of response according 
to the regression model; black circle NSRI 
associated with PLORT  50%; error bars 
standard error of the estimate. 
 
 
3 Discussion 
The NSRI integrates the potency of a hypnotic and an opioid to synergistically suppress the 
response to a noxious stimulus.  In this study, we have shown that the PK of the NSRI and PTOL 
to predict the probability of response to a 2-s, 50-mA, and 100-Hz tetanic stimulus is higher 
compared with all other investigated predictors.  As expected, the PK of the mainly hypnotic 
endpoints (loss of eyelash reflex and OAAS) was intermediate, and the PK of 
electroencephalogram-based predictors (BIS and AAI) was low.   
The predictive performance of propofol effect-site concentrations, BIS, and AAI to 
predict loss of consciousness in our study was as high as in a previous study in which PKs of 
0.89–0.94 were reported.13  The performance in predicting a response to noxious 
stimulation with these variables was 0.82–0.87 with pure propofol anesthesia13 and 0.72–
0.75 with coadministration of remifentanil.4  These findings reflect the poor sensitivity of 
electroencephalogram-based measurements to the effect of opioids.   
Surrogate endpoints potentially reflecting the analgesic state have been investigated.  
The surgical stress index uses the pulse plethysmography amplitude and the pulse rate 
derived from the pulse oximetry curve and discriminates strong versus light stimulation and 
low versus moderate remifentanil effect-site concentrations.14  The skin conductance 
variation induced by several noxious and nonnoxious stimuli is a sensitive measure of 
stress15,16 but discriminates only between the presence or absence of low remifentanil 
effect-site concentrations (2 ng/ml).16  Whether it discriminates different opioid 
concentration levels or predicts the response to clinical stimuli is not known.  Our 
investigations of the pulse plethysmography response to a 5-s 60-mA tetanic stimulus of the 
ulnar nerve as a surrogate variable to measure the analgesic state or the hemodynamic 
responsiveness of anesthetized patients were disappointing.1,2  One reason was the large 
and probably random interindividual variation1 of the signal (tetanic stimulation-induced 
variation of the pulse plethysmography trace).  Therefore, we assume that baseline 
variability may reduce the predictive performance of any analgesic state index that is derived 
from physiologic signals related to the sympathoadrenergic stress response.  Because the 
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NSRI takes into account predicted effect-site drug concentrations and their interaction only, 
these drawbacks do not apply.  It seems that the prediction error of effect-site drug 
concentrations, which is greater or equal to 20%,8,10 does not degrade the prediction 
performance of the NSRI.  Because the NSRI accounts for the interaction of hypnotic and 
analgesic, it must be superior to single drug concentrations for prediction of any endpoint 
for which hypnotic/analgesic interactions have been demonstrated, that is, responsiveness 
to noxious stimuli during anesthesia.   
In summary, the strengths of the NSRI are a predictive performance for noxious 
stimulation response in the clinically desirable range and its independence of physiologic 
signals as well as test stimuli.  As with other anesthetic depth indicators or drug 
concentrations, the predictive performance expressed as PK does not imply that a given NSRI 
value correctly predicts the response in an individual patient, but it means that the 
probability of response is highly correlated with the NSRI.  The calibration of NSRI and PTOL as 
anesthetic depth indicators was beyond the scope of this study and needs to be 
prospectively evaluated.   
Because of the modification of the underlying hierarchical interaction model, the 
index is flexible for future development so that it can be extended to any combination of 
hypnotic and analgesic drugs.  A discussion of the model modification is provided in the 
appendix.  The interpretation of the NSRI numbers is straightforward.  By definition, an NSRI 
of 50 means that the effect-site propofol and remifentanil concentrations are sufficient that 
the patient will tolerate laryngoscopy with a probability of 50%.  An NSRI of 61 (3.9) means 
that the patient will tolerate a 2-s tetanic stimulus of the forearm with a probability of 50% 
and that this stimulus may be slightly weaker than laryngoscopy.  Different probabilities for 
responses to different stimuli can be mapped on the curve with ease.  Clinically desirable 
ranges of the NSRI during surgery can be inferred from the results of a future proof of 
concept study.   
When the PKMACRO (calculating the PK of a single predictor to one predicted 
variable) and the prediction probability difference macro (PKDMACRO) (comparing the PKs of 
different predictors) were used for validation of anesthetic depth indicators in the past, the 
assumption on independence of the data has been neglected.  The reason for this is inherent 
in the study design with repeated measurements taken at several drug concentrations in the 
same subject.  The resampling technique applied in this study is an attempt to solve this 
problem of the statistical analysis.  Currently, it is not clear how far the resampling method 
affects the boundaries of our parameter estimates and to what extend a sampling bias could 
have been introduced.  To clarify this, a formal evaluation of this technique under a range of 
circumstances in which the “true” bounds are known would be required, which is well 
beyond the scope of this study.  Therefore, we have presented the 2.5–97.5 percentile 
ranges of the different PKs that approximate the 95% CIs and did not calculate any P values.  
To reject the null hypothesis that two PKs are similar, the median PK of one predictor had to 
be outside the 95% CI of PKs of the other.  Therefore, only large differences in the median PKs 
were accepted as significant, which are unlikely to be substantially affected by a potential 
sampling bias; for example, the difference between the PKs of NSRI and PTOL and the PKs of all 
other predictors to predict response to a noxious stimulus (fig. 3).  It is, therefore, unlikely 
that the main message of this study is affected by this yet unsolved statistical problem.   
There are some other limitations of this study.  First, it is a post hoc validation.  
Second, the selected propofol and remifentanil concentrations are not independent of each 
other.  Third, the applied 2-s tetanic stimulus is substantially weaker than strong surgical 
 
114 
 
stimuli such as skin incision,17 which is illustrated by the high NSRI50 for loss of response to 
tetanic stimulation.  Fourth, the data used for this validation were recorded only in a female 
patient population.  Therefore, this study only attests to the usefulness of the NSRI as 
predictor of the response to medium-intensity stimuli during coadministration of propofol 
and remifentanil.  Future studies have to validate the NSRI in the clinical setting for both 
total intravenous and balanced (volatile plus opioid) anesthesia and in both sexes.   
We conclude that the NSRI is a promising anesthetic state index predicting response 
to noxious stimulation responsiveness and, to a lesser extent, the hypnotic state.  Most 
probably, it will improve the dosing of hypnotics/volatiles and opioids.  However, 
prospective validation studies in the clinical setting are needed to judge the use of the NSRI 
in everyday anesthetic practice.   
 
The authors thank Anthony Absalom, M.D., Ph.D. (Professor, Department of Anesthesiology, University Medical 
Center, University of Groningen, Groningen, The Netherlands), for his helpful comments during the preparation 
of this manuscript.   
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4 Appendix : Modification of the Hierarchical Interaction Model 
In this appendix, the steps of model modification as reported by Bouillon7 are described.  
The original model5 was modified to avoid overparameterization.  The resulting modified 
model was found to be mathematically equivalent to a reduced Greco model, implying 
strong synergism.  Its C50 for the opioid can be interpreted in analogy to a C50 for reduction 
of the minimal alveolar concentration of a volatile anesthetic.   
 
41 Model Modifications 
The probability of response to a stimulus is a function of stimulus strength after attenuation 
by the opioid (postopioid_intensity), the C50hypnotic, the slope factor, and the concentration 
of the hypnotic.  As is evident from equation A,5 only the product of Ce50hypnotic and 
postopioid_intensity, but not its individual components, is identifiable (Eq. A).   
 
ࡼ࢘ࢋ࢙࢖࢕࢔࢙࢏࢜ࢋ࢔ࢋ࢙࢙ = ૚ −
࡯ࢋࢎ࢟࢖࢔࢕࢚࢏ࢉࣘ
࡯ࢋࢎ࢟࢖࢔࢕࢚࢏ࢉࣘ + ൫࡯ࢋ૞૙ࢎ࢟࢖࢔࢕࢚࢏ࢉ × ࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟൯
ࣘ 
(A) 
 
 
where Presponsiveness = probability that the patient responds to the incoming stimulus, Cehypnotic 
= effect-site hypnotic drug concentration, Ce50hypnotic  = effect-site hypnotic drug 
concentration associated with a 50% probability of nonresponsiveness, and φ = slope 
parameter.   
In the absence of opioid, postopioid_intensity equals preopioid_intensity, as shown 
in equation B.   
 
࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟
= ࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟ ൭૚ −
࡯ࢋ࢕࢖࢏࢕࢏ࢊࢽ
൫࡯ࢋ૞૙࢕࢖࢏࢕࢏ࢊ ∗ ࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟൯
ࢽ + ࡯ࢋ࢕࢖࢏࢕࢏ࢊࢽ
൱ 
(B) 
 
 
where preopioid_intensity = intensity of the incoming stimulus, Ceopioid  = effect-site opioid 
concentration, Ce50opioid = the common opioid concentration reducing the intensity of an 
incoming stimulus by 50%, and gamma (γ) slope parameter.   
From this, it follows that stimulus strength cannot be estimated per se, if only one 
stimulus is investigated and preopioid_intensity must be fixed to 1 to obtain the C50 of the 
hypnotic.  For n stimulus strengths, the number of parameters describing stimulus strength 
equals n - 1.  These parameters describe relative strength of stimulus compared with the 
reference stimulus with the intensity of 1.  Alternatively, the model can be parameterized in 
terms of one C50 for the hypnotic per stimulus applied.   
The model describing postopioid_intensity was also simplified.  Because the original 
estimate of the slope factor almost equaled 1, the model was collapsed to a fractional Emax 
model.  In the original model, the multiplication of the C50 of the opioid with the preopioid 
pain intensity was believed to be necessary to account for the fact that higher opioid 
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concentrations are needed to attenuate more severe pain.  Although not obvious, this 
behavior is also displayed by the modified model (Eq. C).   
 
 
࢖࢕࢙࢚࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟ = ࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ_࢏࢔࢚ࢋ࢔࢙࢏࢚࢟ ቆ૚ −
࡯ࢋ࢕࢖࢏࢕࢏ࢊ
࡯ࢋ૞૙࢕࢖࢏࢕࢏ࢊ + ࡯ࢋ࢕࢖࢏࢕࢏ࢊ
ቇ 
(C) 
 
 
It is therefore the absolute value of postopioid_intensity and the C50 hypnotic that 
determine the concentration of hypnotic needed to achieve a certain probability of 
nonresponsiveness for a certain preopioid stimulus strength.   
We would like to further illustrate this with a straightforward example.   
 
i. Simplest case: preopioid stimulus intensity = 1, Ceopioid = 0, and Pnonresponsiveness = 0.5.  
The Cehyp equals the C50 of the hypnotic.   
ii. Add opioid to decrease Cehyp for Pnonresponsiveness = 0.5 by 50%.  The Ceopioid that lowers 
the preopioid_intensity from 1 to a postopioid_intensity of 0.5 equals the Ce50opioid (Eqs. 
B and C).   
iii. Add opioid to decrease Cehyp for Pnonresponsiveness = 0.5 by 50%, for another stimulus 
with preopioid_intensity of 2.  According to equation B (original model), the Ceopioid = 6 x 
Ce50opioid, whereas according to equation C (modified model), the Ceopioid = 3 x Ce50opioid.   
 
Therefore, the most simplified equation C already predicts a profound increase of the opioid 
concentration needed to attenuate stimulus intensities higher than 1.  A simulation 
spreadsheet is provided in Supplemental Digital Content 1, http://links.lww.com/ALN/A578.   
The following parameter estimates (SE) were obtained in a reanalysis of the data 
from the previous study5: Ce50propofol, TOSS = 2.99 (0.75) g/ml, Ce50propofol, TOL = 8.46 (1.98) 
g/ml, and Ce50remifentanil, TOSS = 1.16 (0.48) ng/ml, whereas the Ce50remifentanil, TOL is implicitly 
modeled and not estimated from the data.  The non-linear mixed effects modeling objective 
function was 80.2.   
 
42 Discussion 
When we reanalyzed the data from the original study,7 the non-linear mixed effects 
modeling objective function value of the modified hierarchical model and the Greco model 
was equal, whereas it was 69 in the original model.5  However, the small SEs of the 
parameter estimates in the original model are indicators of overparameterization.   
Furthermore, the rather high Ce50 of propofol for hypnosis (4.82 g/ml) does not 
compare well with results from other studies18,19 and clinical experience.  In contrast, the C50, 
propofol for tolerance of shaking and shouting (corresponding to the C50, propofol for loss of 
consciousness) estimated with the modified model was 2.99 g/ml, which is well within the 
range of publisheddata.13,19,20   
A structural benefit of the model is the ability to convert it into a reduced Greco 
model,7 simplifying comparisons with existing studies.  The C50, opioid in our model equals the 
reciprocal of that model according to equation D.   
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࡯૞૙,࢕࢖࢏࢕࢏ࢊ =
૚
ࣕ′
 
(D) 
 
where C50, opioid  = opioid concentration associated with half maximal attenuation of a 
stimulus in our model and ϵ’ = the modified Greco interaction parameter for constellations 
in which the opioid effect in the absence of hypnotic is too weak to be identified but 
profoundly changes the potency of a coadministered hypnotic.  This situation was 
encountered in the interaction study by Mertens et al.19  The proof of interconvertability of 
the two models has been described elsewhere.7  Interestingly, the Ce50, remifentanil estimated 
with the simplified Greco model from the propofol–remifentanil interaction data is 1.39 and 
1.45 ng/ml for return of consciousness and for tolerating laryngoscopy, respectively, which is 
almost identical despite completely different stimulation strength and approximates the 
C50,remifentanil estimated with our modified hierarchical model (1.16 ng/ml).   
The model for the probability of nonresponse in this study was, therefore, 
parametrized according to equation E.   
 
 
 
ࡼ࢔࢕࢔ି࢘ࢋ࢙࢖࢕࢔࢙
= ۉ
ۈ
ۇ ࡯ࢋࢎ࢟࢖࢔࢕࢚࢏ࢉ
࡯ࢋ૞૙ࢎ࢟࢖࢔࢕࢚࢏ࢉ ∙ ࢖࢘ࢋ࢕࢖࢏࢕࢏࢏࢔࢚ࢋ࢔࢙࢏࢚࢟ ቆ૚ −
࡯ࢋ࢕࢖࢏࢕࢏ࢊ
൫࡯ࢋ૞૙࢕࢖࢏࢕࢏ࢊ ∗ ࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ࢏࢔࢚ࢋ࢔࢙࢏࢚࢟൯ + ࡯ࢋ࢕࢖࢏࢕࢏ࢊ
ቇ
ی
ۋ
ۊ
ࣘ
૚ +
ۉ
ۈ
ۇ ࡯ࢋࢎ࢟࢖࢔࢕࢚࢏ࢉ
࡯ࢋ૞૙ࢎ࢟࢖࢔࢕࢚࢏ࢉ ∙ ࢖࢘ࢋ࢕࢖࢏࢕࢏࢏࢔࢚ࢋ࢔࢙࢏࢚࢟ ቆ૚ −
࡯ࢋ࢕࢖࢏࢕࢏ࢊ
൫࡯ࢋ૞૙࢕࢖࢏࢕࢏ࢊ ∗ ࢖࢘ࢋ࢕࢖࢏࢕࢏ࢊ࢏࢔࢚ࢋ࢔࢙࢏࢚࢟൯ + ࡯ࢋ࢕࢖࢏࢕࢏ࢊ
ቇ
ی
ۋ
ۊ
ࣘ 
(E) 
 
 
 
where Pnonresponse = probability of tolerance of a given stimulus, Cehypnotic = effect-site 
hypnotic drug concentration, Ce50hypnotic = effect-site hypnotic drug concentration 
associated with a 50% probability of nonresponse, preopioid_intensity = intensity of the 
stimulus without opioid attenuation, Ce50opioid = effect-site opioid drug concentration 
reducing the preopioid_intensity by 50%, and Ceopioid = effect-site opioid concentration.   
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Chapter 7  Probability to tolerate laryngoscopy and noxious 
stimulation response index as general indicators of the 
anaesthetic potency of sevoflurane, propofol, and 
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Abstract 
 
Background : The probability to tolerate laryngoscopy (PTOL) and its derivative, the noxious 
stimulation response index (NSRI), have been proposed as measures of potency of a 
propofol–remifentanil drug combination.  This study aims at developing a triple drug 
interaction model to estimate the combined potency of sevoflurane, propofol, and 
remifentanil in terms of PTOL.  We compare the predictive performance of PTOL and the NSRI 
with various anaesthetic depth monitors.   
 
Methods : Data from three previous studies (n=120) were pooled and reanalysed.  
Movement response after laryngoscopy was observed with different combinations of 
propofol–remifentanil, sevoflurane–propofol, and sevoflurane–remifentanil.  A triple 
interaction model to estimate PTOL was developed.  The NSRI was derived from PTOL.  The 
ability of PTOL and the NSRI to predict observed tolerance of laryngoscopy (TOL) was 
compared with the following other measures : (i) effect-site concentrations of sevoflurane, 
propofol, and remifentanil (CeSEVO, CePROP, and CeREMI); (ii) bispectral index; (iii) two measures 
of spectral entropy; (iv) composite variability index; and (v) surgical pleth index.   
 
Results : Sevoflurane and propofol interact additively, whereas remifentanil interacts in a 
strongly synergistic manner.  The effect-site concentrations of sevoflurane and propofol at a 
PTOL of 50% (Ce50; SE) were 2.59 (0.13) vol % and 7.58 (0.49) μg ml−1.  A CeREMI of 1.36 (0.15) 
ng ml−1 reduced the Ce50 of sevoflurane and propofol by 50%.  The common slope factor 
was 5.22 (0.52).  The PTOL and NSRI predict the movement response to laryngoscopy best.   
 
Conclusions : The triple interaction model estimates the potency of any combination of 
sevoflurane, propofol, and remifentanil expressed as either PTOL or NSRI.   
 
Key words : drug interactions; laryngoscopy; propofol; remifentanil; sevoflurane 
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Editor’s key points 
• The probability to tolerate laryngoscopy (PTOL) and its derivative, noxious stimulation 
response index (NSRI), may be useful to quantify and compare the potency of volatile and 
i.v. anaesthetics, but it is not clear whether or not there are differences in the interactions of 
an opioid with a volatile anaesthetic and with an i.v. anaesthetic.   
• A triple interaction model, which was developed using data from previous studies, 
indicated that sevoflurane and propofol interact additively, whereas remifentanil interacts in  
a strongly synergistic manner.   
• The triple interaction model can estimate the potency of any combination of sevoflurane, 
propofol, and remifentanil.   
 
 
Adequate anaesthesia can be defined as the combination of an accurate level of hypnosis 
with sufficient analgesia to avoid response to a noxious stimulation, where ‘response’ 
includes a variety of modalities, such as movement, haemodynamic response, or arousal. 
Most contemporary anaesthetic depth monitors are based on the processed EEG and 
correlate mainly with hypnotic drug effect; however, they do not reliably predict a response 
to noxious stimulation.1 2  Recent attempts to measure analgesia, based on the variability of 
the processed EEG signal3 or on changes in the autonomic nervous system as measured by 
pulse plethysmography,4 5 were only partly successful. Similar decreasing accuracy was 
found for the propofol effect-site concentration (CePROP) as a measure of drug effect in the 
presence of opioids.1 2   
For decades, the probability of response to skin incision, defined as the minimal 
alveolar concentration (MAC), has been used to quantify and compare the potency of 
volatile agents.6–9  More recently, Bouillon and colleagues10 defined tolerance of 
laryngoscopy (TOL) as an absence of movement response to laryngoscopy, and they 
proposed the probability to tolerate laryngoscopy (PTOL) as an alternative to MAC when using 
propofol instead of volatile agents.  For ergonomic reasons and in order to cope with the 
clinical conformity of standard depth of anaesthesia monitoring, Luginbühl and colleagues11 
normalized and calibrated PTOL towards a new index called the noxious stimulation response 
index (NSRI).  The NSRI is a numerical depth of anaesthesia indicator that is directly derived 
from PTOL and was first described for propofol and remifentanil anaesthesia.  The NSRI and 
PTOL are therefore interchangeable; they merely differ in scale.  The NSRI is scaled between 
100 (when no anaesthetic drugs are administered) and zero (indicating extensive combined 
drug effects), whereas PTOL scales from zero to one.   
Until now, specific PTOL results have been found in three different drug interaction 
studies, resulting in separate response surface models for propofol–remifentanil,10 
sevoflurane–propofol,12 and sevoflurane–remifentanil.13  In order to use PTOL (and NSRI) as 
general probabilistic parameters to represent the lack of responsiveness to a noxious 
stimulation in both i.v. and volatile anaesthesia conditions, supplemented with opioids, one 
needs to solve the problems of whether synergy of remifentanil with propofol is stronger 
than synergy with sevoflurane and whether the slope of the propofol–remifentanil and the 
sevoflurane–remifentanil response surfaces are different.  This may be clarified by 
developing a triple interaction surface model, merging the information from the previously 
published dual drug models,10 12 13 hereby also rescaling and expanding previously published 
PTOL and NSRI scales.   
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For clinicians, a general PTOL and its derivative, NSRI, would enable estimation of the 
concentration of sevoflurane that is equipotent to a given propofol concentration when used 
in combination with remifentanil.  The primary purpose of the present study was to define a 
triple interaction response surface model to express the potency of any combination of 
sevoflurane, propofol, and remifentanil in terms of PTOL and NSRI by merging the raw data 
from three previously published studies.10 12 13  The secondary purposewas to test the ability 
of PTOL and NSRI, calculated with the new triple interaction model parameters, to predict the 
observed TOL.  We compared the performance of PTOL and NSRI with other measures, such 
as single drug effect-site concentrations of sevoflurane, propofol, and remifentanil (CeSEVO, 
CePROP, and CeREMI), current hypnotic effect monitors, such as the EEG-derived bispectral 
index (BIS; Covidien, Boulder, CO, USA)14 and two measures of the EEG-derived spectral 
entropy, state entropy and response entropy (SE and RE; GE Healthcare, Helsinki, Finland),15 
and newer analgesic effect monitors, such as the BIS-derived composite variability index 
(CVI; Covidien)3 16 and pulse plethysmograph derived surgical pleth index (SPI; GE 
Healthcare).5   
 
1 Methods 
 
We performed a response surface analysis of the pooled raw data from three previously 
published studies on interactions between sevoflurane, propofol, and remifentanil.10 12 13 17  
The Ethics’ Committees from these original studies (Ghent University Hospital, Gent, Belgium 
and Stanford University, Stanford, CA, USA) both agreed that the anonymized original 
databases could be re-used for this analysis.  As the original studies were executed and 
published long before the introduction of the public registration requirements, no 
registration of the original studies was possible.   
The characteristics of the study populations are summarized in Supplementary File 1 
and in the Results section.  The study design and drug administration protocol have been 
described in detail in each of the studies.  Briefly, combinations of propofol–remifentanil,10 
sevoflurane–propofol,12 and sevoflurane–remifentanil13 17 were administered using a 
modified crisscross design according to Short and colleagues.18  Propofol and remifentanil 
were administered as computer-controlled infusions targeting effect-site or plasma 
concentrations using the pharmacokinetic and pharmacodynamic models by Schnider19 20 
and Minto,21 22 respectively.  While Bouillon and colleagues10 used targeted plasma 
concentrations and observed an equilibration time of 15 min, Schumacher and colleagues12 
and Heyse and colleagues13 17 applied target effect-site concentrations with an equilibration 
time of 12 min.  Sevoflurane was titrated to achieve predetermined end-tidal concentrations 
using an ADU ventilator with an integrated AS3 monitor (GE Healthcare).  These equilibration 
times are considered sufficient for all drugs to allow equilibration between the plasma and 
effect-site concentration.  Acceptable prediction errors of the Schnider and Minto models 
were confirmed in the propofol–remifentanil study by means of repetitive blood sample 
analysis for propofol and remifentanil published previously.23  A steady state for sevoflurane 
was confirmed through end-tidal measurements of sevoflurane concentrations.  In all three 
studies, after equilibration of plasma and effect-site concentrations, a series of stimuli was 
applied and the presence or absence of movement response recorded.  However, only TOL 
was used in our final analysis after initial model validation (see Results section).   
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The following drug effect monitors were used : BIS (BIS Version 3.22, A1000; 
Covidien) by Bouillon and colleagues;10 BIS (Version 4.0, A-2000; Covidien); and SE and RE 
(M-Entropy; GE Healthcare) by Schumacher and colleagues12 and Heyse and colleagues.17  
Additionally, Heyse and colleagues17 computed the composite variability index (CVI; 
Covidien) and the surgical pleth index (SPI; GE Healthcare) off-line from the recorded raw 
EEG and pulse plethysmography data, respectively.  Detailed information can be found in the 
original publications.   
 
11 Pharmacodynamic model 
 
The synergistic interactions between propofol and remifentanil and between sevoflurane 
and remifentanil were best described by the modified hierarchical model,13 11 23 whereas the 
additive interaction between sevoflurane and propofolwas best described by the Greco 
model.12  We therefore postulated that the interaction of the three compounds could be 
described by considering any combination of the three drugs as a virtual newdrug with the 
potency ‘U’.13 24  
Equation (1) is the sigmoidal response function for a dichotomous effect :  
 
 
ࡼࢀࡻࡸ =
ࢁࢽ
૚ + ࢁࢽ
 
Equation (1) 
 
where PTOL is the probability of tolerance of laryngoscopy  is the slope parameter that 
represents the steepness of the concentration – effect relationship, and U is the combined 
potency of the drugs according to Equation (2) : 
 
 
ࢁ = ൬
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
+
࡯ࡼࡾࡻࡼ
࡯૞૙ࡼࡾࡻࡼ
൰ ∙ ቆ૚ + ൬
࡯ࡾࡱࡹࡵ
࡯૞૙ࡾࡱࡹࡵ
൰
ࢽࡻ
ቇ 
Equation (2) 
 
where CeSEVO, CePROP and CeREMI are the effect-site concentrations of sevoflurane, propofol 
and remifentanil, respectively, Ce50SEVO and Ce50PROP are the effect-site concentrations of 
sevoflurane and propofol, respectively, resulting in PTOL = 0.5 if given alone, and Ce50REMI is 
the effect-site concentration of remifentanil that results in an increase of U by a factor 2 or 
an apparent decrease of the Ce50SEVO and Ce50PROP by 50%, and o represents the steepness 
of the concentration-effect relationship of the opioid.   
According to the parameter estimates of the original studies (Table 1), our hypothesis 
was that Ce50REMI, o and  were different for sevoflurane and propofol and we assumed a 
linear interpolation.  The null hypothesis was that these parameters were similar.  Linear 
interpolation was performed according to equations (3)-(5): 
 
 
࡯ࢋ૞૙ࡾࡱࡹࡵ = ࡯ࢋ૞૙ࡾࡱࡹࡵ(ࡿࡱࢂࡻ) ∗ ࡿࡲ + ࡯ࢋ૞૙ࡾࡱࡹࡵ(ࡼࡾࡻࡼ) ∗ (૚ − ࡿࡲ) 
Equation (3) 
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ࢽࡻ = ࢽࡻ(ࡿࡱࢂࡻ) ∗ ࡿࡲ + ࢽࡻ(ࡼࡾࡻࡼ) ∗ (૚ − ࡿࡲ) 
Equation (4) 
 
ࢽ = ࢽ(ࡿࡱࢂࡻ) ∗ ࡿࡲ + ࢽ(ࡼࡾࡻࡼ) ∗ (૚ − ࡿࡲ) 
Equation (5) 
 
where SF is the sevoflurane fraction defined in Equation (6): 
 
 
ࡿࡲ =
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
ቀ ࡯ࡿࡱࢂࡻ࡯૞૙ࡿࡱࢂࡻ
+ ࡯ࡼࡾࡻࡼ࡯૞૙ࡼࡾࡻࡼ
ቁ
 
Equation (6) 
 
Thus, SF=0 if CeSEVO=0, and SF=1 if CePROP=0, and SF is between zero and one for mixtures of 
sevoflurane and propofol.  Note that the final models in the three original studies10–12 23 are 
equivalent to equations (1)–(6), with the following specific constraints : o =1 in the study by 
Bouillon and colleagues,10 and (SEVO)= (PROP) in Schumacher’s study.11   
The purpose of the model developed from the data is to predict PTOL of random 
individuals in a population.  Similar to the MAC, a PTOL of 50% is the concentration where 
50% of a population tolerates laryngoscopy without movement response (TOL).  The 
individual concentration–response of the ‘typical subject’ was therefore not the focus of the 
study, and inter-individual variability was not included in the parameter estimation (naive 
pooling approach).   
 
12 Selection of the final model and parameter estimation 
 
In the first step, the data fromeach studywere separately fitted to the model [equations (1)–
(6)] in order to determine the effect of considering only TOL instead of the whole series of 
stimuli as previously published.  In the second step, a fit of the pooled TOL data was 
performed. In the pooled fit, the parameters Ce50SEVO, Ce50PROP, Ce50REMI, 1, and o were 
estimated assuming that the parameters Ce50REMI, o, and  were identical for te two 
hypnotics sevoflurane and propofol.  Then we tested whether different values for Ce50REMI, 
o, or  for sevoflurane and propofol significantly improved the fit.  In addition, we tested 
whether γowas significantly different from one.  The results were accepted as valid only if 
both minimization and covariance steps were successful, unless stated otherwise.   
The model parameters were estimated using NONMEM 7.2.0 (Icon Development 
Solutions, Hanover, MD, USA), using the Laplace method.  The software was installed on a 
GNU Fortran 95 compiler (http://gcc.gnu.org) with Windows XP operating system (Microsoft, 
Redmond, WA, USA).  PLT Tools (PLTsoft, San Francisco, CA, USA) was used as graphical user 
interface.   
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To determine the final model, non-parametric 95% confidence intervals (CIs) were 
calculated, using a bootstrap analysis based on 2000 sets, stratified according to the original 
studies.  Assuming a χ2 distribution with one degree of freedom, an improvement of the 
objective function value of 3.84, corresponding to a value of P<0.05, was considered 
significant.   
The PTOL was calculated from equation (1) and NSRI from equation (7): 
 
ࡺࡿࡾࡵ =
૚૙૙
૚ + ቀ ࡼࢀࡻࡸ૚ − ࡼࢀࡻࡸ
ቁ
ࡿ 
Equation (7) 
 
where s is a constant (s = 0.63093).   
For further information on the transformation of PTOL to NSRI, see Supplementary File 
2. 
 
13 Model evaluation 
 
The data of responders and non-responders were plotted together with the 50 and 90% 
isoboles, derived from the original models,10 12 13 23 and the final model for visual inspection 
of the goodness of fit.  Additionally, we plotted the observed PTOL against the PTOL predicted 
by all models to compare the ability of the final model for PTOL with the previously published 
models.  The observed PTOL was obtained from the raw data according to the following 
procedure.  For each observation (response or no response to laryngoscopy), the predicted 
PTOL was calculated from the effect-site concentrations and model parameters (Table 1) 
using equations (1) and (2).  Then the predicted PTOL of each observation and the related true 
response (0 or 1) were sorted with increasing value of predicted PTOL. The observed PTOL was 
defined as the average of the response of the index observation and the next 10 
observations with a lower and a higher predicted PTOL.  The observed PTOL is thus a moving 
average over 21 observations, where the missing values at the lower and upper end were 
omitted.  The resulting plots allow a visual inspection of the goodness of fit, as shown in 
Supplementary File 3.  The mean absolute prediction error (MAPE) was calculated as the 
mean of the absolute value of the difference between the observed and predicted PTOL.  For 
clarification to the reader, the ‘observed PTOL’ is used only for this specific model validation.  
Otherwise in this work, ‘PTOL’ always refers to the ‘predicted PTOL’.   
In a second validation, we used the raw data of two original studies for parameter 
estimation and the raw data of the third study for model validation, as shownin the 
Supplementary File 4.   
 
14 Assessment of prediction probability 
 
The prediction probability (PK) is based on multiple comparisons of two data points from the 
total data set, to investigate the degree of association between each predictor and the 
observed tolerance.  A PK value of 0.5 implies no association, thus a poor prediction 
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probability; a value of one implies complete association, thus an excellent prediction 
probability.25 26   
We used PK to assess the performance of predicted PTOL, its derivative, NSRI, and the 
observed BIS, SE, RE, CVI, and SPI to predict TOL.  For comparison, the PK values of the single 
drug concentrations (CeSEVO, CePROP, and CeREMI) were also determined.  Using single drug 
concentrations as estimates of the likelihood of tolerance does not take into account the 
effect of simultaneously administered drugs; therefore, we hypothesized that they are less 
accurate than the predicted PTOL as a result of this limitation.   
The drug concentrations, their related variables, and the monitor records 
immediately before the stimulus series were used as independent variables to predict the 
response.   
To ensure that the predicted PTOL and its derivative, NSRI, are independent of the 
observed PTOL, the calculation of PK for PTOL and NSRI was performed by a two-fold cross-
validation procedure.  The total data set was divided into two subsets, each containing 60 
patients, randomly drawn from the propofol–remifentanil10 (10 patients), sevoflurane–
propofol12 (30 patients), and sevoflurane–remifentanil13 (20 patients) studies.  In each 
subset, a population interaction model was modelled and used for calculating PTOL and NSRI 
in the other subgroup. The parameter estimates for calculating PTOL and NSRI from one 
subgroup were thus used to validate the prediction in the other subgroup.   
Bootstrapping (1000 replicates) was used to determine 95% CIs of the PK values for 
each predictor and also the difference between the PK values of each combination of two 
predictors.  Significance was achieved if the 95% CI of the difference did not include zero 
(P<0.05).   
All PK calculations were performed in Excel 2003 (Microsoft) using VBA macros. 
 
15 Statistical analysis 
 
In all patients, we were able to compare the predictive performance of predicted PTOL, NSRI, 
CeSEVO, CePROP, CeREMI, and BIS to predict TOL (PK performance comparison 1).  In data 
obtained from the sevoflurane–propofol and the sevoflurane–remifentanil studies, SE and 
RE were additionally available as predictors (PK performance comparison 2).  In the data 
obtained from the sevoflurane–remifentanil study, SPI and CVI were also evaluated, as 
predictors of TOL (PK performance comparison 3).  Results of each performance comparison 
should be seen as a separate test of performance because the data sets are different.   
Statistical significance is set to P<0.05 unless stated otherwise.  All model parameters 
are reported as typical values with SE within parentheses. Clinical data are given as mean 
and SD or as median and range, when appropriate.   
 
2 Results 
21 Study population 
 
The characteristics of the populations of the three studies were comparable. The mean 
(range) weight was 69 (50–120), 66 (50–102), and 64 (50–103) kg in the propofol–
remifentanil,10 the sevoflurane–propofol,12 and the sevoflurane–remifentranil13 trial, 
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respectively.  The mean height was 169 (155–184), 172 (150–190), and 172 (157–186) cm, 
the mean age 34 (20–43), 30 (18–58), and 26 (18–54) yr, and the gender ratio (female/male) 
10/10, 33/27, and 26/14, respectively.   
 
22 Common response surface of sevoflurane, propofol, and remifentanil 
 
The results of the reanalysis of the three studies by separate and pooled analysis of the 
laryngoscopy data are summarized in Table 1, together with the results reported in the 
original papers.  The separate reanalysis of each study gave slightly different results from 
those reported in the original paper, because only the laryngoscopy data were included and 
because inter-individual variation of the parameter estimates was not included in our 
analysis.   
In the pooled analysis of the laryngoscopy data fromthe three studies, we could not 
confirm the hypothesis that Ce50REMI and  are different for sevoflurane and propofol. In 
addition, o was not significantly different from one.  When the Ce50REMI was allowed to vary 
between sevoflurane and propofol, the parameter estimates were 1.37 and 1.33 ng ml−1, 
respectively, with an ‘improvement’ of the NONMEM objective function of 0.018.  When  
was allowed to vary between sevoflurane and propofol, the parameter estimates (SE) were 
5.55 (0.74) and 4.71 (0.87), respectively, with an improvement of the NONMEM objective 
function of 0.420.  As a result, the data of the three studies can be well described with only 
four model parameters (Ce50SEVO, Ce50PROP, Ce50REMI, and ), with good precision (i.e. the SE 
values were smaller than in the original papers and in the separate analysis; Table 1).  
Equation (2) may therefore be simplified to : 
 
ࢁ = ൬
࡯ࡿࡱࢂࡻ
࡯૞૙ࡿࡱࢂࡻ
+
࡯ࡼࡾࡻࡼ
࡯૞૙ࡼࡾࡻࡼ
൰ ∙ ൬૚ +
࡯ࡾࡱࡹࡵ
࡯૞૙ࡾࡱࡹࡵ
൰ 
Equation (8) 
 
also known as the reduced Greco model.7 17  Equation (8) is thus the final model of the 
combined effect of sevoflurane, propofol and remifentanil.   
The CIs calculated from the bootstrap analysis are presented in Table 1.  In order to 
calculate PTOL using equation (1), U was calculated using equation (8) by entering the 
parameter estimates of the pooled analysis in the formula (Table 1).  Figure 1 shows the 
presence or absence of TOL as a function of U.   
 
23 Model evaluation 
The 50 and 90% TOL isoboles and the raw data of responders and non-responders are shown 
in Figure 2A-C.  The MAPE was calculated for the following three models: (i) a model as 
published (i.e. computed from the raw data of each single study including the response to all 
applied stimuli); (ii) a model reanalysed from the data of each single study including the 
response to laryngoscopy only; and (iii) the final model computed from the pooled data of all 
three studies including response to laryngoscopy only.  For propofol–remifentanil, the 
MAPEs of the predicted PTOL of the resulting models were 1.8, 2.3, and 3.9%, respectively. 
For sevoflurane–propofol, the MAPEs were 14.6, 6.8, and 6.9%, and for sevoflurane–
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remifentanil, the MAPEs were 5.3, 3.0, and 4.1%, respectively.  Thus, the MAPE values of the 
triple interaction model are close to those of the separate reanalysis of each study and are 
lower than those obtained from the published models, except for propofol–remifentanil, 
where MAPE is low for all models. The reason for the rather large MAPE for the sevoflurane– 
propofol data is visible in Figure 1.  In the absence of remifentanil, the maximal U was only 
1.56, which was only little above the range of U where responders and non-responders were 
observed.  A plot of observed vs predicted PTOL allowing for a visual inspection of the 
goodness of fit is presented in Supplementary File 3.  The result of the cross-validation based 
on parameter estimation from the raw data of two studies and validation with the raw data 
of the third study is presented in Supplementary File 4.   
 
 
 
Fig 1 The observed movement 
response and non-response to 
laryngoscopy is presented as a 
function of the total potency of the 
drug combination expressed as ‘U’ 
[equation (8)]. A value of one 
denotes tolerance of laryngoscopy 
(no movement); a value of zero 
denotes movement response.  Data 
are from the propofol–remifentanil 
study,10 sevoflurane–propofol 
study,12 and sevoflurane–
remifentanil study.13  The sigmoid 
concentration–response curve 
represents equation (1) with the final 
model.   
 
 
24 Prediction probability 
Table 2 shows the results for PK to assess the performance of PTOL, its derivative, NSRI, and 
the observed BIS, SE, RE, CVI, and SPI to predict TOL. For comparison, the PK values of the 
single drug concentrations (CeSEVO, CePROP, and CeREMI) were also determined and are shown 
in Table 2.   
 
3 Discussion 
With a pooled analysis of data from three previously published studies of similar design on 
dual drug interactions, a triple interaction model was developed to describe the anaesthetic 
potency of combinations of sevoflurane, propofol, and remifentanil in terms of PTOL and its 
derivative, the NSRI.  The model that fits the data best can be interpreted as an extension of 
the hierarchical hypnotic–opioid interaction model published previously.10 11 13 23   
We found that the interaction between sevoflurane and propofol is additive when 
their concentrations are normalized to their respective effect-site concentration inducing 
TOL in 50% of the population.  This is a confirmation of earlier work.12 27 28  Remifentanil has 
a strong but equally synergistic effect on sevoflurane and propofol.  In contrast to original 
 
131 
 
publications,10 12 13 the pooled analysis did not support different Ce50 values for remifentanil 
nor different slope factors for sevoflurane and propofol.  This is not surprising, because the 
SE values of both parameters were ∼20% in the study by Heyse and colleagues13 and ∼40% 
in the study by Bouillon and colleagues10 for Ce50, and the 95% CIs for the slopes were 
overlapping in all three studies.  As such, our common Ce50REMI and slope are within the SE 
of the values published previously (Table 1).   
 
 
Fig 2 Goodness-of-fit plot of the tolerance of 
laryngoscopy isoboles (PTOL) for propofol–remifentanil 
(P+R; A), sevoflurane–propofol (S+P; B), and 
sevoflurane–remifentanil (S+R; C) combinations.  
Non-responders and responders to laryngoscopy are 
indicated.  To avoid superposition of multiple 
responses at the same point, concentration values 
were slightly modified by adding a random value with 
mean zero and SD 0.1.  The 50% (continuous lines) 
and 90% (dashed lines) isoboles calculated with the 
original models (blue (A), blue (B), and blue (C))10 12 13 
and the new interaction model (green; Table 1) are 
plotted with the BIS 40 (pink dashed line) and BIS 60 
(pink continous line) isoboles according to the original 
response surface model.10 12 17  For remifentanil 
concentrations >2 ng ml−1, the 90% PTOL isobole is 
between the BIS 40 and BIS 60 isobole, which 
corresponds to clinical dosing practice.  The additive 
isobole for the sevoflurane and propofol interaction 
(straight lines) are well above the BIS 40 isobole, 
which reflects the fact that the EEG-suppressing 
effect of the two hypnotic drugs is much stronger 
than the potency to suppress the response to 
laryngoscopy.  Ce, effect-site concentration; Cet, end-
tidal concentration; BIS, Bispectral Index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Various model validation methods were applied and proved that our final model 
describes the data accurately and represents clinical reality.  In Figure 2, the 50 and 90%PTOL 
isoboles calculated with the triple interaction model and with the previous two-drug 
interaction models10 12 13 are plotted together with the raw data from the three studies to 
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demonstrate the goodness of fit.  Additionally, the clinically used BIS 40 and BIS 60 isoboles 
as predicted from previous studies are shown.10 17  The difference in the shape of the 
isoboles is related to the difference in Ce50 values and the different slopes between current 
and previously published models (Table 1).  For remifentanil concentrations >2 ng ml−1, the 
90% PTOL isobole is between the BIS 40 and BIS 60 isobole, which corresponds to clinical 
dosing practice.  This is consistent with previous data on the sevoflurane–remifentanil 
interaction by Manyam and colleagues,29 who demonstrated that the 95% isobole for 
suppressing response to tetanic stimulationwas between the BIS 60 and 70 isobole at 
remifentanil concentrations greater than ∼3 ng ml−1.  The additive 50 and 90% isoboles for 
the sevoflurane and propofol interaction (straight lines) are well above the BIS 40 isobole, 
which reflects the fact that the EEG-suppressing effect of the two hypnotic drugs is much 
stronger than the potency to suppress the response to laryngoscopy.   
In a general sense, PTOL can be considered an extension of the clinically applied MAC 
concept.6  For the first time, the potency of inhaled and i.v. hypnotic drugs can be compared 
uniformly.  Using our triple interaction model, the potency of any combination of 
sevoflurane, propofol, and remifentanil can be expressed as PTOL or its derivative, NSRI.  For 
example, a CeREMI of 3 ng ml−1 combined with either a CePROP of 3 μg ml−1 or a CeSEVO of 1.03 
vol% will yield a PTOL of 0.7 or an NSRI of 31 and are thus considered equipotent.  A more 
detailed clinical application is shown in Supplementary File 5.  In a simulated anaesthesia 
induction with a bolus of propofol and a remifentanil target-controlled infusion, the time 
when sevoflurane needs to be administered depends on the size of the propofol bolus and 
the remifentanil concentration.  The interaction model allows compensation for the decay of 
the propofol effect-site concentration by increasing the effectsite concentration of 
sevoflurane, in order to maintain a predefined total potency of the drugs in terms of PTOL.   
Table 2 Prediction probabilities (PK) of all studied measures to detect tolerance of laryngoscopy.  Numbers are 
prediction probabilities according to Smith and colleagues25 estimated from the data (95% confidence intervals 
estimated from a bootstrap analysis).  The best predictor for each stimulus is highlighted (bold).  *P<0.05 
compared with CePROP. †P<0.05 compared with CeSEVO, CePROP, CeREMI, and BIS.  ‡P<0.05 compared with CeSEVO, 
CePROP, CeREMI, BIS, SE, and RE.  P<0.05 compared with SPI. §P<0.05 compared with CeSEVO, CeREMI, BIS, SE, RE, CVI, 
and SPI.  PTOL is the ‘predicted PTOL’ calculated from the effect-site concentrations and model parameters.  CeSEVO, 
CePROP and CeREMI are the effect-site concentrations of sevoflurane, propofol and remifentanil, respectively; BIS, 
Bispectral Index; SE, State Entropy; RE, Response Entropy; CVI, Composite Variability Index; SPI, Surgical Pleth 
Index  
  CeSEVO CePROP CeREMI BIS SE RE CVI SPI NSRI 
Whole population (n=120) 
 0.73* 0.46 0.67* 0.71* - - - - 0.92† 
  (0.68-0.77) (0.41-0.51) (0.61-0.72) (0.66-0.77)         (0.90-0.94) 
Subgroups sevoflurane-propofol and sevoflurane-remifentanil (n=100)         
 0.71* 0.41 0.70* 0.65* 0.69* 0.69* - - 0.92 ‡ 
  (0.66-0.76) (0.35-0.47) (0.65-0.74) (0.59-0.71) (0.63-0.75) (0.63-0.75)     (0.89-0.94) 
Subgroup sevoflurane – remifentanil (n=40)             
 0.76¶ - 0.72 0.78¶ 0.78¶ 0.77¶ 0.74 0.57 0.95 § 
   (0.68-0.84)   (0.64-0.80) (0.69-0.86)  (0.68-0.86) (0.67-0.86) (0.62-0.84) (0.48-0.69) 
(0.91-
0.98) 
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In the population, TOL was best predicted by PTOL and NSRI (Table 2), whereas CeSEVO, 
CePROP, CeREMI, and BIS were intermediate (0.7) and CePROP was a poor predictor of TOL.  In 
data obtained from the sevoflurane–propofol and the sevoflurane–remifentanil studies, SE 
and RE were also available and showed a moderate predictive accuracy, similar to BIS.  In the 
data obtained from the sevoflurane–remifentanil study, CVI was found to be a moderately 
accurate predictor of TOL.  The SPI was not able to predict TOL.  Both PTOL and NSRI 
outperformed the other measures in both sub-analyses.   
A limitation of our study is that our triple interaction model is based on pooled data 
from three independently performed two-drug interaction studies, so no patient was given a 
combination of all three drugs.  As a result, our model neither detects nor excludes a 
superimposed triple interaction in patients who receive all three drugs simultaneously.  In a 
large triple interaction study on midazolam, propofol, and alfentanil, Minto and colleagues24 
found significant synergistic interactions of each pair of these compounds but no additional 
triple interaction when three drugs were combined.  A significant and relevant triple 
interaction does not therefore seem likely, considering the additive interaction between 
sevoflurane and propofol, and the strong and similar synergistic interaction of remifentanil 
with both hypnotic drugs.  Our model does produce predictions about PTOL when all three 
drugs are administered simultaneously, and these predictions are open to hypothesis 
testing.  Outside of our model, these predictions are not available because no other triple 
interaction model exists for these drugs in current literature.   
In conclusion, our response surface interaction model allows estimation of the 
potency of any combination of sevoflurane, propofol, and remifentanil as the probability to 
tolerate laryngoscopy.  The PTOL and its derivative, the NSRI, are good predictors of TOL.  
Clinical applicability needs further validation in a prospective study, with surgical and other 
standardized stimuli.   
 
4 Supplementary material 
Supplementary material is available at British Journal of Anaesthesia online. 
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Chapter 8  Discussion 
 
In daily practice, the primary objective of anesthesiologists is to balance the administration 
of anesthetic drugs during general anesthesia in such a manner as to achieve crucial 
objectives like hypnosis, analgesia, immobility and control over the autonomous nervous 
system.  Currently, anesthesiologists have to rely on clinical experience, a partial knowledge 
of interactions, and intuition to guide the patient in a safe drug-dosing practice to achieve 
these objectives.  Synergistically acting agents are meticulously combined, trying to avoid 
side effects and to minimize the administered dose without the use of tools that provide 
practical recommendations how to combine our anesthetic drugs.  Improving the knowledge 
of the interactions involved by means of measuring the desired objectives and linking these 
measurements to pharmacokinetic and dynamic modeling of multiple drugs could optimize 
the process to reach the appointed goals in a more predictable way.  
 
During most anesthetic procedures, multiple drug combinations are used.  However, 
analgesics and hypnotics are combined routinely to realize some fundamental endpoints of 
anesthesia.  Regarding hypnotic-opioid interactions, others described interactions between 
propofol-fentanyl,12–14 propofol-midazolam-alfentanil,11,15 propofol-alfentanil-nitrous 
oxide,16 propofol-alfentanil17–19, propofol-opioids,20,21 propofol-remifentanil,22–27 desflurane-
fentanyl,28 desflurane-remifentanil,29 sevoflurane-fentanyl,30–32 sevoflurane-remifentanil,33,34 
isoflurane-fentanyl35–37, isoflurane-alfentanyl,36 isoflurane-sufentanyl,38 isoflurane-
remifentanil,39... previously.  Some of them hereby also described various strategies for 
modeling pharmacodynamic interactions using response surface techniques.   
 
As during anesthesia, volatile anesthetics such as sevoflurane (with or without nitrous oxide) 
are frequently combined with opioids such as remifentanil, we aimed at describing the 
relationship between those two (or three) drugs.  The published knowledge on these drug 
interactions can be considered incomplete.  Previously, Manyam and colleagues developed a 
response surface for various pharmacodynamic responses using a Logit model approach and 
found synergy between sevoflurane and remifentanil for all responses.40  Unfortunately, as 
this study suffered from non-steady-state conditions at the moment of the observations.  
These researchers improved their data using calculated effect-site sevoflurane 
concentrations and a specific surface model instead of a Logit approach.41  Accounting for 
the lag time between sevoflurane effect-site concentration and end-tidal concentration 
improved the predictions of responsiveness during anesthesia but had no effect on the 
accuracy of prediction of a response to a noxious stimulus in recovery.  They concluded that 
models may be useful in predicting events of clinical interest, but large-scale evaluations 
with numerous patients are needed to better characterize the interaction.  Furthermore, the 
interaction between sevoflurane and remifentanil on continuous measures, like BIS, SE, RE, 
CVI, and SPI, has not yet been described.   
 
As a result, we aimed in this thesis to enlarge the knowledge on the interaction between 
sevoflurane, nitrous oxide and opioids using both dichotomous and continuous measures of 
drug effect and with and without noxious stimulation.  Secondly, we hypothesized that the 
applied surface model approach might influence the resulting interaction and has to be 
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explored during the model development.  Thirdly, we aimed at using surface interaction 
models to develop a new predictive anesthetic state index.  Last but not least we hoped to 
develop a triple interaction model, describing the interaction between sevoflurane, propofol 
and remifentanil.   
 
We first studied the pharmacodynamic interaction between sevoflurane and remifentanil 
using dichotomous measures of drug effect.  A number of response surface models have 
been developed to describe the relationship between the concentrations of two drugs and 
their combined clinical effects.  In Chapter 3 we examined the interaction of remifentanil 
and sevoflurane on the probability of tolerance to shake and shout, tetanic stimulation, 
laryngeal mask airway insertion, and laryngoscopy in patients.  Additionally, we investigated 
the performance of five different response surface models to predict the likelihood of 
response.   
 
As expected, the pharmacodynamic interaction between sevoflurane and remifentanil was 
strongly synergistic for both the hypnotic and the analgesic components of anesthesia, as 
illustrated by tolerance to shake and shout, tetanic stimulation, LMA insertion, and 
laryngoscopy.  The main finding of this study is the validity of the modified hierarchical 
model (or Fixed C50O Hierarchical model), assuming an identical Ce50 of the opioid for 
different stimuli.  The slope parameter of the hypnotic as well as the opioid are also identical 
for different stimuli.  Consequently, these three assumptions will result in different Ce50’s of 
the hypnotic for different stimuli.   
 
The Hierarchical models are semi-mechanistic models that have been developed to detect 
synergism for the combination of an analgesic and a hypnotic drug using a simple 
mathematical reconstruction of neuropathic pathways, as opposed to other more 
generalistic models.  These Hierarchical models, as well as the Reduced Greco model, 
assume no relevant opioid effect if given alone, and therefore these models fitted better to 
the data than the Greco and Minto models.  The differences between the Reduced Greco 
model, Scaled C50O Hierarchical model, and Fixed C50O Hierarchical model were rather 
small, and each of these three models fitted reasonably well to the data.  However, the OFV 
and Akaike Information Criterion unequivocally showed that the Fixed C50O Hierarchical 
model resulted in the best fit to our data.  Furthermore, we illustrated the importance of 
exploring the various surface modeling approaches when studying pharmacodynamic drug 
interactions as model selection might influence the results.   
 
 
 
In Chapter 4, we studied the interaction between sevoflurane and remifentanil on bispectral 
index (BIS), state entropy (SE), response entropy (RE), Composite Variability Index (CVI), and 
Surgical Pleth Index (SPI), by using a response surface methodology.  Overall, we 
hypothesized that the nature of the various interactions should be synergistic for the 
continuous measures as this is in concordance with the interaction on dichotomous clinical 
endpoints as we described.  The secondary goal of the study was to investigate whether 
noxious stimulation significantly affects the model structure or the model parameters.  The 
influence of stimulation on this interaction was examined by comparing the data before 
OAA/S score (unstimulated state) with data after laryngoscopy (stimulated state).   
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Although opioids have a rather weak effect on the electroencephalogram, we found an 
additive effect of remifentanil on reduction of BIS, SE, and RE by sevoflurane.  The effect on 
CVI was synergistic.  The SPI was not affected by sevoflurane or remifentanil.  The Greco 
model provided the best fit of the data for BIS and Entropy (SE and RE), whereas the reduced 
Greco model best described CVI.  The findings on (unstimulated) BIS, SE, and RE are in 
agreement with that reported in previous literature.  Nieuwenhuijs et al.114 presented an 
interaction model during sevoflurane–alfentanil anesthesia, suggesting additivity for BIS.  
Bouillon et al.26 found additivity for BIS during propofol–remifentanil anesthesia.  
Schumacher et al.76 found an additive interaction on BIS for combined propofol and 
sevoflurane.   
 
Conversely, the interaction of sevoflurane and remifentanil on clinical endpoints of effect 
(cfr. supra) was not additive but synergistic.  Also, C50remi was 10-fold higher for BIS, SE, and 
RE compared with C50remi for dichotomous endpoints.  Apparently, the opioid effect on the 
electroencephalogram is weak, despite a strong effect on patient responsiveness.  This may 
explain why electroencephalographic variables are poor predictors of responsiveness to 
noxious stimuli.   
 
Interestingly, the structural interaction model was not affected by noxious stimulation, but 
noxious stimulation did increase the C50sevo for BIS, SE, and RE by 20%, whereas the C50remi 
did not change.  In contrast, for CVI all model parameters changed except C50sevo.   
 
For all poststimulation response surface models, the structural model with the lowest 
objective function was identical to the prestimulation model.  For BIS, SE, and RE, the model 
parameters hardly changed, except for C50SEVO (consistently 0.3 vol% higher after 
laryngoscopy).  This pharmacodynamic shift is consistent for BIS and entropy and it is only a 
fragment smaller than the difference between C50SEVO for tolerance of shake and shout and 
laryngoscopy, found in the previous article (0.53 vol%).  For CVI, the changes in the 
poststimulation model are complex.  C50REMI decreased to 3.09 ng/ml.  Gamma and the 
baseline effect (E0) increased.  The increased steepness of the dose–response curve and the 
larger difference between baseline and maximal effect suggest an improved descriptive 
capacity for CVI in stimulated compared with unstimulated conditions.  However, the 
residual SD and the standard errors of the parameters indicate a larger variability in the 
dose–response relationship compared with the unstimulated condition.  For SPI, we were 
not able to extract plausible parameter estimates from our data, neither from 
prestimulation nor from poststimulation observations.  The inability to detect any dose–
response relationship in steady-state conditions, both with or without noxious stimulation, 
lowers the expectations for SPI as a guide for titrating sevoflurane and remifentanil 
anesthesia.   
 
 
 
After generating the data from the sevoflurane - remifentanil interaction studies, we 
initiated a study with similar study design and with the objective to enlarge our knowledge 
regarding the interaction between sevoflurane, remifentanil and nitrous oxide.  To achieve 
our goal we had to administer combinations of nitrous oxide, sevoflurane and remifentanil 
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for a longer period of time, aiming for steady state concentrations.  Especially in the low 
dose range of the applied products, this yielded to “semi-conscious”, uncooperative patients 
with sometimes episodes of aggressive behavior.  Sometimes they didn’t allow mask 
ventilation but simultaneously suffered from hypoventilation resulting in hypoxemia.  After 
examining a few cases we aborted the study to avoid adverse events.  Being persistent, we 
incorporated a period of reflection, and subsequently started a search for available historical 
data with the intention to reanalyze existing data to expand the interaction model that way.  
The results from our quest can be found in Chapter 5.   
 
Katoh described the reduction of minimal alveolar concentration (MAC) and MAC to block 
autonomic reflexes to nociceptive stimuli (MAC-BAR) of sevoflurane by fentanyl.  They also 
tested the MAC reduction evoked by nitrous oxide.31  Because the article of Katoh does not 
provide the model parameters of the logistic regression analysis, it does not allow a flexible 
calculation of the probability of response at any drug level.  Currently, nonlinear mixed effect 
modeling is considered to be the definitive standard for modeling three-dimensional 
response surfaces on interaction datasets.115  A response surface model that describes the 
effects of nitrous oxide has not yet been described.  We hypothesized that the hierarchical 
model could be expanded further to allow flexible inclusion of the effects of 66 vol.% N2O in 
the interaction between opioids and sevoflurane.  Because, in the original dataset, N2O was 
applied at a single concentration level only, the data did not allow a full response surface 
modelling of the three drugs.  Therefore, the influence of N2O was treated as a covariate in 
the hierarchical model of sevoflurane and opioids.   
 
The influence of 66 vol.% N2O was best described by a combination of an additive effect 
corresponding to 0.27 ng/ ml fentanyl and an additive effect corresponding to 0.54 vol.% 
sevoflurane.  With a simple extension, the effect of 66 vol.% N2O can be incorporated in the 
hierarchical interaction model of sevoflurane and opioids and allows to model the triple 
interaction in a response surface.  Although the opioid used was fentanyl, the model may be 
applicable for other opioids also, provided that equipotent doses of the other opioids are 
given.20   
 
 
 
As already mentioned, the third aim of this thesis was to use surface interaction models to 
develop a predictive anesthetic state index.  This resulted in the Noxious Stimulation 
Response Index.  The NSRI is proposed to predict, based on the effect-site concentrations of 
an opioid and an anesthetic, the likelihood of response to a noxious stimulus during 
anesthesia.116  Generally speaking, the NSRI is an index calculated from the weighted 
propofol and remifentanil concentrations, corrected for interaction and normalized to a 
range between 0 and 100, where 100 reflects 100% probability and values approaching 0 
reflect close to 0% probability of responding to laryngoscopy.  By definition, an NSRI of 50 
means that the effect-site propofol and remifentanil concentrations are sufficient that the 
patient will tolerate laryngoscopy with a probability of 50%.   
 
The strength of the NSRI lies in the fact that is has a predictive performance for noxious 
stimulation response in the clinically desirable range and its independence of physiologic 
signals as well as test stimuli.  As with other anesthetic depth indicators or drug 
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concentrations, the predictive performance expressed as PK does not imply that a given NSRI 
value correctly predicts the response in an individual patient, but it means that the 
probability of response is highly correlated with the NSRI.   
 
We conclude that the NSRI is a promising anesthetic state index predicting response to 
noxious stimulation responsiveness and, to a lesser extent, the hypnotic state.  Most 
probably, it will improve the dosing of hypnotics/volatiles and opioids.  However, 
prospective validation studies in the clinical setting are needed to judge the use of the NSRI 
in everyday anesthetic practice.   
 
 
 
Our group studied the interaction between sevoflurane and propofol76, sevoflurane and 
remifentanil117,118 extensively.  Furthermore, data describing the interaction between 
propofol and remifentanil, from a similarly designed study, are available.26  In several 
countries, the combination of sevoflurane, propofol and opioids is used on a daily basis, 
making the rationale for a triple interaction study self-evident.  So we performed a response 
surface analysis of the pooled raw data from three published studies on interactions 
between sevoflurane, propofol and remifentanil.  A triple interaction model was developed 
to describe the anaesthetic potency of combinations of sevoflurane, propofol and 
remifentanil in terms of a generalized PTOL and NSRI.  With the new interaction model the 
potency of any combination of sevoflurane propofol and remifentanil can be expressed as 
PTOL or as NSRI.   
 
The model that fits the data best is an extension of the hierarchical hypnotic-opioid 
interaction model published previously.26,97,117,119  We found that the interaction between 
sevoflurane and propofol is additive when their concentrations are normalized to their 
respective effect-site concentration inducing TOL in 50% of the population.   
 
In contrast, remifentanil has a strong but equally synergistic interaction with both hypnotics.  
According to the hierarchical interaction model,97 the Ce50 REMI is the remifentanil effect-site 
concentration reducing the Ce50 of sevoflurane and/or propofol by 50%.  In contrast to 
previous publications26,117 the pooled analysis did not support different Ce50s for 
remifentanil or different slope factors for propofol and sevoflurane.  As a consequence, the 
response surface defined by the final model has a similar shape for propofol and 
sevoflurane.  This is not surprising, because the SE values of both parameters were ∼20% in 
the sevoflurane-remifentanil study120 and ∼40% in the propofol-remifentanil study26 for 
Ce50, and the 95% CIs for the slopes were overlapping in all three studies.  As such, our 
common Ce50REMI and slope are within the SE of the values published previously (cf Chapter 
7, Table 1).   
In a general sense, PTOL can be considered an extension of the clinically applied MAC 
concept.88  For the first time, the potency of inhaled and i.v. hypnotic drugs can be compared 
uniformly.  Using our triple interaction model, the potency of any combination of 
sevoflurane, propofol, and remifentanil can be expressed as PTOL or its derivative, NSRI.  For 
example, a CeREMI of 3 ng ml−1 combined with either a CePROP of 3 μg ml−1 or a CeSEVO of 1.03 
vol% will yield a PTOL of 0.7 or an NSRI of 31 and are thus considered equipotent.  In a 
simulated anaesthesia induction with a bolus of propofol and a remifentanil target-
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controlled infusion, the time when sevoflurane needs to be administered depends on the 
size of the propofol bolus and the remifentanil concentration.  The interaction model allows 
compensation for the decay of the propofol effect-site concentration by increasing the 
effect-site concentration of sevoflurane, in order to maintain a predefined total potency of 
the drugs in terms of PTOL.   
 
In our study NSRI predicted tolerance to laryngoscopy substantially better than single drug 
effect-site concentrations or electro-encephalographic depth of anaesthesia monitors (BIS, 
SE, RE, CVI).  However, the latter predicted response to non-noxious stimulation (shake and 
shout) slightly but significantly better than the NSRI.  In data obtained from the sevoflurane–
propofol and the sevoflurane–remifentanil studies, SE and RE were also available and 
showed a moderate predictive accuracy, similar to BIS.  In the data obtained from the 
sevoflurane–remifentanil study, CVI was found to be a moderately accurate predictor of TOL.  
The SPI was not able to predict TOL.  Both PTOL and NSRI outperformed the other measures 
in both sub-analyses (cf Chapter 7, Table 2).  The reason why pharmacologic depth of 
anaesthesia indicators, such as NSRI or PTOL are potentially superior to electro-
encephalographic depth of anaesthesia monitors in predicting responsiveness, is the fact 
that NSRI is affected by each of the drugs (propofol, volatile anaesthetics and opioids).  
Conversely, BIS, SE and RE mainly reflect changes of propofol and/or volatile anaesthetics 
and are far less affected by opioids.  Additionally, at moderate drug concentrations the 
effect of propofol or volatile anaesthetics on BIS or other EEG monitors shows a plateau, 
where an increase in drug-concentration does not change the monitor readings much.121–123  
Therefore, NSRI may be more descriptive for a change in anaesthetic condition compared to 
EEG derived monitors.   
 
There are certainly limitations to our study.  Our triple interaction model is based on pooled 
data of three independently performed two-drug interaction studies, so no patient was 
given a combination of all three drugs.  As a result, a triple interaction of the three drugs 
could not be detected, nor excluded.  However, a significant and relevant triple interaction 
does not seem likely, taking into account the additive interaction of sevoflurane and 
propofol, and the similar synergistic interaction of remifentanil with both hypnotic drugs.  
This assumption is supported by the large triple interaction study on midazolam, propofol 
and alfentanil by Minto et al., who found significant synergistic interactions of each pair of 
these compounds but no triple interaction.11  A reanalysis of their raw data from 400 
patients revealed that the parameter estimates did not change if the 50 patients receiving all 
three drugs were included or not.   
 
 
 
This thesis generates some perspectives for further research.  The data and equations 
presented in this thesis can easily be applied in advisory systems that provide bedside 
pharmacokinetic-dynamic information based on the demographics of the patient and the 
administered drug doses.  Such devices are currently being commercialized for clinical 
practice.  However, prospective validation is still mandatory to evaluate the population-
based reference as a tool for the clinician to target desired levels of responsiveness in an 
individual case.  Optimizing the pharmacokinetic/pharmacodynamic model to the individual 
 
143 
 
patient with feedback mechanisms shifting the response surface to the optimum for each 
particular patient is a potential line of approach in the long term future.   
Furthermore, these systems use fixed potency ratios between different opioids to 
extrapolate the interaction surfaces between hypnotics and various opioids.  Other 
hypnotics, like midazolam or diazepam are also routinely used in daily practice.  At this 
moment, the influence of midazolam (or diazepam) on the continuous measurements of 
hypnotic effects of the interaction between sevoflurane, propofol and opioids remains to be 
clarified.  Additional, prospective, clinical studies are needed to confirm or develop these 
response surfaces.   
 
 
 
Today, several commercially available monitors measure the hypnotic effect in a continuous 
way.  In contrast, measuring the balance between nociception and anti-nociception remains 
a challenge.  By normalizing the nociceptive stimulus (eg. laryngoscopy) and using 
pharmacological data, the NSRI bypasses the need for measuring this balance and predicts 
the response to noxious stimulation and, to a lesser extent, the hypnotic state.  Most 
probably, it will improve the dosing of hypnotics/volatiles and opioids.  However, 
prospective validation studies in the clinical setting are needed to judge the use of the NSRI 
in everyday anesthetic practice.   
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Chapter 9  Summary - Samenvatting 
 
We aimed in this thesis to enlarge the knowledge on the pharmacodynamic interaction 
between sevoflurane, nitrous oxide and opioids using both dichotomous and continuous 
measures of drug effect.  Secondly, we hypothesized that the applied response surface 
model approach might influence the resulting interaction and has to be explored during the 
model development. Thirdly, we aimed at using a response surface interaction model to 
develop a new predictive anesthetic state index.  
 
First, we studied the interaction between sevoflurane and remifentanil using tolerance to 
shake and shout, tolerance to a tetanic stimulus, tolerance to the insertion of a laryngeal 
mask and tolerance to laryngoscopy as clinical measures.  Additionally, we studied the 
influence of the various surface modeling approaches on the interaction model using these 
data. We also studied the response surface model approach during sevoflurane-remifentanil 
interaction using various EEG and autonomic nervous system derived continuous measures 
with or without noxious stimulus (“the pharmacodynamic shift”).  As nitrous oxide is still 
used to supplement inhaled anesthetics such as sevoflurane, we reanalyzed existing data 
and we hypothesized that the hierarchical model could be expanded further to allow flexible 
inclusion of the effects of 66 vol.% N2O in the interaction between opioids and sevoflurane.   
 
In an attempt to use drug interaction models as the input of a predictive anesthetic state 
index, we developed the NSRI (noxious stimulation response index).  The NSRI is proposed to 
predict, based on the effect-site concentrations of an opioid and a hypnotic, the likelihood of 
response to a noxious stimulus, being the tolerance to laryngoscopy.  More recently, we 
enlarged and adapted the original NSRI to deal with triple interaction models estimating the 
potency of any combination of sevoflurane, propofol and remifentanil in terms of the 
probability to tolerate laryngoscopy.   
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Het objectief van dit proefschrift was het vergroten van de kennis van farmacodynamische 
interacties tussen sevoflurane, lachgas en opiaten, dit zowel voor dichotome als voor 
continue parameters van drugeffect.  Daarnaast onderzochten we de hypothese dat de 
toegepaste techniek om de response surface te bepalen de resultaten van de interactie zou 
kunnen beïnvloeden en derhalve dient te worden onderzocht tijdens het investigeren van 
een interactie.  Tot slot hebben we getracht om via een interactiemodel, een index te 
ontwikkelen die invloed van anesthetica op ons brein tracht te voorspellen.
In eerste instantie hebben we de interactie tussen sevoflurane en remifentanil onderzocht 
voor vier verschillende dichotome parameters : score op de “Observer's Assessment of 
Alertness Sedation (OAA/S) schaal, tolerantie van een tetanische stimulus, tolerantie voor de 
plaatsing van een laryngeaal masker en de tolerantie voor laryngoscopie.  Daarnaast 
onderzochten we of het toepassen van verschillende interactiemodellen een invloed had op
de resultaten van deze data.  We bestudeerden eveneens de invloed van de aan- of 
afwezigheid van een pijnlijke stimulus op de interactie tussen sevoflurane en remifentanil op 
meerdere afgeleide parameters.  Deze parameters zijn afgeleid van het EEG signaal ofwel 
worden deze beïnvloed door autonoom zenuwstelsel.  Ten einde het hiërarchisch 
interactiemodel voor sevoflurane - remifentanil ook toepasbaar te maken voor gebruik 
samen met lachgas, werd een historische dataset opnieuw geanalyseerd.
Om aan het derde objectief van dit proefschrift te voldoen werd de NSRI (Noxious 
Stimulation Response Index) ontwikkeld.  Deze index heeft als doel om, op basis van de 
effect-site concentaties van een opiaat en een hypnoticum, de kans op een respons bij 
laryngosopie, of bij uitbreiding een pijnlijke stimulus, te voorspellen.  In de laatste publicatie 
van dit werk hebben we de originele NSRI aangepast zodat deze voor elke combinatie van 
sevoflurane, propofol en remifentanil de kans op respons bij laryngoscopie kan inschatten.
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Describing U50(θ) from Minto’s model, using a quadratic function : 
 
Suppose that only drug A is present, evoking an effect equal to 50% of maximal effect, then 
θ = 0 and U50(0) = U50,A.  Since only drug A is present UA = 1 and UB = 0.  Applying this in 
Equation 14 U50,A must be equal to 1.   
Applying this in Equation 16 reveals  
 
Equation 24 
ࢁ૞૙(૙) =  ࢁ૞૙,࡭ =  ࢼ૙ = ૚ 
 
 
Suppose that only drug B is present, evoking an effect equal to 50% of maximal effect, then θ 
= 1 and U50(1) = U50,B.  Since only drug A is present UA = 0 and UB = 1.  Applying this in 
Equation 14 U50,B must be equal to 1.   
Applying this in Equation 16 reveals  
 
Equation 25 
ࢁ૞૙(૚) =  ࢁ૞૙,࡮ =  ࢼ૙ +  ࢼ૚ +  ࢼ૛ = ૚ 
 
Combining and simplifying Equation 24 and Equation 25 yields :  
 
Equation 26 
ࢼ૚ = − ࢼ૛ 
 
Applying the former equations in Equation 16 results in Equation 17 : 
 
 
ࢁ૞૙(ࣂ) = ૚ − ࢼ૛,ࢁ૞૙ࣂ + ࢼ૛,ࢁ૞૙ࣂ
ଶ  
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Equation 21 can be rewritten in the following from :  
 
Equation 27 
ࡼࡺࡾ =
ࡴ࣐
ࡴ࣐ + (ࡴ૞૙ × ࡼ࢕࢙࢚ࡻࡵ)࣐
 
 
Equation 28 
ࡼࡺࡾ =
ࡴ࣐
ࡴ૞૙࣐
ࡴ࣐
ࡴ૞૙࣐
+ ࡴ૞૙
࣐ × ࡼ࢕࢙࢚ࡻࡵ࣐
ࡴ૞૙࣐
 
 
Equation 29 
ࡼࡺࡾ =
ࢁࡴ࣐
ࢁࡴ࣐ + ࡼ࢕࢙࢚OI
࣐  
 
Equation 30 
ࡼࡺࡾ =
ࢁࡴ࣐
ࡼ࢕࢙࢚ࡻࡵ࣐
ࢁࡴ࣐
ࡼ࢕࢙࢚ࡻࡵ࣐ + ૚
 
 
Equation 30 now resembles Equation 7.  Combining those two equations U can be easily 
deducted : 
 
Equation 31 
ࢁ =
ࢁࡴ
ࡼ࢕࢙࢚ࡻࡵ
 
 
 
Combining Equation 31 with Equation 20 results in : 
 
Equation 32 
ࢁ =
ࢁࡴ
ࡼ࢘ࢋࡻࡵ ൬૚ − ࡻ
ࢽ
(ࡼ࢘ࢋࡻࡵ × ࡻ૞૙)ࢽ + ࡻࢽ
൰
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Equation 33 
ࢁ =
ࢁࡴ
ࡼ࢘ࢋࡻࡵ ൮૚ −
ࡻࢽ
ࡻ૞૙ࢽ
ࡼ࢘ࢋࡻࡵࢽ × ࡻ૞૙ࢽ
ࡻ૞૙ࢽ
+ ࡻ
ࢽ
ࡻ૞૙ࢽ
൲
 
Equation 34 
ࢁ =
ࢁࡴ
ࡼ࢘ࢋࡻࡵ ൬૚ − ࢁࡻ
ࢽ
ࡼ࢘ࢋࡻࡵࢽ + ࢁࡻࢽ
൰
 
 
Equation 35 
ࢁ =
ࢁࡴ
ࡼ࢘ࢋࡻࡵ
ࡼ࢘ࢋࡻࡵࢽ + ࢁࡻࢽ
− ࢁࡻ
ࢽ
ࡼ࢘ࢋࡻࡵࢽ + ࢁࡻࢽ
 
 
Equation 36 
ࢁ =
ࢁࡴ
ࡼ࢘ࢋࡻࡵ × ࡼ࢘ࢋࡻࡵࢽ
ࡼ࢘ࢋࡻࡵࢽ + ࢁࡻࢽ
 
 
Equation 22 
ࢁ =
ࢁࡴ
ࡼ࢘ࢋࡻࡵ
ቆ૚ +
ࢁࡻࢽ
ࡼ࢘ࢋࡻࡵࢽ
ቇ 
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List of abbreviations 
 
AAI   A-Line autoregressive index 
BIS  Bispectral index 
Ce  effectsite concentration 
CVI  Composite Variability Index 
E0   baseline effect 
Emax   maximal effect 
EEG  electroencephalogram 
MAC  minimal alveolar concentration 
MAC-BAR minimal alveolar contentration to block autonomic reflexes 
NONMEM Non Linear Mixed Effect Modeling 
NSRI   Noxious Stimulation Response Index 
OAAS  Observers Assessment of Alerteness Sedation scale 
OVF  Objective Function Value 
Px  probability of event x 
PK  prediction probability 
RE  Response Entropy 
SE   State Entropy 
SPI  Surgical Pleth Index 
TOL  tolerance of laryngoscopy 
Ux  normalized concentration of drug x  
 
